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Chapter 1 
INTRODUCTION 
Aspirin, acetylsalicylic acid, is the most frequently consumed drug in pregnancy,47 
mostly taken without a prescription because of headache or a minor ailment. 226,277 
Numerous preparations containing acetylsalicylic acid are freely available over the counter 
under a variety of proprietary names, and in many cases pregnant women and their 
doctors may be unaware that aspirin is being taken. 
For many years obstetricians have advised against the use of aspirin as a simple 
analgesic in pregnancy, based on a general tendency to discourage all drug taking in 
pregnancy as well as on fears of specific complications of aspirin, such as teratogenic 
effects, maternal and fetal hcmorrhage, and premature closure of the ductus arteriosus. 
But the negative attitude towards the usc of aspirin in pregnancy is changing rapidly since 
evidence has become available that a daily low dose of aspirin (60-80 mg) may markedly 
reduce the incidence of hypertensive disorders and fetal growth retardation in pregnant 
women at risk. 
Hypertensive disorders are a common complication of the second half of 
pregnancy. In a recent population-based study of almost 200.000 births in the USA the 
prevalence of pregnancy-induced hypertensive disorders was 43.1 per 1000 in singleton 
pregnancies. This large study confirmed earlier observations that nulliparity, advanced 
maternal age (> 35 years of age), and multiple pregnancy are associated with a markedly 
increased risk. 214 
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For the past 40 years, hypertensive disorders of pregnancy, in particular 
preeclampsia-eclampsia, were the first or the second -after pulmonary embolism- cause of 
maternal mortality in England and Wales,56.1.12 responsible for 15-20% of maternal deaths. 
In a study of maternal mortality in the Netherlands, 1988-1991, 37% of maternal 
mortality was attributable to preeclampsia-eclampsia.22 • In developing countries, maternal 
mortality is 100-200 times higher than in Europe and North America. In these countries 
deaths from hemorrhage and infection account for a large part of the excess,61 followed 
by preeclampsia-eclampsia. Analysis of a large, mainly hospital-based, set of data 
collected by the World Health Organization indicates that hypertensive disorders of 
pregnancy may be held responsible for 10-15% of the maternal mortality in various 
developing countries in Africa, Asia, Latin America, and the Caribbean. 61 
The impact of gestational hypertension on fetal mortality is disputed, due to 
differences in criteria of selection and diagnosis between various studies. According to the 
World Health Organization hypertensive disease during pregnancy is the main cause of 
perinatal mortality and morbidity .• 42 Indeed, there seems to be no doubt that pregnancy-
induced hypertensive disease associated with proteinuria, that is preeclampsia, is 
accompanied by a perinatal morbidity and mortality that is substantially higher than in 
normotensive pregnancies. The main threat to the fetus is an insufficient supply of 
nutrients through the placenta leading to growth retardation and low birth weight. 
However, in the absence of proteinuria pregnancy-induced hypertensive disease is not 
associated with fetal growth retardation and carries a perinatal mortality that is similar to 
that in normotensive pregnancies. 142 On the other hand, fetal growth retardation caused by 
an insufficient placenta supply line is not necessarily associated with gestational 
hypertension. 263 
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No other disease in pregnancy has been surrounded for so long by so many 
uncertainties and controversies, concerning its etiology, pathophysiology, treatment and 
prevention. 35 The development of high blood pressure during pregnancy signals a 
disturbance of the physiological adaptation of the maternal circulation, the mechanism of 
which depend to a large extent on changes in maternal prostaglandin synthesis. In normal 
pregnancy the synthesis of prostacyclin (POI,), an endothelium-derived vasodilator and 
inhibitor of platelet aggregation, increases markedly, which leads to a dominance in the 
biological balance with platelet derived thromboxane A, (TXA,) , a strong vasoconstrictor 
and inductor of platelet aggregation. Some women fail to develop or maintain these 
physiological adaptational responses to pregnancy; in these women a relative dominance 
of TXA, over POI, results in vasocontriction and platelet aggregation.26o Hypertension is a 
frequent, but not obligatory, sign of the circulatory maladaptation that may cause 
disturbances in maternal systemic and uteroplacental perfusion, responsible for the 
vascular injury and clinical signs and symptoms of preeclampsia - eclampsia and fetal 
growth retardation.263 
The view that diffuse activation and injury of vascular endothelium constitutes a 
key factor in the pathogenesis of preeclampsia is receiving support from several lines of 
evidence. Recently, Roberts and Redman,05 suggested that the endothelial dysfunction in 
preeclamptic patients leads to a loss of normal endothelial depressor functions, which 
results in increased sensitivity to normally circulating pressor agents. Elevated circulating 
levels of markers of endothelial cell activation and damage, such as cellular fibronectin,'" 
laminin,' and Von Willebrand factor l85 were demonstrated in patients with preeclampsia. 
Elevated levels of plasma endothelin-I were reported" although recent studies failed to 
demonstrate differences between plasma endothelin-I concentrations'S or urine excretion" 
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in normotensive and preeclamptic women. Endothelial damage may affect synthesis of 
endothelium-derived nitric oxide and cause altered control of arterial tone. 146 
The endothelial activation and injury in preeclampsia may also disturb the finely 
tuned balance of physiological coagulation, fibrinolysis and platelet activation,'62 as 
demonstrated by the increased production of thromboxane by platelets'" and placental 
tissue,'" and a reduced placental synthesis of prostacyclin.2" Etevated platelet 
thromboxane synthesis and reactivity has been recognized as an important 
pathophysiologic mechanism in the development of the uteroplacental circulatory 
insufficiency that may accompany pregnancy-induced hypertensive disorders.'66 
Because of the hypothesis that the maternal and uteroplacental circulatory 
disturbance in pregnancy-induced hypertensive disease and fetal growth retardation 
depends at least in part on a functional imbalance between two prostaglandins with 
opposing physiological effects, thromboxane and prostacycHn, it was attempted to correct 
the putative imbalance by means of dietary and pharmacologic manipulation of 
prostaglandin synthesis, in particular with low-dose aspirin, as already suggested by 
Wallenburg in 1980,210 Review of early small trials of low-dose aspirin suggested 
reductions of about three-quarters in the incidence of preeclampsia, but these results were 
not always confirmed in larger trials." Because of this apparent discrepancy, a large 
randomized trial of low-dose aspirin for the prevention and treatment of preeclampsia 
(Collaborative Low-dose Aspirin Study in Pregnancy [CLASP]) was designed. When the 
CLASP study was conducted, between 1988 and 1992, it became increasingly difficult to 
randomize patients between active treatment and placebo, possibly due to the results of 
the smaller trials suggesting a high efficacy of prophylactic treatment with low-dose 
aspirin,24 and to information disseminated in the lay press. 191 
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Results of previous studies suggest that long-term daily low-dose aspirin has no 
demonstrable effect on hemostasis in pregnant women as indicated by the bleeding 
time,I4.281 but no data are available in the accessible literature on the effect on the 
fibrinolytic system. Prostaglandins, involved in the initiation and maintenance of labor,II6 
also have an effect on fibrinolytic variables. I6 An effect of low-dose aspirin, through 
inhibition of prostaglandin synthesis, can therefore not be excluded; this could be of 
particular importance after normal or abnormal placental separation, when coagulation in 
the placental bed is balanced by a marked increase in fibrinolytic capacity. 
Based on the considerations presented above the objectives of this thesis can be 
summarized as follows: 
I. to review the literature on the general principles of dietary and pharmacologic 
manipulation of prostaglandin synthesis in pregnancy. 
2. to review the literature on the pharmacology, pharmacokinetics, and prophylactic 
and therapeutic applications of aspirin in pregnancy. 
3. to assess changes in patterns of prescription in the Netherlands of low-dose aspirin 
for prevention and treatment of pregnancy-induced hypertensive disorders and fetal 
growth retardation. 
4. to present and discuss the CLASP trial. 
II 
5. to investigate the effects of labor on variables of the fibrinolytic system. 
6. to investigate the effects of low-dose aspirin during pregnancy on prostaglandin 
and fibrinolytic variables before and after parturition. 
7. to formulate guidelines for the application of low-dose aspirin in obstetric practice 
on the basis of the results of the studies presented and discussed in this thesis. 
The results of the studies related to these objectives are described in chapters 2-8 
of this thesis. 
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Chapter 2 
PRINCIPLES OF MANIPULATION OF 
PROSTAGLANDIN SYNTHESIS IN PREGNANCY* 
Manipulation of the prostaglandin synthesis in pregnancy with the aim to correct 
an unfavorable prostacyclin-thromboxane balance and to prevent or treat pregnancy-
indnced hypertensive disorders and fetal growth retardation can only be understood 
against the background of basic prostaglandin biochemistry and of the physiological 
changes in the prostaglandin system that occur in normal preganancy. Dietary and 
pharmacologic approaches that are available to manipulate the prostaglandin system will 
be discussed in this chapter. 
2.1. General biochemical, physiological and pathophysiological background 
Prostaglandins (prostanoids) and other derivatives of eicosanoic (20-carbon) 
polyunsaturated fatty acids (PUPAs) are collectively termed 'eicosanoids'." They are 
known to function as autacoids, locally active biochemical mediators released by cells on 
demand in response to appropriate chemical or physical stimuli. 
* The maill subs/alice of this chapter was published ill: Wallenburg HCS, Bremer HA. Principles and 
applications of melll/plliarioll of proslaglalldill synthesis ill pregnancy. Baill Clill Ohstel GYlloeco[ 
1992; 6: 859-91. 
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Figure 2,1 Basic structure of pros/anoie acid 
Biochemisrry of eicosanoids 
Por the purpose of a discussion of the manipulation of eicosanoid synthesis, we 
may distinguish two main steps in the formation of these autacoids. The initial step 
consists of the biosynthesis and storage of arachidonic acid, the immediate fatty acid 
precursor of eicosanoids with two double bonds (dienoic) in their long chains, which 
constitute the physiologically most important eicosanoids in man. Eicosanoids with one 
(monoenoic) or three (trienoic) double bonds are derived from different PUPAs and have 
biological properties that differ from those of products derived from arachidonic acid; 
they seem to be not important in man under physiologic conditions, but they may 
modulate the synthesis of dienoic eicosanoids. Arachidonic acid is either ingested as a 
dietary constituent or synthesized by desaturation and elongation of 18-carbon (linoleic 
and gamma-linolenic acid) or 20-carbon (dihomo-gamma-Iinolenic acid) PUPAs. The 
enzymes involved in these biochemical processes are not specific and various fatty acids 
may compete for shared enzymes. 50 Because linoleic acid is an essential fatty acid that 
cannot be synthesized de novo in human tissues and must be supplied by food, the 
formation of arachidonic acid and its precursors will depend on the composition of the 
diet and may be influenced by dietary manipulation. 97 
Much of the arachidonic acid is utilized for energy requirements, but some 
becomes esterified to the phospholipids of cell membranes and to other lipid pools and 
may participate in the second step of eicosanoid synthesis, the actual formation of active 
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prostanoids. To that purpose, arachidonic acid must first be liberated from its ester bonds 
by the hydrolytic action of phospholipases, activated in the presence of calcium and 
calmodulin." Once released from its cellular stores, the arachidonic acid is either rapidly 
reincorporated into phospholipids, or metabolized to a series of oxygenated products 
through the action of a ubiquitous complex of enzymatic oxygenases, including 
cyclooxygenase, lipoxygenase, and epoxygenase. 153 Cyclooxygenase - also termed 
prostaglandin endoperoxide synthase or PGR-synthase - catalyzes the conversion of 
arachidonic acid into the very unstable cyclic endoperoxides PGG, en PGR" which are 
transformed, enzymatically as well as nonenzymatically, into a variety of active 
compounds, including the "classical" prostaglandins E, and F,., prostacyclin (PGI,) and 
thromboxane (TXA,). The cyclooxygenase products are often referred to as prostanoids, a 
terminology that will be used interchangeably with that of prostaglandins (Fig.2.1). 
Through the lipoxygenase pathway arachidonic acid is converted to leukotrienes with 4 
double bonds (4-series), potent mediators in inflammatory and hypersensitivity reactions 
which also interact at various levels with the cyclooxygenase pathway."o Also the 
eicosanoids of the epoxygenase pathway are biologically active and may interact with 
cyclooxygenase products. 73 Other PUF As may undergo the same r""ctions resulting in the 
formation of monoenoic (I-series) or trienoic (3-series) prostanoids, and of leukotrienes 
of the 3- and 5-series. Because the capacity of the human body for the synthesis of 
prostanoids is about 1000 times greater than the amount actually produced, activation of 
the eicosanoid system is countered with negative feed back r""ctions of self-catalyzed 
inactivation. 145 
An exogenous agent that interferes with the availability or functioning of the 
various enzymes of the arachidonic acid cascade will necessarily inhibit the formation of 
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prostanoids to some degree. In 1971 Vane discovered that inhibition of the 
cyclooxygenase enzyme is the mechanism by which acetylsalicylic acid (aspirin) and 
nearly all nonsteroidal anti-inflammatory agents prevent the formation of the classical 
prostaglandins, PGI, and TXA,.249 This finding not only provided a new tool for the 
investigation of the physiologic and pathophyiologic effects of endogenous prostanoids in 
vivo, but it also opened up new pathways for clinical research on prevention and 
treatment in a variety of diseases, including obstetric disorders, and thus put the clinician 
in the middle of the field of prostanoid research. 
Prostal/oids al/d maternal adaptation in pregnancy 
Over the past 10 years studies in vivo and in vitro have convincingly shown that 
the impressive adaptation of the systemic and uteroplacental circulations in pregnancy 
depends to a large extent on changes in prostanoid synthesis,'" in particular involving 
prostacyclin and thromboxane A,.260 Prostacyclin, with its principal site of synthesis in 
vascular endothelium and in pregnancy also in trophoblast, brings about relaxation of 
vascular and uterine smooth muscle leading to vasodilation and inhibition of myometrial 
contractility. In addition, it is an extremely potent inhibitor of the aggregation of platelets. 
Thromboxane A" synthesized mainly by platelets and in pregnancy also in the uterus and 
some other pregnancy-associated tissues, causes vasoconstriction, platelet aggregation, 
and stimulates myometrial contraction. 158 The formation of prostacyclin by endothelial 
cells serves to keep platelet adherence and aggregation on normal vascular endothelium 
at bay. In normal pregnancy prostacyclin production increases markedly, leading to a 
dominance of the biologic effects of prostacyclin over those of thromboxane A,. 166.'" II is 
generally accepted that these pregnancy-induced changes in prostanoid balance determine 
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the vasodilation and reduced systemic vascular resistance that is characteristic of normal 
pregnancy."O.285 Prostacyclin is most likely also responsible for the reduced sensitivity in 
pregnancy of the maternal vascular system to angiotensin-II and other vasopressors. 264 In 
the uteroplacental vascular system and in the placenta prostacyclin produced by 
trophoblast cells serves as a brake on the aggregation of platelets and thus prevents 
thrombosis and placental infarctionY' 
What induces the activation of prostacyclin synthesis in pregnancy? The answer to 
this question remains one of the mysteries of reproduction. It is tempting to speculate that 
the message somehow comes from the fertilized ovum,195 and immune recognition of the 
fetal allograft has been postulated as the main stimulus.26O 
Proslanoids and malemalmaladaptation in pregnancy 
Because the cause-and-effect relationhip between putative immunological triggers, 
biochemical mediators, and physiological adaptational responses is not yet understood, it 
is also not clear why some apparently healthy young women fail to develop or maintain 
the physiological adaptational responses to pregnancy. In these women the increase in 
prostacyclin production does not occur or is not sufficiently maintained, resulting in a 
relative dominance of the opposing effects of thromboxane A,. Thromboxane dominance 
appears to be the main mediator of what Wallenburg has called circulatory maladaptation 
disease,260 characterized by a relatively increased vascular resistance, increased vascular 
sensitivity to angiotensin-II and other vasopressors, and the development of thrombosis in 
the uteroplacental circulation resulting in placental infarction. 76,272 The clinical expression 
of circulatory maladaptation disease includes pregnancy-induced hypertensive disorders, 
and uteroplacental circulatory insufficiency with fetal growth retardation. 26O Theoretically, 
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there could be various causes of maternal circulatory maladaptation; insufficient feto-
maternal immuno-stimulation ( e.g. in a first pregnancy), inadequate response of the 
target organ due, for instance, to chronic hypertension or diabetes mellitus with 
vasculopathy, or factors inhibiting the biochemical cascade of prostanoid synthesis.263 The 
latter may be caused by lupus anticoagulant or anti cardiolipin antibodies, which are 
known to interfere with the synthesis of prostacyclin from arachidonic acid. 222 Some 10 
years ago the recogn,ition of relative thromboxane dominance as an important mechanism 
in the pathophysiology of circulatory maladaptation disease and the knowledge that aspirin 
is a potent inhibitor of platelet thromboxane synthesis led to first attempts to use aspirin 
in the prevention or early treatment of pregnancy-induced hypertensive disorders and fetal 
growth retardation.259,270 
2.2. Dietary manipulation 
The dietary manipulation of prostanoid synthesis is in particular associated with 
the consumption of fish and fish oil. A small number of observational studies suggest a 
reduced occurrence of pre-eclampsia and eclampsia, longer gestation, and higher 
birthweights in populations with a high consumption of marine fish compared with areas 
with a lower consumption of fish. 3,62,174 A questionnaire study in over 6500 pregnant 
women in Denmark who did not smoke during pregnancy showed a significant positive 
association between fish consumption and placental weight, birthweight, and neonatal 
head circumference, but not gestational age.175 As Olsen and Secher'76 have recently 
pointed out, these observations are supported indirectly by the results of a controlled trial 
conducted by the People's League of Health during 1938-39 in London."] In this study in 
over 5000 pregnant women, allocated alternately to dietary supplements of vitamins, 
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minerals, and halibut liver oil, or no treatment, a significant reduction in the occurrence 
of preeclampsia and preterm delivery was observed in women receiving halibut liver oil 
compared with non treated women. The usual explanation of the beneficial obstetric effects 
that are said to be associated with consumption of fish oil is that marine fat has a high 
content of PUFA precursors of 3-series prostanoids which compete with the formation of 
arachidonic acid resulting in a shift in prostanoid synthesis in favor of the biological 
effects of prostacyclin. 3 
Biochemical, physiological alld pallwphysiological background 
Two classes of PUFAs are involved in the processes of desaturation and elongation 
leading to the formation of direct prostanoid precursors (Fig.2.2). One class consists of 
PUF As with the first of their 3 to 6 double bonds at the third C-atom counting from the 
methyl end of the long chain (",3). Members of this class occur in some vegetable oils 
(linseed oil), but the main source of the precursor of 3-series prostanoids and 5-series 
leukotrienes, eicosapentaenoic acid (EPA), is marine fish. EPA is reversibly converted to 
C22:6,,,,3 and both PUFAs are synthesized by algae and phytoplankton, and taken up by 
man in fish and other sea-foods. In particular fat marine fish such as herring, sardine, 
mackerel, tuna and cod are a rich source of EPA and other ",3 PUF As. 10 The second 
class, that contains the 1- and 2-series prostanoids, counts its first double bond at the 6th 
C-atom (",6) and is derived from linoleic and gamma-linolenic acid in various vegetable 
oils such as corn, sunflower and safflower oil. The immediate precursor of the 2-series 
prostanoids, arachidonic acid, can also be taken up directly from meat, but since the 
average diet in developed countries contains less than 0.2% of energy as arachidonic acid, 
most of the tissue arachidonic acid is derived from Iinoleate. 144 
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DIET I 
I I 
FISH OIL VEGETABLE OIL VEGETABLE OIL 
(e.g. linseed) (e.g. safflower, sunflower, 
corn, evening primrose) 
C,.!,W-3 c,.,1W-6 
a-Linolenic Acid Linoleic Acid 
1 11 6 Desaturation 1 
C,.",W-3 C18:3,ro-6 
1 ,)"Linolenic Acid Elongation ... 
C,o",W-3 C20:3 ,ro-6 
1 Dihomo",(-Linolenlc Acid 115 Desaturation ~ 
. C,o,s,W-3 C,o",W-6 
Eicosapentaenoic Acid Arachidonic Acid 
... 
, 
3-series prostanoids I 
5-serles ·Ieukotrienes 
2-series prostanoids I 11-serles prostanoids 
4-serles leukotrienes 3-serles leukotrlenes 
Figure 2,2 Scheme of the die/Of}' sOl/rces alld processes of elol/galion alld desaturn/ioll of PUFAs resulting 
ill Ihe jonnalioll of proslalloids alld lel/ka/rielles, PUFAs (Ire indicated by Cn=' where" is the /lumber of 
carbon atoms alld 111 the /lumber of double bonds; tiJlI indicates the I11l1l1ber of carbolJ atoms COlli/fed/rom the 
methyl elld of fhe IOllg chain to the first double bOlld. 
Human metabolism is unable to change .,3 to .,6 PUPAs, or vice versa. Although 1- and 
3-series prostanoids are not important in man under physiologic conditions, both classes 
of PUPAs are required for many physiological purposes, such as cell membrane structure 
and transport and oxidation of cholesterol. 
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The dietary essential PUFAs in both classes compete with one another and with 
dietary saturated fats for incorporation in cell membranes and lipid pools, and for the 
shared enzymes which catalyze elongation and desaturation. In addition, EPA and 
dihomo-gamma-Iinolenic acid may compete with arachidonic acid at the level of 
cyclooxygenase and Iipoxygenase.50,87 For that reason, endogenous synthesis of 2-series 
prostanoids can be modified quantitatively and qualitatively by manipulating the absolute 
and relative amounts of ",3 and ",6 PUFAs in the diet, and such dietary manipulation 
could affect the function of the many physiologic systems in which prostanoids are 
involved. 
A major part of the research on dietary manipulation in nonpregnant individuals 
concerns attempts to shift the hemostatic balance towards increased vasodilatation and 
reduced platelet activity with the aim to prevent or treat vascular disease and thrombotic 
events.96 In the majority of studies the approach has been to manipulate the ",3 PUFAs, in 
particular using supplementation of the diet with EPA-rich fish oils or purified EPA. The 
scientific enthusiasm for this approach is based on the resuits of epidemiologic studies 
indicating a low incidence of hypertensive, thrombotic and atherosclerotic disorders 
among Greenland Eskimos" and certain groups in Japan ll " who all have a high 
consumption of fish and sea mammals. Intake of EPA-rich fish meat, fish oil, or purified 
EPA has been shown to lead to a reduced formation of dienoic TXA, by collagen-
stimulated platelets and an increased synthesis of trienoic thromboxane (TXA,), which 
shows only 10% of the biological activity of TXA,."·I22 In addition, consumption of EPA 
increases the formation in vivo of trienoic 1117-prostacyclin (PGI,), biologically equipotent 
with dienoic POI" whereas synthesis of the latter remains unchanged or may even 
increase slightly."·I'1 These and other experiments indicate that EPA competes with 
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arachidonic acid for incorporation in tissue and plasma phospholipids as well as at the 
level of the cyclooxygenase enzyme, resulting in inhibition of TXA, and its platelet-
aggregatory effects while stimulating the synthesis of vasodilator PGI,. There is evidence 
that EPA may also affect the arachidonic acid cascade in more complex ways, e.g. by 
inhibition at the level of ~6-desaturation. 
The biochemical changes in eicosanoid synthesis associated with manipulation of 
the ",3 class of PUFAs explain some, but not all, preventive and therapeutic effects of a 
diet rich in fish or supplemented with purified EPA with regard to hypertensive, 
thrombotic and atherosclerotic disease as observed in epidemiologic studies and in a large 
number of clinical trials.",I'1 It should be realized that the content of various ",3 PUFAs 
is extremely variable in different species of fish, which makes the extrapolation of fish 
consumption to marine ",3 fatty acid consumption difficult. For that reason and also 
because of the marked variations in the design of published studies and the complexity of 
the mechanisms involved, the putative beneficial effects of dietary supplementation with 
EPA, although suggestive, remain as yet disputed,'1 
Even more controversial are the effects of dietary manipulation of the ",6 PUFAs, 
with supplements of linoleic acid and dihomo-gamma-linolenic acid, usually as safflower 
or sunflower oil. Some studies have used evening primrose oil, which not only has a high 
content of Iinoleate (75%), but also contains about 9% of gamma-linolenic acid and 
various substances regarded as cofactors for prostanoid production. Dietary 
supplementation with linoleic acid has been shown to stimulate synthesis of PGE and 
PGF, whereas prostacyclin formation remained unaffected. 1'1 A diet rich in linoleate 
appears to reduce platelet TXA, formation, a biochemically unexpected effect that seems 
to be based on incorporation of linoleic acid into platelet lipids without bioconversion into 
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arachidonic acid. 97 A high dietary content of linoleic acid has been linked to reduced 
blood pressure, an effect that could be mediated by conversion of linoleic acid to 
arachidonate and subsequent formation of 2-series prostanoids. However, many later 
studies have failed to confirm such an association yl It has been suggested that evening 
primrose oil could alleviate the symptoms of the premenstrual syndrome through an 
increased synthesis of PGE" but a recent double-blind placebo-controlled study failed to 
support such claims. 118 
The majority of the studies on dietary manipulation of prostanoid synthesis are not 
properly controlled and they have applied dietary supplementation in various forms from 
various sources in variable doses for variable periods of time. For that reason, many 
doubts and uncertainties remain with regard to the biochemical and biological effects and, 
in particular, the clinical consequences of the manipulation of dietary PUFAs with the aim 
to prevent or treat hypertensive, thrombotic and atherosclerotic disorders. 
Obstetric applications of dietmy manipulation 
There is no evidence to suggest that a dietary deficiency of .,3 or .,6 PUFAs is 
involved in the pathophysiology of maladaptation disorders of pregnancy. MacGillivrayl" 
in a small-scale study in Aberdeen found no difference in the amount of linoleic, gamma-
linolenic or arachidonic acid between the diets of 15 preeclamptic women and 29 
normotensive pregnant controls. The few studies on plasma levels of free and esterified 
arachidonic acid in women with preeclampsia have not revealed any difference with 
normotensive pregnant women,17J,274 but plasma levels of total PUFAs, and of EPA, 
linoleic, and a-linolenic acid were found to be somewhat reduced in term preeclamptic 
women.274 The authors suggest that this could represent altered fatty acid metabolism with 
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altered storage or mobilization from lipid pools. Experience with dietary manipulation of 
prostanoid synthesis in pregnancy is extremely limited. Worley'" mentions a study by 
Gant et a!. who are said to have found no difference in the incidence of pregnancy-
induced hypertension among pregnant women who received a large daily dietary 
supplement of dihomo-gamma-Iinoleic acid when compared with placebo-treated women; 
however, no data of this study are presented or could be found in the literature. Moodley 
and Norman lso report a study in which they randomly allocated 47 primigravid patients 
with mild to moderate pregnancy-induced hypertension (BP 140/90 mm Hg or more) in 
the third trimester to supplementation with a daily dose of 4 g of evening primrose oil or 
matched placebo for a minimllm period of two weeks. No differences were found between 
the two groups with regard to blood pressure, or course and outcome of pregnancy. This 
is in fact a therapeutic rather than a prophylactic study. Also using a daily dose of 4 g of 
evening primrose oil during 7 days O'Brien et a1 171 investigated the effect of dietary 
supplementation with (')6 PUPAs on the pressor response to infusion of angiotensin II in 
10 normotensive pregnant women accepted for therapeutic termination of pregnancy in the 
early second trimester, and in 5 healthy nonpregnant female and 5 male volunteers. The 
diastolic pressor response to angiotensin II was significantly blunted in treated pregnant 
and nonpregnant subjects as compared to non treated controls, and the effect was greatest 
in pregnant women. The systolic response was somewhat reduced in treated pregnant 
women, but not in nonpregnant subjects. Effects on platelet behavior and prostanoid 
synthesis were not measured. Accepting that the physiologically reduced sensitivity of the 
vascular system in pregnancy to the pressor effects of angiotensin II is largely determined 
by prostacyclin dominance, these results provide indirect evidence that shortterm dietary 
supplementation with ",6 PUFAs may shift prostanoid synthesis towards an increased 
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prostacyclin dominance, perhaps by reducing platelet TXA, formation, as discussed 
previously. 
The effects of supplementation with ",3 PUFAs on pregnancy duration, and on 
weight and length of the newborn were investigated in 533 healthy women in week 30 of 
pregnancy who were randomly assigned in a ratio of 2 : 1 : 1 to fish oil (about 2.7g ",3 
fatty acids per day), olive oil, or no supplemenl. 177 Fish oil supplementation was 
associated with a small but significant increase of, on average, four days in the duration 
of pregnancy compared with women taking olive oil, but no differences were found with 
regard to neonatal weight and length adjusted for gestational age. These results are in 
contrast with those of the earlier epidemiologic study which showed no association 
between fish consumption and gestational age at delivery. 175 Data on the occurrence of 
pregnancy - induced hypertension are not presented. 
In conclusion, the theoretical basis of dietary manipulation of ",3 and ",6 PUFAs to 
produce physiologically beneficial changes of prostanoid synthesis remains largely 
speculative, and the results of the studies discussed above are hypothesis-generating rather 
than providing evidence that such manipulation could reduce the risk of pregnancy-
induced hypertensive disorders, preterm labor, or fetal growth retardation. 
Side-effects of dietmy manipulation 
An important aim of dietary PUFA manipulation is to reduce platelet activity, 
which could cause problems in pregnancy and delivery due to an increased bleeding 
tendency. Although to the best of our knowledge no toxic effects of ",3 or ",6 PUFAs 
have been reported in any of the studies in nonpregnant subjects, the highly unsaturated 
",3 fatty acids are easily oxidized, which may produce substances that could be toxic in 
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the mother or the fetus.'" The longterm effects of dietary manipulation of fatty acids are 
not known, but the possibility of deleterious effects due to an increased production of 
peroxides and radicals has been suggestedY' In 1988 the American Food and Drug 
Administration banned the use of evening primrose oil as food or drug.'" Considering the 
rapidly growing public interest in the preventive and therapeutic use of PUF As, in 
particular of EPA in fish oil, and in view of recent medical publications already 
proposing EPA as a reasonable alternative to aspirin in the prevention and treatment of 
pregnancy-induced hypertensive disorders,66,'07 further research on its maternal and fetal 
effects should have a high priority. 
2.3. Pharmacologic manipulation 
Two decades ago Lewis and Schulman l34 published the first retrospective 
observation that gestation was prolonged by an average of 7 days in 103 women who used 
3.25 g or more of aspirin daily during the last 6 months of pregnancy because of 
musculoskeletal or arthritic disease as compared with women who took no aspirin. In 
42% of these women, gestation lasted 42 weeks or more as compared to only 3% in 
controls who did not take aspirin. Labor lasted 12 h in treated women, and 7 h in 
untreated controls. These effects were attributed to suppression of endogenous prostanoid 
synthesis, and one year later this principle was applied therapeutically to the inhibition of 
preterm labor using indomethacin. 291 The retrospective study by Crandon and Isherwood" 
indicating that preeclampsia occurred less frequently in regular aspirin users than in 
pregnant women who took no aspirin, forms another landmark in the history of 
pharmacologic manipulation of prostanoid synthesis to prevent and treat maladaptation 
disorders of pregnancy. 
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Phanl1acologic, physiological {[nd pmhophysiological background 
Three enzyme systems in the eicosanoid cascade can be pharmacologically 
inhibited: the phospholipases, the cyclooxygenase, and the specific isomerases that 
catalyze the conversion of endoperoxides into the specific prostanoids. Finally, end organ 
receptors may be inhibited by specific antagonists. A few agents have been claimed to 
stimulate prostacyclin synthesis by complex mechanisms. 
Inhibition of phospholipases 
There are a very large number of drugs and chemical compounds that have been 
reported to inhibit various phospholipases and thus the availability of arachidonic acid for 
prostanoid synthesis, including glucocorticoids. The numerous and widespread effects of 
glucocorticoids and other phospholipase· inhibiting drugs preclude their pharmacologic use 
for specific inhibition of prostanoid synthesis in pregnancy. 
Inhibition of cyc/ooxygenase 
A heterogeneous group of pharmacologic agents, many of them chemically 
unrelated, have antiinflammatory, analgesic, and antipyretic effects and are frequently 
designated as nonsteroidal antiinflammatory drugs (NSAIDs) or, after their prototype, 
aspirin-like drugs. Apart from acetylsalicylic acid (aspirin) and sodium salicylate, para-
aminophenol derivatives (e.g. acetaminophen), acetic acid (e.g. indomethacin) and 
propionic acid (e.g. ibuprofen, fenoprofen, naproxen) derivatives are well known 
representatives. It is generally believed that inhibition of cyclooxygenase, and thus the 
formation of all prostanoids derived from arachidonic acid, is responsible for many of the 
beneficial activities and side effects of NSAIDs, although this concept has been 
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challenged.' Individual agents have different mechanisms for inhibition of cyclooxyge-
nase, but their effect is always dependent on reaching the enzyme and, for that reason, 
the distribution and pharmacokinetic properties of the drugs are important factors determi-
ning their activity. 
A review of the pharmacology, pharmacokinetics, and potential applications of 
aspirin in pregnancy will be presented in the chapter 3. 
Inhibition of isomerases 
The evidence implicating platelet TXA, as a major factor in the pathophysiology of 
occlusive vascular events has led to the development of selective inhibitors of 
thromboxane synthase, the isomerase catalyzing the conversion of PGH, into TXA,. 
Several compounds (e.g. dazoxiben, dazmagre!, pirmagrel, furegrelate) have undergone 
clinical testing in coronary and peripheral vascular disease, as yet with disappointing 
results. 69 Only dazoxiben has been used in a small number of pregnant patients. On 
theoretical grounds it was expected that selective inhibition of TXA, synthesis would lead 
to an accumulation of PGH, with favorable redirection to formation of PGI, ("steal 
mechanism"). However, PGH, itself has biological effects similar to those of TXA" and 
redirection of PGH, to prostacyclin is apparently not effective enough to antagonize the 
functional effects of accumulating PGH,.69 
Inhibition of thromboxGne receptors 
Receptor antagonists do not interfere with eicosanoid synthesis but prevent TXA, 
(and PGH,) from activating platelet and vascular receptors. Some of these agents 
(daltroban, sulotroban, and others) have undergone preliminary clinical testing in 
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nonpregnant individuals with variable results. 69 A new approach is the combination of 
TXA, synthase inhibition with TXA, receptor antagonism in one drug, such as ridogrel. 181 
Stimulation of prostacyclin symhesis 
In the past decade mainly five pharmacologic agents have been reported to 
stimulate POI2 synthesis in experimental conditions in vitro: nitroglycerin, nafazatrom, 
dipyridamole, magnesium sulfate, and the experimental drug proadifen. These findings 
have not been confirmed in viVO. IS •7o.m Of these agents, dipyridamole is the only drug 
that has been tested in clinical trials,7o also in pregnant women,'47 the results of which do 
not support its use as an antiplatelet agent. 
2.4. Conclusions 
There appears to be a sound scientific rationale for attempts to prevent and 
perhaps treat maladaptation disorders in pregnancy through manipulation of the eicosanoid 
cascade. Selective modulation of prostanoid formation can be achieved by dietary or 
pharmacologic interference with various steps in the synthetic cascade. Also, the effects 
of eicosanoids on end organ receptors can be manipulated. As yet, limited experience 
with dietary manipulation of prostanoid synthesis has provided no evidence of a beneficial 
effect on the course and outcome of pregnancy. There is a need for more fundamental 
research as well as for well-controlled multicenter clinical trials, not only to assess the 
putative benefits but also the possible side effects and risks of dietary prostanoid 
manipulation. With regard to pharmacologic manipulation of prostanoid synthesis in 
pregnancy extensive experience has accumulated with the use of acetylsalicylic acid 
(aspirin), which will be presented and discussed in chapter 3. 
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Chapter 3 
ASPIRIN IN PREGNANCY* 
Selective inhibition of platelet thromboxane synthesis by an intermittent low oral 
dose of acetylsalicylic acid (aspirin) will suppress thromboxane dominance and may 
restore the physiological prostacyclin-thromboxane balance in pregnant women with 
circulatory maladaptation to relative dominance of the biological effects of prostacyclin. 
This concept forms the rationale of clinical attempts to prevention or early treatment of 
pregnancy-induced hypertensive disorders and fetal growth retardation in pregnant women 
at risk with low oral doses of aspirin. After a brief review of the history, pharmacology, 
and pharmacokinetics of acetylsalicylic acid, in particular as related to pregnancy, this 
chapter presents an assessment of the rationale, the potential benefits and possible 
disadvantages of the use of aspirin in pregnancy. 
3.1. History 
In 1758 an English clergyman in Chipping Norton, Edward Stone, experimented 
with an extract of the bark of the willow tree (Salix alba) and found it effective in 
reducing fever. 
• 11/e main slIbstallce of Illis chapfer was published ill: Bremer HA, Wallenburg HCS. Aspirill ill 
pregnalley. Felal Mat Med Rev 1992,' 4: 37-57. 
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In 1763 he reported his discovery to the President of the Royal Society.21' It took more 
than 60 years before an active component was isolated from the willow bark and was 
called salicin; salicylic acid was prepared some years later. At about the same time 
salicylic acid was also obtained from a distillate of the flowers of the shrub Spiraea 
ulmaria, the meadow sweet, and in 1860 it was prepared synthetically. Although effective 
in reducing fever and relieving pain, salicylic acid and its sodium salt appeared to be 
extremely irritating to the gastric mucosa. In 1893 Felix Hoffmann, a chemist who 
worked for Bayer in Elberfeld, Germany, became interested in acetylsalicylic acid, 
developed already 40 years earlier, as a possible alternative to sodium salicylate. 
Acetylsalicylic acid could be prepared quite easily by combining salicylic acid and acetic 
acid anhydride and it proved as effective as sodium salicylate in reducing pain and fever 
without causing gastric irritation. The drug was officially registered in 1899 under the 
name aspirin: Hall for acetyl and uspirin" derived from one of the natural sources of 
salicylate, the Spiraea genus of plants. 75 Aspirin has a wide spectrum of effects dependent 
on a number of variables, including dosage; it is effective as an antiplatelet J analgesic, 
antipyretic, and anti-inflammatory drug. It was only in 1971 that Vane discovered that 
aspirin acts by reduction of prostanoid biosynthesis through acetylation and inhibition of 
cyclooxygenase, a key enzyme in the arachidonic acid cascade. 249 
3.2. Pharmacology and phal111aCokinetics 
Acetylsalicylic acid covalently acetylates the active site of the enzyme 
cyclooxygenase, thereby irreversibly inhibiting prostanoid synthesis. 
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Cyclooxygenase catalyzes the oxygenation and peroxydation of arachidonic acid to the 
instable prostaglandin endoperoxides, PGG, and PGH" which are selectively converted to 
the primary prostaglandins, prostacyclin and thromboxane A, by the action of specific 
enzymes, as discussed in the previous chapter, Prostaglandins are mediators of 
inflammation, pain, and fever, and the therapeutic effects of aspirin are mainly due to 
inhibition of prostanoid biosynthesis in varying degrees in cells and organ systems 
throughout the body.1S7 In platelets the principal product of endoperoxyde conversion is 
thromboxane A" an important link in the mechanism of platelet aggregation.21' For that 
reason, inhibition of thromboxane A, synthesis by aspirin has a marked effect on platelet 
aggregation. In vitro platelet aggregation induced by arachidonic acid and other agonists 
such as ADP and low doses of collagen is inhibited, as is the release reaction." Also 
adhesion of platelets to collagen under conditions of stasis or low flow is reduced. 
However, thrombin and high doses of collagen cause a full aggregation response despite 
the inhibition of thromboxane synthesis caused by aspirin.170 
Because the reaction between aspirin and the cyclooxygenase enzyme is 
irreversible, the duration of the inhibitory effect is determined by the rate at which new 
enzyme is synthesized. 17o Platelets lack nuclei and are therefore unable to synthesize 
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cyclooxygenase, so that following administration of aspirin platelet aggregation remains 
impaired for the duration of platelet life span. 170.", Recovery of thromboxane synthesis 
and platelet aggregation depends on the formation of new, uninhibited platelets from 
megakaryocytes. Since circulating platelets are affected on a cohort basis, clearance of 
irreversibly inhibited platelets depends on platelet lifespan. Indeed, return of platelet 
function after a single dose of aspirin has been shown to correlate with platelet 
turnover. 271 This explains the observation that intermittent long-term administration of low 
doses of aspirin, even as low as 20 mg per day, causes 95 per cent inhibition of 
thrombin-induced platelet thromboxane production with marked inhibitory effects on 
platelet aggregation in vitro.71 In contrast, nucleated cells such as endothelium can easily 
replace cyclooxygenase and their capacity to synthesize prostanoids will recover rapidly 
after aspirin exposure. 110.170 Aspirin is easily de-acetylated to salicylic acid (salicylate), a 
very weak inhibitor of cyclooxygenase, which has no measurable effect on platelet 
aggregation at concentrations achieved in ViVO. 1I7 It acts mainly on the lipoxygenase 
pathway that leads to formation of leukotrienes and a variety of other biologically active 
eicosanoids.27 
Platelet action contributes to hemostasis in an intricate and dynamic interaction 
with vascular endothelial reactivity, intravascular flow dynamics, and the coagulation 
system. 262 Because of the complexity of physiological platelet behavior, the inhibitory 
effects of aspirin on platelet function observed ex vivo cannot be simply extrapolated to 
predict effects on hemostasis in vivo. For instance, although aspirin inhibits platelet 
adhesion to collagen in vitro, adhesion at physiological rates of shear and hematocrit 
levels is not affected.'" Nevertheless, aspirin is extensively employed as an antiplatelet, 
antithrombotic agent in the primary and secondary prevention of arterial thrombotic 
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disease. 45 ,188.241 
Other factors that determine the systemic effects of aspirin are its absorption and 
de-acetylation by the liver. Aspirin is rapidly absorbed after oral administration, partly 
from the stomach but mainly from the upper small intestine. 104.160 The rate of absorption 
is determined by many factors, in particular the disintegration and dissolution rates of 
tablets or capsules, the pH at the mucosal surfaces, and the gastric emptying time. '04 
Gastric emptying is known to be slower in pregnant than in nonpregnant women, 101 but 
the effect of pregnancy on aspirin absorption has not been systematically investigated. 
Following oral ingestion of a single dose of aspirin peak levels of salicylate in plasma 
occur after approximately 30 minutes,'17,272 
Elimination after a single therapeutic dose follows a biexponential curve; the half-
life of the first exponent is 2-5 min for aspirin and salicylate, whereas the half-life of the 
second exponent is 13-19 min for aspirin and much longer (3.5-4.5 hr) for salicylate.208 
Salicylate is excreted in the urine, mainly as glycine and glucuronic acid conjugate. 104 
The liver is the main de-esterifier of aspirin; at least 80 % of acetylsalicylic acid is 
de-acetylated to salicylate during the first pass of blood through the liver. 208.272 The 
systemic effects of aspirin depend on the amount of acetylsalicylic acid that escapes the 
rapid hepatic de-acetylation and are therefore strongly dependent on dosage. '70•I80 
(Fig.3.2). This is most likely also the reason that no aspirin is secreted in breast milk at 
modest therapeutic doses, in contrast to salicylate. '62 
Salicylates, including acetylsalicylic acid, cross the placenta rapidly because of 
their high lipid solubility.'09 Fetal plasma concentrations of salicylate reach about 80-90 
per cent of maternal levels, 60-90 min after administration of an intravenous dose of 
aspirin to the mother; fetal aspirin levels reach about one-third of maternal 
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concentrations. I09 Maternal-fetal equilibration is slow because approximately 75 per cent 
of maternal salicylate is bound to plasma proteins.209 Considering the marked first-pass 
hepatic de-acetylation, a very low concentration of acetylated salicylic acid may be 
expected to reach the placenta after a low dose of aspirin taken by a pregnant woman. 
Elimination of salicylate from the fetus is slow because of a low capacity of the glycine 
and glucuronic acid pathways of conjugation. 133 
In view of the problems associated with the measurement of levels of acetylated 
salicylic acid, determination of thromboxane synthesis by neonatal platelets can provide 
an indirect but sensitive approach to asses placental transfer of aspirin. Ylikorkala et a1.286 
studied the effect of maternal ingestion of a single dose of 100 or 500 mg of aspirin 
between 30 minutes and 10 hours before birth on thromboxane production by platelets in 
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umbilical blood. The 100 mg dose caused a small reduction in fetal platelet thromboxane 
synthesis when compared to a control group without aspirin intake, but the reduction was 
significantly greater with 500 mg of aspirin. No inhibition of platelet thromboxane 
synthesis in cord blood was observed with maternal use of a low dose of 20,229 37.5,204 
60,229 or 80'29 mg of aspirin per day during approximately two weeks before delivery. 
However, longterm use of a daily dose of 60 mg of aspirin throughout the second and 
third trimester caused a 63 per cent reduction, as compared with placebo, in platelet 
thromboxane production in umbilical cord blood. I' It should be noted that neither a single 
maternal dose of 100 mg of aspirin during labor'" nor a daily dose of 80 mg during two 
weeks before delivery'29 had a noticeable effect on fetal prostacyclin synthesis, as judged 
by measurement of 6-ketoprostaglandin F,. levels in cord blood'29 or in neonatal urine.'86 
In conclusion, most of the known effects of aspirin are due to acetylation of the 
enzyme cyclooxygenase with inhibition of prostanoid formation. Because of the marked 
first-pass hepatic de-acelylation, the half-life of aspirin in the circulation is much shorter 
than that of salicylic acid. Peak levels of circulating aspirin and placental transfer are 
highly dose-dependent. The small amount of aspirin that reaches the fetus in case of 
longterm maternal intake of a low dose of aspirin in the order of magnitude of 60-80 mg 
per day causes a reduction in thromboxane synthesis by fetal platelets, but it does not 
affect fetal prostacyclin production. 
3.3. Obstetric indications for the use of aspirin 
Raliollaie 
As outlined above, the inhibition of cyclooxygenase by aspirin is irreversible and 
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recovery of prostanoid synthesis depends on the ability of the cell to synthesize new 
enzyme. Intermittent administration of a low dose of aspirin of 60-80 mg / day or even 
less l70 inhibits platelet thromboxane synthesis almost completely but has little or no effect 
on prostacycJin formation."·267 The selective inhibition of platelet thromboxane synthesis 
by low oral doses of aspirin may be explained by the fact that platelets passing through 
the gut capillaries are exposed to relatively high concentrations whereas, due to the high 
first-pass de-acetylation by the liver, the concentration of acetylsalicylic acid in the 
systemic circulation remains too low to markedly affect the cycJooxygenase enzyme and 
prostacyclin formation in vascular endothelium. "2 In addition, Walsh has pointed out that 
there are approximately 1000 times as many vascular endothelial cells capable of forming 
prostacycJin as platelets producing thromboxane A,.272 The dose-dependent selectivity of 
cycJooxygenase inhibition by aspirin is not complete and some suppression of prostacycJin 
synthesis has been noted, even with daily doses of 60 mg." However, even if vascular 
prostacylin synthesis is slightly reduced after ingestion of a low dose of aspirin, it will 
recover rapidly because of the formation of new cycJooxygenase. Alternate-day dosing 
has been proposed to enhance the selectivity of the inhibitory effect of low doses of 
aspirin on platelet thromboxane synthesis,86 but the best pharmacologic selectivity has 
been obtained with the use of a controlled-release preparation which 'dribbles' aspirin into 
the presystemic circulation. 37 
There is growing evidence that aspirin modifies the cell-mediated immunologic 
response and cytokine production,8J but as yet we do not know how this may fit into the 
concept of maternal maladaptation to pregnancy. 
Prostanoids are also essential in the initiation and maintenance of parturition. Their 
release into amniotic fluid and maternal serum has been demonstrated in women in active 
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labor,"6 and exogenous prostaglandins ~ and F2~ stimulate uterine activity,lIS For that 
reason, pharmacologic inhibition of the cyc\ooxygenase enzyme could present a rational 
approach to suppress unwanted myometrial activity, and aspirin has been used as a 
tocolytic agent in cases of threatened or active preterm labor.'93 
Inhibition of pretenn labor 
After the publication in 1973 of the study of Lewis and Schulman as mentioned in 
the previous chapter, that showed prolongation of pregnancy and labor in women taking 
aspirin during the last 6 months of pregnancy, 1J4 aspirin was administered in daily doses 
from 6 g orally60 to 10 g intravenously'" for tocolytic treatment in patients with 
threatened or active preterm labor. In one report, the investigators claim successful 
inhibition for more than seven days in six out of 10 cases.'" Considering the availability 
of betamimetic adrenergic drugs as effective tocolytic agents and the potential hazards of 
high doses of aspirin (see below), there seems to be no indication for the use of aspirin in 
the treatment of premature labor. If the use of a cyc\ooxygenase inhibitor is indicated, 
indomethacin appears to be far more effective with less side.effects. "'.'65 
Hypertensive disorders and ietal growtlt retardation 
In 1979 results of a retrospective study suggested that preeclampsia occurred less 
frequently in regular aspirin users than in non-aspirin using pregnant women. 49 In two 
early anecdotal reports on treatment of established preeclampsia, relatively high doses of 
aspirin (1.5-1.8 g per day) were used."'''' Although platelet counts showed improvement, 
one of the two fetuses died after one week. In a later study, five preeclamptic and 
thrombocytopenic women received 85 mg of aspirin per day in divided doses." Platelet 
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Table 3.1 Characteristics of randomized controLled clinical trials of low-dose aspirine to prevent pregnancy-induced hypertensive disorders. 
Reference 
Beaufi ls et aL 
(12) 
Io'allenburg et al 
(265) 
Benigni et aL 
(14) 
Schiff et aL 
(218) 
McParLand et aL 
(149) 
Uzan et aL 
(247) 
IncLusion criteria 
History of compl icated 
pregnancy 
Vascular risk factors 
Normotensive primigravidae, 
positive A-II test at 
28 weeks 
History of compL i cated 
pregnancy 
Chronic hypertension 
Positive roil-over test in 
women at ri sk for pre-
eclamptic toxemia 
NuLliparous women with 
repeated abnorma L wave 
forms on DoppLer 
uLtrasound examination 
Poor obstetric history 
Exclusion criteria 
secondary hypertens i on 
Renal disease 
History of hypertension 
CardiovascuLar disease 
Antiphosphol i pid 
antibodies 
History of thrombocytopenia 
History of coaguLation 
disorders 
History of heart fai lure 
Chronic renal/pulmonary 
disease 
Hepatic disease 
Bleeding disorders 
Oiabetes mel L itus 
Systemi c Lupus 
erythematosus 
Twi n pregnancy 
Ren<ll disease 
Cardiovascular disease 
Diabetes 
Treatment protocoL 
ASA 150 mg/day plus 
dipyridamoLe 
300 mg/day from 
3 months untit 
del ivery 
ASA 60 mg/ day from 
28 weeks gestation 
unti L del ivery 
ASA 60 mg/day from 
12th week unti 1 
del ivery 
ASA 100 mg/day 
during the third 
trimester 
ASA 75 mg/ day from 
24 weeks untit 
deL ivery 
ASA 150 mg/day or 
ASA 150 mg/day plus 
plus dipyridamoLe 
225 mg/ day. from 
15-18 weeks unti 1 
delivery 
No. 
treated 
48 
23 
17 
34 
48 
156 
No. 
controls Placebo 
45 No 
23 Yo, 
16 Yo, 
31 Yo, 
52 Yo, 
73 y", 
CL inical 
end-points 
PIH, PE 
BW 
PIH, PE 
BW 
PIH, 51.' 
PIH, PE 
PIH, PE 
BW 
PIH, PE 
BW 
Cone 1 us ions 
significant reduction 
in PE and FGR 
with ASA 
Significant reduction 
of PE and PIH 
with ASA 
Significant increase 
in duration of 
pregnancy, and 
fetal weight with 
ASA 
Significant reduction 
in PIH and PE 
with ASA 
Significant reduction 
in PE and 
hypertens i on <: 37 
weeks wi th ASA 
Significant reduction 
in PE and FGR 
with ASA 
No. No. Cl inicat 
Reference IncLusion criteria Exclusion criteria Treatment protocoL treated controls pLacebo end-p:>ints Conclusions 
SchrocksnadeL Positive roLL-over test: Preexistent hypertension ASA 80 mg/day from 22 19 Yos PIH, PE Significant: reduction 
et at (220) between 28-32 weeks Impending deL ivery 28-32 weeks unt; L sw in PE and FGR 
Renal disease 38 weeks with ASA 
Hepatic disease 
Heart/punonary disease 
Menta L di sease 
Diabetes meLLitus 
NeopLastic i tness 
Abnonnat ultrasound 
Bodyweight ;> 100 kg 
Medication with anti-
cOilgutans/ana 1get: i C$ 
AcetyLsal ieyL ic at Lergy 
Ital ian Study Between 16 and 32 weeks ASA 50 lJIg/day unti L 5S3 523 No No difference in 
(107) and age under 18 or over deL Ivery PIH/PE, BW 
40 or 
Mild moderate h~rtension or 
NephroP<lthy or 
History of PIH/PE in 
prey; ous pregnancy or 
History of IUGR or 
Current twi n pregnancy 
Hauth et aL Between 20-22 weeks Renal disease ASA 60 mg/day unti L 302 302 Yos Significant reduction 
(91 ) Nulliparous collagen vascuLar disease del ivery in ?E 
Heal thy Diabetes meLLitus 
singLeton MuLti fetaL gestation 
Age under 28 years Chronic hypertension 
Sibai et aL Normotensive Chronic hypertension ASA 60 mg/day until 1570 1565 Ye, ?E, PIH Significant reduction 
(227) NuLLiparous RenaL disease del ivery in ?E 
Between 13-26 weeks Diabetes meLLitus 
ASA :;;:. aspirin; ?IH pregnancy-induced hypertension;?E preecLampsia; BIJ :;;:. birthweigt; FGR fetaL growth retardation 
counts improved but no improvement in fetal condition was observed, and two fetuses 
died. 
Until 1993 ten randomized, controlled clinical trials were executed and reported using 
low-dose aspirin for the prevention of pregnancy-induced hypertensive disease. 12.14. 
91.107.149.218.220.227.247.265 (Table 3.1). All patients entered were judged to be either at high 
risk based on obstetric historyI2,14,247 or tests and observations in the present 
pregnancy,107,149,218,220,265 or at moderate risk. 91,227 The dose of aspirin used varied from 
50 mg l07 to 150 mgI2.247 per day and aspirin was combined with dipyridamole in two 
studies.12.247 In seven trials aspirin was prescribed during the second and the third 
trimester of pregnancy,12,14,91,107,149,227,247 whereas it was used during the third trimester 
only in the remaining three trials. 218 ,220,265 All studies, except two,12,265 were placebo-
controlled. Because the study designs are comparable and criteria and end points are well 
defined, systematic pooling of the results across trials by means of meta-analysis" 
provides more precise estimates of the effects of treatment. IO) Differences for the 
distinctive items, in treated and non-treated groups, were accumulated and expressed as 
"odds ratios" with 95% confidence intervals. The results, covering 2803 treated and 2649 
untreated patients, are presented graphically in figure 3.3. The 95% confidence intervals 
for pregnancy-induced hypertension and perinatal mortali ty cross the line representing an 
odds ratio equal to 1. This means that only proteinuric hypertension (preeclampsia) and 
fetal growth retardation occur significantly less often in aspirin-treated pregnant women 
than in untreated controls. The reported data do not allow to distinguish between perinatal 
deaths related or unrelated to pregnancy-induced hypertensive disorders. A further 
analysis of the data shows that aspirin-treated women have an even chance of cesarian 
section. A striking observation in these controlled studies is the reduction in the incidence 
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of uteroplacental circulatory insufficiency with fetal growth retardation and a birth weight 
below the 10' centile in high risk women receiving low-dose aspirin; this finding reaches 
significance in the meta-analysis. 
Hypertension 
Proteinuria 
Birthweight 
< 10'h centlle 
Perinatal 
mortality 
+ 
0.05 0.1 0.2 0.4 1 
Odds Ratio 
Figure 3.3. Graphic oven'Je!l' of odds ratios and 95% confidcllce intervals of eft'eets of low-dose aspirill 011 
fhe occurrence of hyper/ellSioll, proleilluric hypertension (preeclampJia), alit! fein/-lleollatal sequelae from 
10 randomized cOlltrolled clinical trials (see Table 3,}). 
The positive effect of a low dose of aspirin on birth weight corrected for gestational age 
was also observed in a randomized placebo-controlled, double-blind study in a small 
group of patients with a clinical diagnosis of fetal growth retardation and an abnormal 
Doppler-flow pattern in the umbilical arteries. 243 Results of non-randomized, controlled 
studies in patients with a history of repeated idiopathic severe fetal growth 
retardation,'67.26' fetal death, lupus anticoagulant, anticardiolipin antibodies or systemic 
lupus erythematosus" support these findings (Table 3.2). On the other hand, prophylactic 
treatment with a low dose of aspirin appeared to have no effect on fetal growth in a small 
number of uncomplicated twin pregnancies.'" In contrast with the prophylactic studies 
discussed above, the potential benefits of treatment of established circulatory 
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maladaptation in pregnancy with a low dose of aspirin have hardly been investigated. 
Pregnancy-induced hypertension often occurs early in the third trimester, and if low dose 
aspirin treatment would result in even a moderate delay in the progression of the disease, 
this could have a significant impact on neonatal morbidity and mortality.'" Unfortunately, 
results of a recent randomized, double-blind trial in 47 patients with mild pregnancy-
induced hypertension using a daily dose of 100 mg of aspirin or placebo did not indicate 
any improvement in the hypertensive condition or delay in its progression to 
preeclampsia.217 There is certainly a need for further prospective trials on the therapeutic 
use of low dose aspirin in patients with clinical signs of a pregnancy-induced hypertensive 
disorder or fetal growth retardation. 
The evidence that low-dose aspirin restores a disturbed prostacyclin-thromboxane 
balance in pregnancy to the dominance of the vascular effects of prostacyclin by means of 
selective inhibition of platelet TXA, synthesis is supported by the results of three studies, 
showing that a daily dose of 6O-80mg of aspirin for between one and four weeks 
significantly increases vascular refractoriness to the vasopressor effectsof angiotensin II 
in pregnant women with an elevated'33.26' or physiological'13 angiotensin sensitivity. In 
contrast, oral ingestion of 650mg of aspirin twice with an interval of six hours between 
doses was shown to lead to a marked increase in angiotensin sensitivity,67 because in this 
dose aspirin inhibits the biosynthesis not only of TXA" but also of prostacyclin. 
In all clinical trials published no adverse effects attributable to low-dose aspirin were 
noted, in particular no clinically significant effects on maternal or fetal hemostasis, or on 
the fetal ductus arteriosus, although one study227 reported a slightly increased risk of 
abruptio placentae in aspirin-using pregnant women. 
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TabLe 3.2 Characteristics of cLinicaL triaLs of Low-dose aspirine to prevent fetaL growth retardation. 
No. No. 
Reference IncLusion criteria Exclusion criteria Treatment protocoL treated controLs Randomized PLacebo End-points Cone t us ions 
l.'aLLenburg and History of at Least 1-1.6 mg/kg/day of 2. 2. No No '0 Reduction in 
Rotmans previ ous pregnanci es ASA and 225 1119 of i nci dence of 
(267) with severe idiopathic dipyridamoLe dai Ly FOR 
FGR from 16 weeks untiL 
deL ivery 
ELder et at History of severe FGR ASA 75 1119/ day from .2 No No PE, 8\.1 'Striking' 
(65) and/or hypertension the fi rst or second iRl'rovement 
SLE trimester unti L of pregnancy 
unt; L deL ivery outcome 
Trudingcr et at Abnormal unbiLicaL Severe hypertension ASA 150 mg/day from 22 2. Ye, Yeo '0 Significant (243) artery wave forms on 28-36 weeks until increase in 
DoppLer uLtrasound deL ivery BI.' and head 
gestational age circumference 
between 28 and 36 
weeks 
Trudinger et aL Uncompl i cated twi n ASA 100 mg/day unti L 15 12 Yes Yeo '0 No effect of (242) pregnancy at 28-30 deL Ivery ASP. on 81.' 
FGR :; fetaL growth retardation; ASA = aspiriM; B\.I '" bil"thweight, SlE systemic Lupus erythematosus; PIli = pregnancy-induced hypertension 
The results of the meta-analysis of published trials indicate that prophylactic treatment 
with a low dose of aspirin to prevent preeclampsia and fetal growth retardation is 
effective and safe in women at risk. It should be emphasized that the patients in most of 
the clinical trials presented above were selected on the basis of a high risk, although some 
studies contained patients at small or moderate risk.n .227 A meta-aualysis of the results 
obtained in high-risk pregancies showed more pronounced results. 103 
Allliphospholipid alllibodies 
Lupus anticoagulant and anticardiolipin antibodies to negatively charged phospholipids 
have been identified in patients with systemic lupus erythematosus and other 
autoimmlTIune disorders, and also in patients without apparent disease. 222 There is a 
strong association between the presence of anti-phospholipid antibodies and an increased 
risk of spontaneous abortion, stillbirth, fetal growth retardation, preterm birth, and 
arterial and venous thrombosis. 21,27,59,200 
The lupus anticoagulant and other anti phospholipid antibodies interfere with prostacyclin 
synthesis by endothelial cells, leading to a relative dominance of platelet thromboxane 
action,31 and placental thrombosis and infarction. 26 
Lubbe et a!. reported successful pregnancy outcome in 80% of 25 patients after 
treatment with 40-60 mg prednisone and 75 mg aspirin daily.13'.139 Also other centers 
have reported good results with this combination,"·I67 but some have not." As yet no 
controlled studies are available to reliably assess the prophylactic and therapeutic effects 
of low-dose aspirin in pregnant patients with anti phospholipid antibodies. 
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3.4. Possible side-effects of the use of aspirin in pregnancy 
Gelleral 
The general side-effects that can be caused by ingestion of aspirin and other salicylates 
may also occur in pregnant women. Adverse effects such as gastric irritation, nausea, 
diarrhea, constipation, bronchospasm, effects on renal function, skin rashes, and angio-
edema are usually - but not always - associated with a high aspirin intake or with aspirin 
hypersensitivity. Aspirin may impair the effect of drugs which act by stimulating the 
synthesis of arachidonic acid metabolites. 52 Since they are not specific for pregnancy, 
these potential side-effects will not be reviewed. 
The effects of aspirin on hemostasis are not characteristic for pregnancy, they will be 
discussed in some more detail because of their important obstetric consequences. 
Pregnancy-specific complications of the use of aspirin may be due to unwanted effects of 
inhibition of prostanoid synthesis, such as prolongation of pregnancy and labor, and to 
transfer of the drug across the placenta leading to immediate or delayed disturbances in 
embryonic or fetal development and functions. 58 
Effects all maternal hemostasis 
The clinical test used most often to asses effects on hemostasis in vivo, determination of 
the skin bleeding time, has shown disparate results in aspirin users. Several authors have 
reported an increase in bleeding time in healthy nonpregnant volunteers after a single dose 
of 0.65-1.5 g of aspirin, 194.278 but Mielke'50 demonstrated that aspirin increased template 
bleeding time only if venous congestion was induced and a horizontal incision was made. 
Frith and Warlow17 analyzed 70 patients who had taken aspirin for prophylaxis of 
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thromboembolism for 35 months and could not demonstrate a significant difference in 
bleeding time between aspirin takers and controls. A daily low dose of 60 mg of aspirin 
during four months was shown to reduce platelet thromboxane generation to 10% of 
control values in a small group of pregnant women, but no significant prolongation of 
bleeding time was observed." Determination of the bleeding time is probably not a 
reliable test to use as a predictor of clinically significant bleeding in individual patients.206 
The effects of aspirin on hemostasis in various clinical conditions must be determined in 
properly designed clinical trials. 
Large studies on cardiovascular prophylaxis involving long-term use of aspirin in 
doses between 75 and 500 mg per day have not shown any relevant increase in bleeding 
tendencyyX),188,235,241 On the other hand, a recent report suggests a significant increase in 
blood transfusion requirements and in the need for hemostatic products after coronary 
artery bypass grafting in 101 patients using long-term prophylaxis with a daily dose of 75-
300 mg aspirin compared to 101 control patients not taking aspirin.2" A daily dose of 75 
mg of aspirin taken during 12 days was shown to cause an increase in gastric mucosal 
bleeding in healthy volunteers. 192 In a recent report Baker et al. 8 describe two cases of 
possible low-dose aspirin-induced gastropathy, one after 6 weeks of 75 mg aspirin daily in 
a pregnant woman with pregnancy-induced hypertension and one in a healthy woman 
taking 60 mg aspirin daily for 10 days who participated in a study of cyclooxygenase-
dependent platelet reactivity. Only few studies have specifically assessed the risk of 
maternal bleeding associated with the use of aspirin in pregnancy and peripartum. Lewis 
and Schulman l34 carried out a retrospective survey of 103 patients who took a daily dose 
of 3.25 g of aspirin or more during at least the last 6 months of pregnancy. Aspirin users 
had an average estimated blood loss at delivery of 340 ml, about 100 ml more than in 
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control groups not taking aspirin. Postpartum hemorrhage of 1000 ml or more occurred 
once in patients receiving aspirin and not in the control groups. 
It is the Australian study by Collins and Turner" that is most often cited to emphasize 
the bleeding risk associated with the regular consumption of aspirin and salicylate in 
pregnancy. During the 28 months of the study, 144 regular users of "analgesic powders" 
containing aspirin and salicylate combined with other drugs were identified by testing 
urine specimens. The user group was divided into 63 constant takers with a reported 
consumption of 2 to 12 powders per day, and 81 intermittent takers using an aspirin-
containing drug at least once a week throughout pregnancy. The rates of anemia 
(hemoglobin of 10.5 g% or less), antepartum and postpartum hemorrhage, and blood 
transfusion at delivery were significantly increased in the group of constant takers 
compared with controls matched for age and parity. Except for the incidence of anemia, 
the occurrence of these complications was also elevated in intermittent takers, although 
the difference with the control group was not significant. This study can be criticized on 
two main points. First, as part of an abusive habit the women not only used high doses of 
aspirin and salicylates, but also unknown amounts of "other drugs" which may have 
affected pregnancy outcome. Second, aspirin takers were clearly identified to the 
attendant obstetricians, which introduces an important potential observer bias, in 
particular because the amount of antepartum and postpartum hemorrhage appears to have 
been based on estimate rather than accurate measurement of blood loss. 
In 1982 Stuart et al.237 reported a prospective case-control study in which they 
evaluated the effects of ingestion of aspirin within 10 days of delivery on maternal and 
neonatal hemostasis. In the small subgroups of women who took 5 to 10 g of aspirin 
within five days of delivery (n = 10) or immediately postpartum (n = 7) they found slightly 
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lower postpartum hemoglobin levels. In several controlled studies involving pregnant 
women taking high doses of aspirin in the peripartum period for tocolysis" I•282 or 
antithrombotic prophylaxisl69 no major bleeding problems were observed during or after 
delivery. Recently, the possible association between maternal bleeding at delivery and 
aspirin exposure in the last to days of pregnancy has been assessed in a large set of data 
derived from the Collaborative Perinatal Project. 25 In 2269 women who took aspirin the 
estimated blood loss .at delivery was slightly less than that in 7606 women not exposed to 
aspirin. There has been no report of increased maternal bleeding tendency in the low dose 
aspirin studies in pregnancy carried out so far. 
A recent editorial l41 discusses the potential risk of epidural hematoma following 
epidural anesthesia in patients taking aspirin. It supports the earlier recommendation by 
O'Sullivan l78 that women taking aspirin during pregnancy should stop their medication 7-
to days before delivery and have a bleeding time performed before epidural block is 
undertaken. Certainly with regard to the use of low dose aspirin this advice appears to be 
based on theoretical considerations, rather than on reliable data with regard to the risks of 
aspirin use with extradural anesthesia. As pointed out earlier, the bleeding time test is a 
poor predictor of clinically significant bleeding. 206 
In conclusion, even a low dose of aspirin affects platelet function but the available 
clinical evidence does not support the theoretical increase in risk of bleeding in 
pregnancy, peripartum, Of in the puerperium in women taking aspirin in low or analgesic 
doses. 
Prolongation of pregnancy and labor 
Following the retrospective study by Lewis and Schulman I" showing a striking 
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increase in tile mean length of gestation and labor in women taking high doses of aspirin 
during the last 6 months of pregnancy (see chapter 2.3) Waltman et at. 27J demonstrated 
that 650 mg of aspirin, taken every six hours for ten doses, significantly prolonged the 
mean instillation-abortion interval in patients undergoing mid-trimester saline-induced 
termination of pregnancy. A prolongation of gestation in women taking aspirin was also 
reported by other authors, but in these studies no correction was made for induction of 
labor. 43 ,2J7 On the other hand, intravenous administration of I g of aspirin as an analgesic 
during labor apparently did not cause clinically relevant prolongation of the first stage of 
labor.20,154,252 
The few studies available suggest that therapeutic doses of aspirin taken in the last 
part of pregnancy and before delivery could be associated with some prolongation of 
pregnancy and labor. Not only the dose of aspirin but also the interval between the last 
dose and the beginning of labor will be important because, as discussed earlier, 
prostaglandin synthesis in myometrial cells and decidua may be expected to recover 
rapidly. 
Teratogenic ejJects 
Teratogenic effects attributed to salicylates were first reported in the late fifties by 
Warkany and Takacs,276 who found that injection of extremely high doses of salicylates in 
pregnant rats resulted in a variety of fetal malformations, in particular craniorachischisis. 
Their findings were confirmed in many other studies in rodents. In all animal experiments 
the dose of aspirin required to achieve even a small proportion of malformed offspring 
was close to that causing embryonic or maternal death; the extrapolated dose in the 
human would have to be in the order of magnitude of 30 g per day. Warkany, speaking at 
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the Ciba Symposium on Congenital Malformations in 1960, emphasized how cautious one 
should be in applying the results of laboratory experiments to the problem of human 
malformations, and added: " If we are not careful we may hear very socn that aspirin 
causes malformations. ,,' That was exactly what happened, based on the results of four 
large case-control studies and some case histories. 
Richards'o, examined the drug histories of 833 women with infants with congenital 
malformations, and compared them with those of matched controls with healthy children. 
The reported use of aspirin in the study group was 22% as compared with 14% in 
controls. However, the only defect with a significantly higher occurrence in aspirin users 
was talipes. In a retrospective study with a similar design Nelson and Forfar'63 also found 
a small but significant excess of aspirin taking in mothers with malformed infants as 
compared with control women who delivered children without malformations. In another 
case-control study Saxen'" found that 14.9 % of 599 mothers with children with oral 
clefts had taken salicylates during the first trimester, which was nearly three times more 
than the 5.6 % reported by control mothers. The results of a retrospective study involving 
300 mothers of children with congenital heart disease suggest a small excess of aspirin-
taking as compared to controls; however, the difference is only statistically significant if 
aortic stenosis, coarctation of the aorta, and hypoplastic left heart syndrome are 
considered together. 183 We found five case reports on a possible association of aspirin 
taking with congenital malformations in which 12 infants are described with various 
malformations such as cyclopia, phocomelia, nephro-blastomatosis and others.2,13,19,148,216 
All these studies indicating a small increase in the risk of teratogenicity associated with 
aspirin taking in pregnancy were designed as case-control studies" after the fact": data on 
aspirin exposure were collected after the birth of the (malformed) baby. Such a study 
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design is known to be liable to a great number of potential biases. Important confounders 
are drug recall, which may be more complete in women with an abnormal infant than in 
control women with healthy babies, and observer bias because the interviewers are aware 
of Ihe oulcome of pregnancy." This bias was avoided in Ihe large cohorl sludy by Slone 
el al. 231 based on data from Ihe Collaborative Perinatal Project. In this project all dala 
concerning drug exposure were collecled before birth. After controlling for a wide range 
of potential confounding factors no differences were demonstrated between the occurrence 
of congenilal malformations in children of 5,128 heavily exposed mothers who took 
aspirin at least eight times in any of the first four monlhs of pregnancy, in 9,736 children 
of mothers who took aspirin less frequently, and in 35,418 children whose mothers were 
not exposed to aspirin during the first four months of pregnancy. No single malformation 
occurred more frequently in the aspirin groups Ihan in women who had not used aspirin. 
For example, the relative risk of cardiovascular malformations in the heavily exposed 
group was 0.75, that of central nervous abnormalities 0.94. The large numbers involved 
make this a very powerful study. Another large study analyzed prescriptions issued to 
approximalely 10,000 women by general practitioners between 8 weeks before and 20 
weeks after conception.51 The investigators noted a 6 % excess of general prescriptions 
issued to women who were delivered of a congenitally malformed baby compared to the 
rest of the population. However, fewer prescriptions for aspirin containing medications 
than expected were issued to women with a malformed baby, although the difference was 
not statistically significant. Although additional drug taking without prescription was 
recorded, the use of "over-the-counter" aspirin may well have been underreporled. Turner 
and Collins"6 reported major congenital abnormalities in 6 of 144 infants of mothers who 
regularly look several grams of salicylates during pregnancy. This rate did not differ 
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significantly from that found in a group of matched controls not exposed to aspirin. The 
possible association between aspirin taking in pregnancy and cardiac abnormalities was 
recently assessed by Werler et al. 277 The use of aspirin in the first trimester of pregnancy 
reported by mothers of 1,381 affected children was compared with that among the 
mothers of a control group of 6,966 infants with other malformations. No excess of 
aspirin taking was apparent in the group of mothers with offspring with cardiac 
malformations. 
We conclude that evidence obtained in large prospective studies, in particular the 
Collaborative Perinatal Project, indicating that aspirin in therapeutic doses is not 
teratogenic outweighs data from retrospective case-control studies, case reports and 
animal studies suggesting that the use of extremely high doses of aspirin in pregnancy 
may be associated with a (small) increase in the relative risk of various fetal 
malformations. 
Effects on felal and neonalal hemoslasis 
The hemostatic mechanisms of the newborn are immature; it takes six to nine months 
before they have become comparable to those in adult Iife.'44 In the healthy neonate this 
does not seem to cause clinical problems,80 but in the case of transplacental exposure to 
maternal aspirin the risk of bleeding could be increased, in particular in the ill or 
premature infant. The first report relating maternal aspirin ingestion and neonatal bleeding 
was published in 1948108 and described a case of fatal neonatal cerebral hemorrhage after 
a maternal suicide attempt with 200 g of aspirin. Two later anecdotal reports""o also 
relate an excessively high maternal aspirin intake to severe neonatal hemorrhage. In 1970 
Bleyer and Breckenridge l ? compared the occurrence of neonatal bleeding in 14 infants 
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whose mothers took more than 300 mg of aspirin in the week before delivery and in 17 
newborns who were not exposed to aspirin in any form during three weeks before birth. 
In the exposed group three of 14 newborns had minor bleeding problems compared with 
only one baby in the control group. This is a well-designed study because drug histories 
were taken before delivery and the neonates were assessed without knowledge of maternal 
aspirin taking, but the numbers are too small to draw firm conclusions. A larger 
prospective study was reported by Rumack et al. in 1981.210 They investigated 108 infants 
born at or before 34 weeks' gestation or weighing 1500 g or less. The mothers' drug 
history was taken on the second day after delivery and the mothers of 17 infants appeared 
to have taken one or more aspirin tablets within one week of delivery; 20 infants had 
been exposed to acetaminophen; and 71 infants had no antenatal exposure to aspirin or 
acetaminophen. Between 3-7 days after birth all infants underwent brain scanning. Twelve 
of the newborns in the aspirin group (71 %) showed evidence of cerebral hemorrhage, 
compared with 50% in the acetaminophen and 44% in the control group. The authors 
conclude that aspirin taken late in pregnancy causes a significant increase in the risk of 
intracranial hemorrhage in the newborn and they state that " ... the use of aspirin during 
the last three months of pregnancy is highly questionable and probably inappropriate." 
The conclusions of this study have been challenged and defended."·232 An important point 
of criticism was that differences were only statistically significant at the 5 per cent level 
when a one-tailed Fisher test was used, and not when the correct two-tailed test was 
applied.'" On the other hand, Corby" defended the study in an Editorial comment, 
stating that the interest of the clinical investigator is not equal to that of the statistician. 
The results of the study by Rumack et al. were supported by Stuart et a1.,237 who reported 
neonatal bleeding consisting of petechiae and microscopic hematuria in nine of 10 infants 
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whose mothers used 5-10 g of aspirin within five days of delivery; also these authors 
warn against taking aspirin in pregnancy and at delivery. In contrast, several other studies 
have not shown an association between high maternal aspirin ingestion and neonatal 
bleeding."1.169.282 Although long term maternal lise of a low dose of aspirin has been 
shown to inhibit fetal platelet thromboxane synthesis,14 no neonatal bleeding was noted in 
any of the low dose aspirin studies reported. 
The most powerful study on this issue so far is that by Brent et al. 25 based on a large 
data base from the Collaborative Perinatal Project. Term and preterm babies were 
assessed separately and no differences were found between infants of mothers who had 
taken aspirin within 10 days of delivery and infants not exposed to aspirin with regard to 
the incidence of cerebral hemorrhage, neonatal hemoglobin and hematocrit. This study 
has the statistical power to have an 80 per cent chance of showing an increase in the rate 
of cerebral hemorrhage from the background 0.2 to 0.6 per cent, a I ml blood loss, and a 
0.4 per cent fall in hematocrit." 
In conclusion, results obtained in one large study in women using analgesic doses of 
aspirin" and clinical experience in trials of low dose aspirin do not support the view that 
maternal aspirin taking is associated with an increase in fetal or neonatal bleeding risk, 
except perhaps in case of intoxicating doses. 
Flfecls Oil Ihe dl/clIIS anerioslIs alld pl/lmollo/Y cil'ClIlalioll 
The physiology of the regulation and modulation of the patency of the ductus 
arteriosus during fetal and neonatal life was recently reviewed."o Patency of the ductus 
appears to be maintained by the relaxing effects of prostaglandin E, and prostacyclin 
produced in the ductal wall. In the newborn contraction of smooth muscle in the wall of 
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the ductus due to the combined effects of increasing oxygen tension and decreasing 
prostanoid synthesis results in functional closure between 10-96 hours after birth. The 
actual constrictor mechanisms remain to be defined." Prostanoids are also involved in the 
vascular dilation that takes place in the neonatal lung immediately after birth to allow an 
increase in blood flow to the expanding lungs at a low perfusion pressure."·33.,. 
The recognition of the important role of eicosanoid action in keeping the ductus open 
in fetal life has led to the use of the cyclooxygenase inhibitor indomethacin as an effective 
pharmacologic tool in the treatment of patent ductus arteriosus in the, usually premature, 
neonate. 79 For the same reason, fetal cyclooxygenase inhibiton may be expected to carry a 
risk of premature constriction or perhaps even closure of the ductus, with diversion of 
right ventricular outflow into the pulmonary vascular bed. Increased pulmonary blood 
flow may result in pulmonary arterial hypertrophy.'2'.'2' In addition, cyclooxygenase 
inhibition at birth could interfere with pulmonary vasodilation and lead to pulmonary 
hypertension and right heart failure. Indeed, such effects have been shown to occur after 
high doses of aspirin and indomethacin in experimental animals"·'2'.225 and, although 
rarely, in pregnant women treated with indomethacin for tocolysis.I30.250 High fetal levels 
of acetylsalicylic acid are needed to produce measurable effects on the fetal circulation. 
For instance, in their studies in chronically catheterized fetal lambs Heymann and 
Rudolph had to administer 50-90 mg of aspirin per kg of fetal weight directly into the 
fetal stomach to obtain reversible constriction of the ductus arteriosus." It is unlikely that 
such levels can be reached in human pregnancy, even with maternal intake of toxic 
amounts of aspirin. 
Only three reports are available, involving nine infants, to examine the clinical 
evidence of an association between the use of aspirin in pregnancy and effects on the fetal 
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ductus and pulmonary circulation. Arcilla et al. 7 describe a baby with severe neonatal 
cardiorespiratory distress born at 37 weeks' gestation from a mother treated for two 
weeks with "salicylates" and penicillin for acute polyarthritis; the dose of salicylate is not 
stated. Hemodynamic studies at four hours of age showed a ductus arteriosus which ended 
blindly at its aortic end. The authors conclude that this represents a case of premature 
closure of the fetal ductus. Levin et al. 128 report autopsy findings in an infant whose 
mother took 1.2-1.6 g of aspirin per day throughout pregnancy. The baby showed all the 
features of premature closure of the ductus as well as hypertrophy of the pulmonary 
artery and tricuspid insufficiency. Finally, Perkin et al. 184 relate maternal use of aspirin in 
pregnancy to persistent pulmonary hypertension in seven newborns with high salicylate 
levels and no ductus shunt. 
Larger clinical studies in women using therapeutic doses of aspirin have not revealed 
any evidence of premature constriction or closure of the fetal ductus, although this 
complication was usually not specifically examined,.,·I'. The observation that maternal 
use of aspirin in the last two weeks of pregnancy is associated with a reduction in the 
incidence of patent ductus arteriosus in small preterm babies" cannot be used to support a 
putative increase in the risk of closure of the fetal ductus in utero. Doppler 
echocardiography has not shown any evidence of constriction of the ductus arteriosus in 
30 women receiving a low dose of aspirin in the last 2-3 weeks of pregnancy.229 A recent 
study on daily maternal low-dose aspirin intake did not show an effect on central or 
regional circulation in the fetus. 1S1 No neonatal cardiovascular or pulmonary complica-
tions were noted in the low-dose aspirin studies reported so far. Wallenburg et al. 265 
specifically mention that autopsy findings in a stillborn baby from a mother taking a daily 
dose of 60 mg of aspirin from 28 to 41 weeks did not show any abnormalities of the 
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ductus or the pulmonary vasculature. 
In conclusion, although high doses of aspirin can cause constriction of the ductus 
arteriosus and cause pulmonary hypertension in the fetal lamb, clinical evidence does not 
support the occurrence of this complication in human pregnancy. If some degree of 
constriction of the fetal ductus would occur, it could well be reversible after birth 
following discontinuation of cyclooxygenase inhibition.82•m All this makes it extremely 
unlikely that premature closure of the fetal ductus arteriosus is a risk associated with the 
use of the low doses of aspirin recommended for the prevention of gestational 
hypertensive disorders and fetal growth retardation. 
Miscellaneolls 
Drugs taken by the pregnant woman and transferred across the placenta could have 
delayed effects on development and function later in life. Learning impairment in the 
offspring of rats treated with salicylate was reported by Butcher et ai. 30 They state that 
aspirin may act as a "behavioral teratogen" by inhibiting learning in the offspring at 
maternal doses too low to produce anatomical malformations. In another study in rats, 
Voorhees et al. 258 observed developmental delays in offspring produced by a single high 
dose of aspirin on day 11 of gestation. 
In a prospective follow-up study by Streissguth et al. 236 of 1,529 women exposed to 
drugs in pregnancy, aspirin and acetaminophen were the medications most frequently 
taken. A cohort of 421 of their children was examined at four years of age and a tenpoint 
decrement in intelligence quotient (IQ) was observed in children with antenatal aspirin, 
but not acetaminophen, exposure; girls were more affected than boys. The authors 
emphasize that the study was not undertaken to examine the possible adverse effects of 
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aspirin or acetaminophen exposure in utero; the observed relationship was a post hoc 
finding. In a study that was designed to assess the relationship between maternal aspirin 
intake during the first 20 weeks of pregnancy and the child's IQ at four years of age, Kle-
banoff and Berendes1l9 examined data relating to a prospective multicenter study on 
pregnancy and child development as part of the Collaborative Perinatal Project. In these 
19,226 pregnancies, 10,159 women were exposed to aspirin during at least the first 20 
weeks of pregnancy; the control group consisted of 9,067 women who did not report any 
use of aspirin at the initial antenatal visit. The mean IQ at four years of age in children 
exposed to aspirin was 2.1 points higher than that in unexposed children. Although this 
difference is statistically highly significant, it seems practically irrelevant and the authors 
emphasize that the results should not be interpreted as claiming that antenatal aspirin 
exposure has a beneficial effect on child development. However, this prospective and 
powerful study makes an adverse effect of aspirin exposure on IQ unlikely. 
In 1963 Reye et al. 20l described the clinical and pathological features of a group of 21 
children with a disease that has become known as Reye's syndrome: acute encephalopathy 
with fatty degeneration of the viscera. Exogenous toxin exposure was suggested as a 
likely cause of the syndrome. 239 Epidemiologic evidence has linked the disease to the use 
of aspirin.",I68 Although there are two case-reports of possible Reye's syndrome in 
neonates,88,179 no association has ever been described between maternal aspirin usage and 
the syndrome in the newborn. 
The occurrence of retrolental fibroplasia has been reported in a neonate whose mother 
used unspecified doses of aspirin throughout pregnancy; no other cases have been 
published since.219 
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3.5 Conclusions 
Aspirin has been around for almost a century and even today it appears to be 
frequently taken in pregnancy as a mild analgesic, usually without a prescription. 
Although the use of over-the-counter drugs should be discouraged, in particular in 
pregnancy, a large body of observational data has provided no scientific evidence that 
therapeutic doses of aspirin are associated with teratogenicity, increased maternal or fetal 
bleeding tendency, premature closure of the ductus arteriosus, or any other complication 
of pregnancy. 
Meta-analysis of the results of 10 controlled trials involving over 5400 pregnant women 
with various risk factors indicates that selective inhibition of platelet thromboxane 
synthesis with a low daily dose of aspirin in the second and third trimester may 
significantly reduce the incidence of proteinuric preeclampsia and low birthweight but not 
pf nonproteinuric gestational hypertension. It should be realized that six of the 10 trials on 
which this evidence is based comprised fewer than 200 women; that the risk varied 
between low and very high; that the doses of aspirin used varied from 50 to 150 mg per 
day, and that prophylactic treatment was started at any time between early in the second 
and early in the third trimester (Table 3.1). The occurrence of publication bias favoring 
positive results of low-dose aspirin prophylaxis cannot be excluded. 
No reliable data are yet available with regard to the prophylactic effects of low dose 
aspirin in pregnant women with anti phospholipid antibodies. Also the potential benefits of 
therapeutic low dose aspirin in women with established pregnancy-induced hypertensive 
disease or fetal growth retardation remain to be investigated. Although there are no 
apparent maternal and fetal hazards associated with the use of low dose aspirin in 
pregnancy, we feel that low dose aspirin prophylaxis should not be adopted into routine 
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obstetric practice until more reliable risk-benefit ratios have been determined in a large 
randomized, placebo-controlled clinical trial. 268 
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Chapter 4 
LOW-DOSE ASPIRIN IN PREGNANCY: CHANGES 
IN PATTERNS OF PRESCRIPTION IN THE 
NETHERLANDS* 
4.1. Introduction 
Aspirin, acetylsalicylic acid, is one of the most frequently consumed drugs, also in 
pregnancy. It is usually taken without a prescription as an over-the-counter drug for 
minor ailments. Until recently many gynecologists warned against the use of aspirin in 
pregnancy, based on a general tendency to advice against all drug taking in pregnancy as 
well as on fears of specific complications of aspirin, such as teratogenic effects, maternal 
and fetal hemorrhage, and premature closure of the fetal ductus arteriosus." This attitude 
may be changing following the publication of reports that a daily low-dose of aspirin may 
prevent the occurrence of preeclampsia and fetal growth retardation in women at risk, and 
could reduce the severity of these complications once they have developed."·lo3 In order 
to assess the effect of these reports on patterns of prescription of low-dose aspirin for 
preventive and therapeutic use in high-risk pregnancies an anonymous written inquiry was 
held among practicing gynecologists in the Netherlands in 1989 and repeated in 1991. The 
results of both inquiries were analyzed and compared. 
* 11/e main substallce of Ihis chapter was published ill: Bremer HA, \Val/ellhurg ReS. Low-dose aspirin ill 
pregnancy: changes in patterns of prescriptioll ill Vie Netherlallds. Ellr J Ohsfel Gyl/eeo! Reprod Bioi 
1993; 52: 29-33. 
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4.2 Material and Methods 
In April 1989 a questionnaire was sent to each of the 38 university and university-
affiliated hospitals in the Netherlands with a postgraduate training program in obstetrics 
and gynecology, and to the 122 hospitals with an obstetric unit but without a postgraduate 
training program. These hospitals represent 275 and 344 gynecologists, respectively. In 
May 1991 an identical questionnaire was sent to the then functioning 28 training hospitals 
(240 gynaecologists) and 120 non-training hospitals with an obstetric unit (378 gynecolo-
gists). The inquiry was anonymous. A reminder was sent to all hospitals three weeks after 
the initial mailing. The questionnaire differentiated between prophylactic prescription of a 
low-dose of aspirin to prevent pregnancy-induced hypertension (PIH), proteinuric 
preeclampsia (PE), and fetal growth retardation (FGR), and therapeutic prescription with 
the intention to treat these complications. Other questions concerned the number of 
pregnant women that actually had been prescribed low-dose aspirin in the previous four 
months, indications for prescription, type and dose of aspirin, and the duration of aspirin 
taking during pregnancy. General questions referred to the number of gynecologists 
practicing in the obstetric department, to whether or not the reply was given on behalf of 
other gynecologists in the department, and to the annual number of deliveries. 
4.3 Results 
The response rate to both inquiries was similar; 83 forms (52%) were returned in 
1989, and 86 (58%)in 1991. Considering hospitals with postgraduate training in obstetrics 
and gynecology, and those without a training program, responses were 74% and 43%, 
respectively, in 1989 and 64% and 57% in 1991. With few exceptions the responding 
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departments stated that they replied on behalf of all gynecologists practicing in that 
department. Converting the response rates into numbers of gynecologists, the inquiry 
comprised 377 (61 %) of the practicing 619 gynecologists in the Netherlands in 1989 
(training 69%, non-training 54%) and an almost equal number (383 or 62%) in 1991 
(60% and 63%, respectively). 
In 1989 53% of the respondents had prescribed low-dose aspirin for prevention of 
PIH-PE and FOR in the previous four months (training 50%, non-training 56%). In 1991 
these figures had increased to 79% of the respondents in the same period of time (training 
73%, non-training 83%). In 1989 25% of the responding gynecologists had prescribed 
low-dose aspirin with therapeutic intentions in the previous four months (training 26%, 
non-training 24%); in 1991 the figures rose to 48% (50% and 45%) in the same period of 
time. The main indications for prophylactic prescription of low-dose aspirin were a 
history of PIH-PE in one or more previous pregnancies, FOR in one or more previous 
pregnancies, or an increased risk of developing PIH-PE in the presence of chronic 
hypertension, lupus anticoagulant, or systemic lupus erythematosus. In table 4.1 these 
indications are compared for 1989 and 1991. The differences between 1989 and 1991 are 
small with regard to the main indications for which Dutch gynecologists prescribed low-
dose aspirin in pregnancy, but in 1991 gynecologists involved in postgraduate training 
show a distinct trend towards prescribing low-dose aspirin for prophylactic purposes in 
patients with a lower risk as judged from their obstetric history. 
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Table 4.1. Percentage of respondents in postgraduate training and non-training hospitals in the Netherlands in 1989 and 1991 
accepting indications to prescribe Low-dose aspirin in pregnancy for prophyLaxis of pregnancy-induced hypertension, 
preecLampsia, and fetal growth retardation. 
Indications Training hoseitnLs Nontraining hosg:itaLs TotaL 
1989 1991 1989 1991 1989 1991 
(n=96) (n=106) (n=105) (n=199) (n=201 ) (n=305) 
History of PIH'PE 65% 70% 64% 55% 64% 63% 
in 1 pregnancy 14% 35% 26% 28% 20% 32% 
in ~ 2 pregnancies 51% 35% 38% 27% 44% 31% 
History of FGR 94% 87% 99% 94% 97% 91% 
in 1 pregnancy 53% 56% 68% 66% 56% 61% 
in ~ 2 pregnancies 41% 31% 31% 28% 41% 30% 
History of essentiaL 72% 74% 56% 67% 64% 71% 
hypertension, 
renaL hypertension 
SlE, lupus anticoaguLant, 
antiphosp/'loL ipid antibodies 
with obstetric history 29% 46% 14% 7% 21% 27% 
without obstetric history 43% 28% 42% 60% 42% 44% 
n ::; m.l'Ilber of prescribing respondents; % = percent of nlJflber of respondents. PIH = pregnancy-induced hypertension; 
PE = preecLampsia; FGR = fetaL growth retardation; SlE = systemic Lupus erythematodes. 
The main indications to prescribe low-dose aspirin for therapeutic reasons were PIH-
PE and FGR. Additional indications comprised a variety of disorders, including 
coagulation problems. The therapeutic indications are summarized in Table 4.2 and show 
marked differences in prescription patterns in 1989 and 1991 between gynecologists 
involved and not involved in a postgraduate training program. In departments with 
postgraduate training, prescription of low-dose aspirin for treatment of PIH fell to zero, 
whereas almost half the number of responding gynecologists not involved in postgraduate 
training continued to prescribe low-dose aspirin on that indication. On the other hand, the 
percentage of gynecologists prescribing low-dose aspirin for treatment of FGR rose from 
20 to 54 in postgraduate training departments, and fell from 82 to 60 in departments 
without a training program. The number of gynecologists using low-dose aspirin to treat 
various other conditions in pregnancy almost tripled between 1989 and 1991. 
In 1989 and in 1991 more than 90% of the respondents who prescribed aspirin used 
tablets or capsules of acetylsalicylic acid in daily doses ranging from 60 to 80 mg. 
The remaining 10% prescribed calciumcarbasalate in comparable doses. The gestational 
age at the start of prophylactic low-dose aspirin showed a marked shift between the years 
of the inquiry. In 198924% but in 1991 only 6% of the respondents prescribed low-dose 
aspirin before 12 weeks'gestation, whereas in 1989 39% and in 1991 63% started 
between 12 and 14 weeks; the remaining respondents prescribed low-dose aspirin between 
15-20 weeks in both years. In 1989 and 1991 40% would stop prophylactic treatment 
between 36 and 38 weeks 'gestation , and 60% would continue until delivery. 
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TabLe 4.2. Percentage of respondents in postgraduate training and nontraining hospitals in the NetherLands in 1989 
and 1991 accepting indications to prescribe Low-dose aspirin for treatment of obstetric cOfq:lL ications. 
Indications Trainins hospital Nontrainins hospital ~ 
1989 1991 1989 1991 1989 1991 
(n=50) (n=72) (n::044) (n=108) (no:94) (n=180) 
Pregnancy- induced hypertens i on 52% 0% 39% 48% 46% 24% 
P reec Lamps i a 52% 44% 39% 23% 46% 34% 
FetaL growth retardation 20% 54% 82% 60% 49% 57% 
Other 24% 44% 0% 27% 13% 36% 
n '" number of prescribing respondents; % :: percent of nunber of respondents. 
The total annual number of deliveries supervised by all respondents was 73,800 in 
1991. Of those, 65,610 took place in hospitals were aspirin was being prescribed, and 
8190 in hospitals were aspirin was never prescribed for obstetric indications. The 
hospitals where patients were offered prophylactic aspirin treatment had an annual 
delivery rate of 58,560; hospitals offering therapeutic treatment had an annual rate of 
36,660 deliveries. In the first four months of 1991 the respondents prescribed 
prophylactic low-dose aspirin in approximately 550 patients, and 171 received therapeutic 
low-dose aspirin, which results in a calculated preventive treatment rate of 2,8% and a 
therapeutic treatment rate of 1,4 % in the hospitals where aspirin was being prescribed for 
obstetric reasons. In 1989 these figures were 1,4% and 1,0%, respectively. 
4.4 Discussion 
The response to both inquiries was only 50-60%, comprising approximately 60% of 
all practicing gynecologists in the Netherlands, and it cannot be accepted that prescription 
patterns of respondents and nonrespondents are similar. Since the inquiry was anonymous, 
we do not know whether or not the gynecologists who responded in 1991 were the same 
as those who returned the questionnaire in 1989. For that reason, conclusions concerning 
the general attitude of Dutch gynecologists with regard to prescription of low-dose aspirin 
in pregnancy should be drawn with care. Between 1989 and 1991 a striking increase of 
about 25 % appears to have occurred in the number of gynecologists prepared to prescribe 
low-dose aspirin in pregnancy for prophylactic or therapeutic reasons. The increase was 
similar in departments with and those without a postgraduate training program. The rapid 
increase in popularity of the prophylactic use of low-dose aspirin in pregnancy may be 
explained by the publication in the period of time covered by the inquiries of the 
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promising results of three randomized controlled clinical trials. 14 ,149,218 However, the 
single controlled study published in the same period of time on the therapeutic use of low-
dose aspirin showed no effect on the clinical course of pregnancy-induced hypertension. 217 
The trend towards prescribing prophylactic low-dose aspirin in patients at relatively lower 
risk of PIH-PE and FGR noted in departments with a postgraduate training program 
cannot be explained on the basis of published reports of controlled trials, which have all 
involved high risk patients.24 ,103 
The rapid increase in the Netherlands in the prescription rate of low-dose aspirin in 
pregnancy that is apparent from our inquiries could indicate that a growing number of 
gynecologists are already becoming convinced that such treatment could have beneficial 
prophylactic and even therapeutic effects, although little more evidence has recently 
become available. This may, in part, explain the steady reduction in the number of 
patients recruited for the randomized, double-blind international Collaborative Low-dose 
Aspirin Study in Pregnancy (CLASP), in which 20 centers in the Netherlands participate. 
The same phenomenon has been observed in other countries; in New Zealand the CLASP 
trial could not start at all, because gynecologists and patients were already convinced that 
low-dose aspirin in pregnancy is effective, and they refused on ethical grounds to 
participate in a placebo controlled study. 100 It is well possible that recruitment for 
participation in the CLASP trial among Dutch gynecologists, that started after the first 
questionnaire was sent out in 1989, has in itself contributed to the increasing belief in the 
effectivity of prophylactic low-dose aspirin. However, this remains speCUlative, because 
we have no information on the participation in the CLASP trial of respondents to the 
inquiries. 
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Chapter 5 
CLASP: A COLLABORATIVE LOW-DOSE ASPIRIN 
STUDY IN PREGNANCY FOR THE PREVENTION 
AND TREATMENT OF PREECLAMPSIA AND 
FETAL GROWTH RETARDATION* 
In chapter three it was concluded that low-dose aspirin should not be adopted into 
routine obstetric practice until reliable risk-benefit ratios have been determined in large 
clinical trials. 
In March 1986 Doctors Collins, Grant and Redman from Oxford, de Swiet from 
London, and Wallenburg from Rotterdam, discussed the design of a randomized, double-
blind, placebo-controlled, multicenter intervention study on the prophylactic and 
therapeutic effects of daily low-dose aspirin in pregnancy. Their discussion resulted in a 
protocol of a Collaborative Low-dose Aspirin Study in Pregnancy (CLASP) that was 
submitted to the UK Medical Research Council (MRC) for financial support in August 
1987. 
* The main substallce of this chapter was published ill,' CLASP Collaham/h'e Group. CLASP; a 
randomised trial oj low~dose aspirill for fhe pre~'ellfioll alld treatmelll oj pre-eclampsia amollg 9364 
pregl/ollt women. Lalleel 1994,' 343: 619-29. Paris oflhe article are quoted \'erbatim with pennissioJl. 
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The trial would be organized and coordinated by the National Perinatal Epidemiology 
Unit and the Clinical Trial Service Unit in Oxford. The Clinical Trial Service Unit and 
the Radcliffe Infirmary switchboard would provide a 24-hour randomization service. A 
first meeting of potential collaborators was held at the Royal College of Obstetricians and 
Gynaecologists in september 1987. 
The MRC endorsed the study and agreed to fund it for three years. Additional support 
was obtained from the Clinical Trial Service Unit (Oxford), Sterling Winthrop, Bayer 
Europe, and the European Aspirin Foundation. The first woman was recruited into the 
trial in January 1988. 
CLASP became an international study with the participation of Hong Kong and 
Canadian centers in October and November 1988. Also many obstetric centers in The 
Netherlands showed an interest to participate in the trial. Because it was thought that the 
recruitment in the Netherlands would benefit from the appointment of a national study 
coordinator, an application for funding of a Dutch study coordinator was submitted to the 
Dutch Preventiefonds, but was rejected. Fortunately, financial support by Bayer, 
Leverkusen, made it possible in July 1989 to appoint a Duch study coordinator (the 
author of this thesis) and to establish a Coordinating Center in the Department of 
Obstetrics and Gynecology of the Erasmus University Hospital-Dijkzigt. The first Dutch 
centers joined in 1989 and twelve more countries started their participation during the 
course of the study. 
The results of the CLASP trial were reported in an article published by the CLASP 
Collaborative Group in The Lancet in March 1994;38 that article forms the basis of this 
chapter. All parts of this chapter that are quoted from the article are marked with '. 
Because of concern expressed by the CLASP Steering Committee that analysis of the 
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results at a national level might give misleading information, at variance with the whole 
trial, and because individual countries had been recruiting patients into the trial to 
provide a global result, it is not possible to present a separate analysis of the results of 
the patients reeruited in the Netherlands. For that reason, the overall results of the trial 
will be presented and discussed, but data on the Dutch participation in the trial will be 
included where possible and relevant. 
5.1 Intl'oduction' 
Preeclampsia is a common complication of the second half of pregnancy that can 
progress to various dangerous maternal crises. It can also cause intrauterine growth 
retardation (IUGR), fetal death, and, because elective delivery remains the only effective 
management approach, neonatal death due to complications of prematurity. Preeclampsia 
originates in the placenta, probably as the result of under-perfusion of the uteroplacental 
circulation associated with structural and occlusive changes in the spiral arteries. 197 Some 
cases of fetal growth failure without maternal hypertension show the same spiral artery 
lesions, which suggests that these cases may differ from preeclampsia only in the 
maternal response to a common placental pathology. 196 Consequently, if prophylaxis 
against preeclampsia were effective, it might prevent not only that disorder but also some 
cases of IUGR without overt preeclampsia. 
Preeclampsia is associated with deficient intravascular production of prostacyclin and 
with excessive production of thromboxane." These findings and the evidence for 
activation of the clotting system in preeclampsia and IUGR with early involvement of the 
platelets I" have led to the use of antiplatelet agents (usually low-dose aspirin) in an 
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attempt to prevent, or ameliorate, the condition. Even a moderate delay (eg, I or 2 
weeks) in the development of severe preeclampsia could be important, since neonatal 
survival at the beginning of the third trimester improves rapidly with increasing maturity. 
Low-dose aspirin (60-150 mg per day) is a widely used and well-tolerated antiplatelet 
treatment, which irreversibly inhibits almost all platelet cyclooxygenase activity, thereby 
blocking synthesis of the vasoconstrictor and platelet- aggregating agent thromboxane. In 
preeclampsia, aspirin can to some extent rectify the intravascular imbalance between 
thromboxane and prostacyclin.218 The first anecdotal report of the use of aspirin to 
prevent preeclampsia" was followed by several small controlled trials reporting large 
reductions in the incidence of proteinuric preeclampsia with low-dose aspirin (in some 
cases with the addition of dipyridamole, another antiplatelet agent). But, similarly large 
benefits have not been consistently observed in larger randomised controlled 
trials. 91,107,227,247,257 
The evidence for a better outcome for the fetus with antiplatelet therapy is less clear; 
reduced rates of IUGR have been reported in only a few trials12•247 and no randomised 
study has clearly shown a reduction in perinatal mortality. There are also concerns about 
possible side-effects of antiplatelet treatment in pregnancy, in particular haemorrhage in 
the mother, fetus, or newborn baby. Early reports of haemorrhagic complications came 
from observational studies of women who had taken high doses of aspirin during 
pregnancy.42 More recently, a large trial of low-dose aspirin in healthy primigravidae 
reported a small but significant increase in placental bleeding with low-dose aspirin. 227 
Our randomised, placebo-controlled trial (Collaborative Low-dose Aspirin Study in 
Pregnancy [CLASP]) was designed to be large enough to provide reliable evidence about 
the overall safety of low-dose aspirin use in pregnancy and to find out whether treatment 
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really produces worthwhile effects on morbidity and on fetal and neonatal mortality, 
either overall or in selected subgroups of pregnancies judged to be at high risk of severe 
preeclampsia or JUGR. 
5.2 Patients and methods 
9364 women were recruited into the trial from 213 centres in 16 countries over 5 
years from January, 1988, to December, 1992. Local research ethics committee approval 
was required for a hospital to be included as a trial cenlre. 
Egilibility* 
Women were eligible if they were between 12 and 32 weeks of gestation and, in the 
opinion of the responsible clinician, were at sufficient risk of preeclampsia or JUGR for 
the use of low-dose aspirin to be conlemplated, but without clear indications for or 
against its use. Women could be considered for: 
Prophylactic entry. Women with a history of preeclampsia or JUGR in a previous 
pregnancy, chronic hypertension, renal disease, or other risk factors, such as maternal 
age, family history, or multiple pregnancy. 
Therapeutic entry. Women with signs or symptoms of preeclampsia or JUGR in the 
currenl pregnancy. 
Contraindications included an increased risk of bleeding, asthma, allergy to aspirin, 
or a high likelihood of immediate delivery. The fundamental criterion for entry was Ihat 
the responsible clinician was uncertain whelher or not 10 recommend aspirin in the 
individual pregnancy. The range of women studied was expected to be wide, but their 
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heterogeneity could be defined to some extent by characteristics recorded at entry. In 
consequence, the effects of aspirin were to be assessed not just overall but also in various 
categories of women (such as those studied in previous trials with more restricted entry 
[see below]). 
The study was explained to eligible women (with an information booklet to provide 
further details), who were asked to give consent to take part. 
Randomisatiol1* 
Women were enrolled in the study by clinical staff telephoning a central 24-hour 
service at the Clinical Trial Service Unit in Oxford. Identifying information and baseline 
details were recorded (Table 5.2) directly on computer before a specific trial treatment 
pack containing aspirin or placebo tablets was allocated. (Women could be randomised 
after 8 weeks' gestation but were instructed not to start taking the trial tablets until a date 
calculated to correspond to 12 weeks' gestation.) A minimisation algorithm280 was used to 
limit differences between the treatment groups for certain prognostic baseline variables. 
After randomisation, no woman was excluded from the trial, irrespective of whether 
treatment was actually dispensed or taken. For the purposes of analysis women were 
counted in the treatment group to which they had been originally allocated (i.e., 
intention· to-treat analyses are reported). 
Trealmem* 
Women were assigned treatment with either one 60 mg film-coated aspirin tablet 
daily or a matching placebo tablet (containing microcrystalline cellulose and corn starch). 
The dose of aspirin was chosen to keep side-effects to a minimum, and yet be sufficient 
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to inhibit maternal cyclooxygenase-dependent platelet aggregation,14 and was one that had 
been reported to prevent preeclampsia. 265 Women were asked to take the study treatment 
every day until delivery unless advised otherwise by their doctors. 
A standard letter was provided to inform the family doctor of the patient's entry into 
the trial. We recommended that other aspirin-containing preparations be avoided, with 
paracetamol used, if necessary, for analgesia. Study treatment was not revealed, even 
after delivery, unless there was a clear medical or personal reason for the treatment to be 
made known. 
Follow-up' 
A single-page follow-up form was completed after hospital discharge of both mother 
and baby (or at 6 weeks post partum, if either had not been discharged). Brief details 
were recorded of compliance with study treatment, use of antihypertensive or 
anticonvulsant drugs, and major events that occurred after randomisation (especially the 
development of preeclampsia, any fetal loss, or any maternal or neonatal bleeding). The 
birthweight and vital status of the baby and any neonatal complications were also 
recorded. Incomplete or inconsistent data were checked and corrected wherever possible. 
Further information about any report of suspected neonatal intraventricular haemorrhage 
was requested, and necropsy reports were sought for any fetal losses or neonatal deaths. 
Liveborn infants in the UK have been flagged through the Office of Population Censuses 
and Surveys for longer-term follow-up of mortality. 
CLASP ill the Netherlallds 
In April 1989 a written inquiry was held among practicing gynecologists in the 
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Netherlands in order to assess the patterns of prescription of low-dose aspirin for 
preventive and therapeutic use in pregnancies at risk for pregnancy-induced hypertensive 
disease and fetal growth retardation (chapter 4). The questionnaire was accompanied by 
an invitation for the introductory meeting of centers interested in participation in the 
CLASp-trial in the Netherlands. In May 1989 this meeting was held and attended by 
almost 100 obstetricians-gynecologists. At this meeting a translation of all CLASP 
material was presented in order to encourage participation. As a result gynecologists in 20 
hospitals, 10 training and 10 non-training, subscribed to take part in the study. The 
national study-coordinator for the Netherlands, the author of this thesis, visited these 
hospitals for detailed explanation regarding the actual participation in the study. After the 
final decision to participate in the study, and after consent from local hospital ethics 
committees had been obtained, the centers were registered by the CLASP Coordinating 
Center in Oxford, from which they received a hospital number, and an identification 
number for the 24-hour telephone randomization service. All applications for 
randomization went through the Dutch Coordinating Center in the Department of 
Obstetrics and Gynecology of the Erasmus University Hospital-Dijkzigt in Rotterdam, 
which provided a 24-hours telephone service for participating centers in the Netherlands. 
After having obtained the necessary patient data from the obstetrician who requested 
randomization the Dutch coordinating center called the CTSU in Oxford and received a 
randomization number that was forwarded to the participating center. The first patient in 
the Netherlands was randomized August 22 1989. During the study the Dutch 
Coordinating Center and the national study coordinator served as an intermediate between 
the Coordinating Center in Oxford and the participating obstetricians-gynecologists in the 
Netherlands. The participating centers were visited by the national study coordinator on a 
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regular basis to provide them with trial medication and stationery, to solve problems, and 
to stimulate recruitment. 
DlI/come measures* 
The main prespecified endpoints were: development of proteinuric preeclampsia; 
estimated duration of pregnancy; crude birthweight; birthweight below the third centile 
for sex and gestational age; stillbirth or neonatal death ascribed to preeclampsia or 
maternal hypertension or associated with IUGR, ascribed to maternal or neonatal 
bleeding, or from any cause; death of the baby at any time attributed to preeclampsia or 
maternal hypertension or associated with IUGR. 
The study outcome of proteinuric preeclampsia required the development of 
hypertension and proteinuria after randomisation. For those with baseline diastolic 
pressure below 90 mOl Hg, hypertension was defined as a rise of at least 25 mm Hg, to 
90 mm Hg or higher. For those with an initial diastolic pressure of 90 mm Hg or above, 
an increment of at least 15 mm Hg was required. Proteinuria was defined as the 
appearance after randomisation of at least 1 + on protein stick-testing during pregnancy, 
without evidence of urinary tract infection. IUGR was defined as a birthweight below the 
third centile for sex and estimated gestational maturity (with values available only for 
gestational ages of 24 to 42 weeks),'" and preterm delivery was defined as that before 37 
weeks' estimated gestation. Stillbirths included all intrauterine deaths at or after 24 
weeks, and neonatal deaths included all deaths after birth up to the age of 28 days. 
Spontaneous miscarriages and induced abortions before 24 weeks and post-neonatal deaths 
up to age 1 year were also recorded. All losses after randomisation up to age I year are 
referred to as total mortality. Two senior investigators, unaware of the treatment groups 
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of the babies' mothers, classified all deaths according to a modification of the systems 
described by Cole, Hey, and colleagues."'" Deaths attributed to maternal hypertension, 
preeclampsia, or unexplained IUGR were grouped together in the analyses, as were those 
attributed to maternal or neonatal bleeding. 
The duration of tablet taking was assessed in two ways. First, the approximate date 
when study treatment stopped was recorded; the proportion of the scheduled treatment 
duration during which the study tablets were taken could then be estimated. Second, to 
check these data, we sent a compliance questionnaire at an average of about 3 months 
after delivery to about 10% of women in the UK whose follow-up data had been received. 
To avoid distress, this sample was selected from women whose infants were believed to 
be alive and well. Correct packing and labelling of active and placebo treatment packs 
and drug stability were also checked throughout the study by destructive testing of a 
random sample of treatment packs. 
Comporisolls alld slalislical melhods' 
The protocol specified five main comparisons: the first in the trial as a whole, and 
the rest with the participants subdivided into four categories according to the principal 
clinical reason for randomisation (i.e., prophylactic, or therapeutic use of aspirin) and the 
principal disorder to be prevented or treated (I.e., preeclampsia irrespective of the 
presence of IUGR, or IUGR alone). In addition, as subsidiary questions, comparisons 
were to be undertaken of prophylactic use according to parity (0,;"1), prophylactic use 
according to time of entry to the trial (5 20 weeks'or > 20 weeks' gestation), and 
therapeutic use according to time of entry to the trial (5 28 weeks' or > 28 weeks' 
gestation). 
80 
We calculated that in a trial of 4000 women there would be a 95 % probability of 
detecting, at a reasonable level of significance (2p<0.02), a decrease of at least a quarter 
in the incidence of proteinuric preeclampsia (assuming a control rate of 5-10%), an 
increase of 100 g in mean birthweight, and an increase of 1 day in mean duration of 
gestation. A trial of this size could not, however, be relied on to detect differences in 
rates of stillbirth and neonatal death ascribable to preeclampsia. After the trial started, 
therefore, the steering committee, unaware of results subdivided by treatment allocation, 
decided to extend recruitment to about 10.000 women, which would provide a high 
probability of detecting a decrease of at least a quarter in such deaths (assuming a control 
rate of 40 per 1000). 
Statistical analyses involved simple comparisons of total numbers affected. 1S9 
Standard methods were used to calculate the apparent ratio of the odds of an outcome 
occurring in the aspirin group compared with the odds in the control group along with its 
confidence interval -95% for principal analyses and, to take account of the number of 
comparisons, 99% for subsidiary and subgroup analyses" Alternatively, the reduction in 
the odds of the event in the aspirin group and its standard deviation (SD) are cited;' an 
odds ratio of 0.8 for example, corresponds to an odds reduction of 20%. (Such odds 
reductions are slightly larger than risk reductions.) 
During recruitment, confidential interim results were reviewed about twice a year by 
an independent data monitoring committee who were to advise the study chairmen if, in 
their view, there was proof beyond reasonable doubt that, either for all women or for any 
category of women, low-dose aspirin was clearly indicated or clearly contraindicated. The 
steering committee, collaborators, and administrative staff (except those who produced the 
confidential analyses) remained ignorant of the interim results. No reason to stop the trial 
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Table 5.1 Participating coul/tries, cellfers and "umhers o/patiellts recruited into CLASP 
No. of women No. of participating Year started 
entered centers 
Argent Ina 143 3 1991 
Austral i a 351 13 1989 
Belgiun (Flanders) 154 3 1989 
Betgiun (Franco) 88 7 1989 
canada 819 7 1988 
Germany 7 1990 
Hong Kong 164 1988 
Israel 159 7 1990 
Malaysia 135 1989 
New Zealand 12 1990 
Russia 515 4 1990 
Spain 8 2 1990 
Swe<fen 241 10 1990 
The Netherlands 486 20 1989 
Unl ted Arab Eml rates 114 1989 
United Kingdom 5961 131 1988 
United States of America 7 1990 
Total 9364 213 
prematurely emerged, so randomisation continued from Jan 1, 1988, to Dec 31, 1992. 
5.3 Results 
9364 women were randomised in 16 countries (Table 5.1), with good balance 
between the treatment groups for the main prerandomisation prognostic factors recorded 
(Table 5.2). 74% were entered for prophylaxis of preeclampsia and only 3% for the 
treatment of lUGR alone. In the Netherlands 486 women were randomized, with a 
median per hospital of 10 (range I - 142). Fifty percent of these patients were 
randomized by 3 hospitals (Table 5.3). Of these 486 women, 87% were entered for 
prophylaxis (preeclampsia 57%, fetal growth retardation 30%); 13% were entered for 
treatment (preeclampsia 7%, fetal growth retardation 6%). In the total group 28% were 
nulliparous; in the Dutch group 18% were nUlliparous at randomization. 62% of the 
women were enrolled at 20 weeks' gestation or earlier. 2% had already developed 
preeclampsia, and 28% were primigravidae. The characteristics of the women entered for 
different reasons varied in the ways that might be expected (Table 5.4). For example, 
those entered for prophylaxis were less likely to be primigravid, especially if entered for 
prophylaxis of lUGR, and smoking was more common among those entered for 
prophylaxis or treatment of lUGR. 
Post-delivery follow-up forms were obtained for 9309 (99.4 %; 4659 aspirin-allocated 
and 4650 placebo-allocated) randomised women, and these women had had 9631 (4810 vs 
4821) babies or fetal losses. Reported compliance with study treatment was good, with no 
difference between the groups allocated aspirin or placebo. Of the 8915 randomised 
women for whom we had information on compliance, 96% started the study medication, 
and 66% and 88% continued study treatment for at least 95% and 80%, respectively, of 
the time between randomisation and delivery. Owing to concern among some anaesthetists 
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Table 5.2. Preralldomisatioll characteristics o/women sllldied. 
No ('Yo) In allocated treatment group 
Aspirin Placebo 
(n=4683) (n=4681) 
Main reason for entry 
Prophylaxis of pre-eclampsia 3467 (74) 3460 (74) 
Prophylaxis of IUGA alone 546 (12) 548 (12) 
Treatment of pre-eclampsia 538 (11) 544 (12) 
Treatment of IUGA alone 132 (3) 129 (3) 
Woman's age (yi") (28.5 SO 5,4)' (28.5 SO 5.5)' 
<20 186 (4) 186 (4) 
20·29 2577 (55) 2582 (55) 
30·39 1792 (38) 1787 (38) 
~40 128 (3) 126 (3) 
Estimated duration of gestation (wk) (19,4 SO 5.6)' (19,4 SO 5.6)' 
<12" 261 (6) 241 (5) 
12-20 2652 (57) 2685 (57) 
>20-28 1259 (27) 1239 (26) 
>28 511 (11) 516 (11) 
Diastolic blood pressure (mmHg) (76.2 SO 12.2)' (76.3 SO 12.1)' 
<90 3780 (81) 3715 (79) 
90·109 858 (18) 938 (20) 
~110 45 (1) 28 (1) 
Features of current pregnancy 
Development of pre-eclampsia'" 110 (2) 108 (2) 
Evidence of lUG A 237 (5) 234 (5) 
Proteinuria (1 + or more) 246 (50) 245 (5) 
Cigarette smoker 970 (21) 945 (20) 
Obstetric history 
Primigravid 1310 (28) 1309 (28) 
Multiparous, no previous problems 335 (7) 331 (7) 
Multiparous, previous problems·· .. 3038 (65) 3041 (65) 
Medical history 
Chronic hypertension 933 (20) 949 (20) 
Aenal disease 223 (5) 190 (4) 
Diabetes 129 (3) 146 (3) 
Mean, SD. 
Women random!sed before 12 weeks' gestation were to start study (reatment at 12 weeks. 
Based on changes In diastolic blood pressure between first recorded measurement!n 
current pregnancy and last prerandomlsation recorded. 
Pre-eclampsia, JUGA, or perinatal death in at least one previous pregnancy. 
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Table 5.3 Recruitment into CLASP in The Netherlands 
Academisch Ziekenhuis Leiden 
AZR·Dijkzigt Rotterdam 
Zuiderziekenhuis Rotterdam 
Rode I(ruis Ziekenhuis Heemskerk 
AHC Amsterdam 
Gemini Ziekenhuis Den Helder 
Lievensberg Ziekenhuis Bergen op Zoom 
Ziekenhuiscentrun Ap(!ldoorn 
Geertru;den Zi ckenhuis Deventer 
Westeinde Ziekenhuis Den Haag 
No.of .... omen 
recruited 
45 
142 
10 
18 
8 
32 
54 
47 
9 
Twenteborg Ziekenhuis Almelo 
St.Elisabeth Ziekenhuis Titburg 
Ziekenhuis Rijnstaete & Vetp 
Hofpoort Ziekenhuis Woerden 
Academisch Ziekenhuis Nijmegen 
Pasteur Ziekenhuis Oosterhout 
St.Jansdal Ziekenhuis Harderwijk 
Ikazia Ziekenhuis Rotteidam 
Medisch Cent run Alkmaar 
St.Clara Ziekenhuis Rotterdam 
No.of women 
recruited 
33 
32 
2 
9 
2 
11 
15 
7 
5 
4 
Table 5.4. Comparison 0/ baseline characteristics o/womell e1lfered for different reasons. 
Prophylaxis of Prophylaxis of Treatment of Treatment 01 
pre·eclampsla fUGR alone pre·eclampsla IUGR alone 
(0:0;6927) (n",1094) (n=1082) (n=261) 
Mean (SO) 
Women's age (yr) 28.7 (5.3) 28.2 (5.0) 27.8 (6.2) 26.7 (5.8) 
Duration of gestation (wk) 18.6 (5.1) 18.1 (5.0) 23.8 (5.6) 27.6 (4.0) 
Systolic blood pressure (mmHg) 124.7 (15.8) 115.1(12.7) 137.6 (17.8) 116.6 (14.5) 
Diastolic blood pressure (mmHg) 76.0 (11.0) 68.8 (9.3) 87.1 (14.1) 70.3 (11.0) 
No. ('Yo) of women 
Current pregnancy 
Development 01 pre· eclampsia 50 (0.7) 0 165 (15.2) 3 (1.1) 
Evidence of IUGR 58 (0.8) 40 (3.7) 128 (11.8) 245 (93.9) 
Proteinuria 238 (3.4) 18 (1.6) 226 (20,9) 9 (3.4) 
Cigarette smoker 1184 (17.1) 441 (40.3) 198 (18.3) 92 (35,2) 
Obstetric history 
Primigravid 1819 (26.3) 29 (2.7) 643 (59.4) 128 (49.0) 
Multiparous, previous problems 4642 (67.0) 1048 (95,8) 307 (28.4) 82 (31.4) 
that epidural anaesthesia might be contraindicated in women taking aspirin,141 clinicians 
were advised that they could stop study treatment a few days before delivery. Even so, 
53 % of women were reported to have continued study treatment to within I day of 
delivery and 69 % to within I week. There was excellent agreement between the 
information provided on the post-delivery form and that obtained from the 1077 (86%) 
respondents to the compliance questionnaire sent to 1256 women. For example, 92% of 
those who were reported to have continued study treatment for at least 80% of the 
scheduled time confirmed that they had done so. 
Incidence aipro/eilll/ric preeclampsia* 
Overall, 6.7% of aspirin-allocated women developed proteinuric preeclampsia after 
randomisation compared with 7.6% of those allocated placebo (figure 5.1). 
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EventsfWomen Entry 
characteristic Aspirin Placebo 
Prophylactic reasons 
for entry, subdivided by: 
Cllnlcallndical10n 
PET ;t;lUGR 257/3449 20013437 
IUGR alone 101543 121 545 
Gestation at entry 
.., 20weeks 176/2733 22212749 
> 20 weeks 91/1259 8011233 
Parity 
nuHiparae 57/ 922 621 915 
multiiparae 21013070 24013067 
All entered 267/3992 30213982 
for prophylaxis {6.7%} (7.6%) 
Therapeullc reasons 
for enl~, subdivded by: 
CHnlca Indication 
PET ;t;IUGR 421 536 421 539 
IUGRalone 41 131 8/ 129 -
Gestational at entry 
~ 28 weeks 36/ 435 321 430 
> 28 weeks 10/ 232 18/238-
All entered 46/667 SO/ 668 
for treatment (6.9%) (7.5%) 
All women entered 313/4659 35214650 
(6.7%) 
Difference In odds between entry for 
prophylactic or for therapeullc reason: NS 
(7.6%) 
... 
... 
Odds ratio & CI 
(Aspirin: Placebo) 
Test for 
differences 
between effect 
in different 
subgroups I 
·i 
; 
~ 
I 
I 
! 
I 
~ i 
I I 
0.5 0.75 1.0 
AspIrin 
better 
------
13%odds 
reduction 
(N8) 
------
------
------
} p,0.06 (Xl, =3.6) 
} NS 
8% oodds 
ducllon 
5) " (N 
12 %odds 
reduction 
(NS) 
I I 
1.25 1.5 
AspIrin 
worse 
Figure 5.1. E./fects of aspirill all proteilluric preeclampsia developillg after randomisatioll. 
Odds ratios (black square: area proportional to amOU1lf of illfol71Ulfion collfributetF), and 99% Cl 
(liorizontalline) are plotted for various subgroups of fhe study population. A black square to the left of the 
solid \'erficalline suggests a benefit (but this is sigllificallt at 2p < 0.01 01l1y if the whole Cl is to the left of 
the solid vertical line). ChP tests for differences between e./fecls observed ill fhe different subgroups are 
given to the right of the solid vef1ical line. 111e overall results for all women and for those entered for 
prophylactic and for therapeutic reasons (alld 95% Cl) are represellfed by diamonds, with the obserwd 
reductions ill the odds of preeclampsia developing gil'en to the right of the solid \'erlicallille. 
PET=preeciampsia,' NS=lIot sigllificallf; Cl=confidence illfervai. 
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This difference represents a reduction with aspirin in the odds of developing proteinuric 
preeclampsia of 12%, but is not significant. There was no good evidence that the effect 
differed between women entered for prophylactic or therapeutic reasons, or for different 
clinical indications, or between nulliparae and multiparae entered for prophylaxis. The 
effect seemed to be greater among women entered for prophylaxis at 20 weeks' gestation 
or earlier (22 % reduction [99% CI 40% reduction to 3% increase]; 2p = 0.02). But the 
apparent effect in this group was not significantly greater than that among those entered 
later for prophylaxis, and the opposite pattern was observed among women entered for 
therapeutic reasons. 
Proteinuria without hypertension severe enough to be recognised as preeclampsia was 
also slightly less common among aspirin-allocated women (II % reduction [99% C[ 28% 
reduction to 11 % increase]; not significant), but new hypertension without associated 
proteinuria was not (I % increase [99% CI 14% reduction to 19% increase]). Only 7 
(0.2%) aspirin- allocated and 7 (0.2%) placebo-allocated cases of eclampsia were 
reported. 
Duration of pregnancy' 
The average duration of pregnancy was about 1 day longer among aspirin-allocated 
than among placebo-allocated women (38.15 [SD 3.82] vs 37.99 [3.93] weeks; 2p=0.05). 
The absolute risks of preterm delivery differed substantially between the categories of 
women studied. Among about 8000 women entered for prophylactic reasons only one-fifth 
of the controls had preterm delivery and the absolute benefit seemed to be about 2 fewer 
preterm deliveries per 100 women allocated aspirin (2p = 0.03; figure 5.2), while among 
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just over 1000 women entered for therapeutic reasons two-fifths of the controls had 
preterm delivery and the absolute benefit seemed to be about 5 per 100 (2p = 0.03). 
This difference in mean gestation was small, but aspirin clearly reduced the likelihood of 
delivery before 37 weeks' estimated gestation (19.7% aspirin-allocated vs 22.2% 
placebo-allocated; 2p = 0.003); 14% fewer aspirin-allocated women delivered preterm 
(95% CI 22% to 5% reduction; figure 5.2). The proportional effect was larger (28% 
reduction [99% CI 46% to 4% reduction]) among women delivering preterm with 
proteinuric preeclampsia (3.0% aspirin-allocated vs 4.1 % placebo- allocated; 2p = 
0.003). 
Entry Events/Women 
characterlsUc Aspirin Placebo 
Prophylactic reasons 
for entryl subdivided by: 
Cllnlcallndlcalfon 
PET ±IUGR 567/3449 649/3437 
IUGRalone 119/ 543 1121 545 
Gestallon at entry 
5:20 weekS 477/2733 49712749 
;> 20 weeks 209/1259 26411233 
Parity 
flull;parae 144/ 922 1841 915 
multiparae 542/3070 57713007 
Allenlered 68613992 761(3982 
for prophylaxis (17.2%) (19.1%) 
Thera~eUIiC reasons 
for en ry, subdivded by: 
Cltnlcal Indication 
PET ±IUGR 167/ 536 2221 539 
IUGRalollB 471 131 501 129 
Gestational at entry 
-"26 weeks 1271 435 1461 430 
:> 28 weeks 1071 232 1261 238 
Alleniered 234/667 272/668 
for treatment (35.1%) (40.7%) 
All women entered 920/4659 1033/4650 
(19.7%) (22.2%) 
Difference In odds between entry for 
prophylactic or for therapeullc reason: NS 
Figure 5.2. Effects of as pi rill all pretel1l1 delive/J' 
Odds ratio & Cl Testfor 
(Aspirin: Placebo) differences 
between effect 
In dlHerent 
I subgroups 
.... I- 1 NS 
4 - 1 ,.003 0:'," 4.7) i 
--jill - 1 NS 
<l> 12%odds 
I reducllon 
I (2p = 0.03) 
I 
lNS 
lNS 
J. 21%odds 
I reduction (2p.O.03) 
t 14% odds reducllon (2p=0.OO3) 
I I I I 
0.5 0.75 1.0 1.'25 1.5 
Aspl,ln Aspirin 
belter worse 
Symbols alld cOllventions as ill figure 5.1. Preterm=delh'eIY before 37 weeh" estimated gestation. 
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Birl!lIveight' 
The average weight of all babies born to women allocated aspirin was 32 g greater 
(95% CI 0 to 64 g; 2p = 0.05) than that in the placebo group (3024 [SD 788] vs 2991 
[810] g). Aspirin was also associated with a slightly smaller proportion of babies with 
IUGR, but this difference was not significant (figure 5.3). Nor did the effects differ 
between those entered for prophylactic reasons and those entered for therapeutic reasons. 
Among women entered for therapeutic reasons, however, aspirin seemed to have 
discrepant effects, with an increased incidence of IUGR among those entered at 28 weeks' 
or earlier, and a decreased incidence among those entered later (p = 0.005 for test of 
interaction). The adverse trend among those entered for treatment of preeclampsia could 
largely be accounted for by differences in the duration of gestation at entry. 
Stillbirlhs alld lIeollata! deaths' 
69 pregnancies of women allocated aspirin and 67 of those allocated placebo ended 
before viability ( < 24 weeks) owing to miscarriage or induced abortion. Among the 
remainder there were 129 (2.7%) stillbirths or neonatal deaths in the aspirin group and 
136 (2.8%) in the placebo group (figure 5.4). This small reduction with aspirin was not 
statistically significant, but the confidence interval is wide, so neither a reduction nor an 
increase of about a quarter can be excluded. Among women allocated aspirin for 
prophylactic reasons, there were slightly fewer stillbirths or neonatal deaths, whereas 
among those allocated aspirin for therapeutic reasons there were slightly more (p = 0.04 
for interaction). However, aspirin was not associated with a significant difference in 
stillbirths or neonatal deaths either overall or in any subcategory. In particular, although 
women allocated aspirin had significantly fewer preterm deliveries, this apparent benefit 
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Entry Events/Babies 
characteristic Aspirin Placebo 
Prophylactic reasons 
for entry, subdivided by: 
Clinical Indication 
PET ±IUGR 
IUGRalone 
Gestation at entry 
.., 20 weeks 
;. 20 weeks 
Parity 
nunparae 
muitiparae 
All entered 
for prophylaxis 
Therapeutic reasons 
for entry, subdlvded by: 
CllnlcallndJcatlon 
PET:!: IUGA 
IUGRalone 
Gestational at entry 
:0; 28 weeks 
;. 28 weeks 
Allentered 
for treatment 
18513570 21313583 
59/553 59/ 551 
1512802 18512833 
8311321 87/1301 
53/ 981 63/ 980 
19113142 20913154 
244/4123 272/4134 
(5.9'7'0) (6.6%) 
941 553 83/ 551 
33/ 134 461 136 
7V 444 52/ 439 
551 243 771 248 
127/687 129/687 
(18.5%) (18.8%) 
All babIes 371{4810 401/4821 
(7.7%) 
Difference in odds between entry for 
prophylactic or for therapeutic reason: NS 
Figure 5.3. Ellals of mpirill 01/ IUGR. 
(8.3%) 
Odds ratio & CI 
(Aspirin: Placebo) 
I 
--
I-
.1 
11%odds 
Test for 
differences 
between effect 
In different 
subgroups 
I reducllon (NS 
I 
I 
! 
1 
.... .. 
i 
I I 
0.5 0.75 1.0 
Aspirin 
better 
------
------
P ",0.06 
j(x',e 35) 
- jP=>0.005 
(;.:,,==7.9) 
2%odd s 
reduct! 
8% odds 
reduction (NS 
I I 
1.25 1.5 
AspIrin 
worse 
on (NS) 
Symbols alld com'eJJtiolls as ill figure 5.1. IUGR=Binlill'eighl below 3"d percentile for sex and gestatiollal 
age. 
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Entry 
characteristic 
Events/Babies 
Aspirin Placebo 
Odds ratio & CI 
(Aspirin: Placebo) 
Test for 
differences 
between effect 
Prophylactic reasons 
for entry, subdivided by: 
Clinical Indication 
PET:tlUGA 
IUGA alooa 
Gestation at entry 
~20weeks 
> 20 weeks 
Parity 
nulliparae 
multiparae 
All entered 
for prophylaxis 
Therapeutic reasons 
for enlry, subdivded by: 
Clinical Indication 
PET:tIUGA 
IUGRalooe 
Gestatlonalat entry 
~28 weeks 
> 28 weeks 
Allenlered 
for treatment 
All babies 
6613570 
11f 553 
551.280.2 
.22113.21 
111 981 
6613142 
77/4123 
(1.9%) 
40/ 553 
121 134 
371 444 
15/ 243 
52/ 687 
(7.8%) 
12914810 
(2.7%) 
6813563 
91 551 
621.2833 
3511301 
2.21 980 ..... _-
7513154 
97/4134 
(2.3%) 
.291 551 
101 136 
.281 439 
11/248 
39/687 
(5.7%) 
136/4821 
(2.8%) 
I I 
0.5 0,75 
Difference In odds belween entry for Aspirin 
prophylac!fc or for therapeutic reason p = 0.04 (X~1 = 4.1) belter 
Figllre 5.4. Effects of aspirin 011 slillbirlhs alld lIeollatal deaths. 
Symbols alld cOl/wl/liolls as iI/figure 5.1. 
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was not reflected in significantly better survival. 
There were no significant differences between the aspirin and placebo groups in the 
numbers of stillbirths and neonatal deaths attributed to preeclampsia, maternal 
hypertension, or IUGR (74 [1.5%] vs 80 [1.7%]) or in those attributed to maternal or 
neonatal bleeding (20 [0.4%] vs 31 [0.6%]). Similarly, for total mortality, there were no 
significant differences in the numbers from any cause (207 [4.3%] vs 226 [4.7%]) or in 
those attributed to preeclampsia, maternal hypertension, or IUGR (95 [2.0%] vs 114 
[2.4%]). 
Early-ol/sel preeclampsia' 
A greater proportion of pregnancies continued beyond 37 weeks' gestation in the 
aspirin-allocated group, and so slightly more aspirin-allocated than placebo-allocated 
women were at risk of developing preeclampsia in later pregnancy. As a result the 
comparisons in figure 5.1 may underestimate any effect of aspirin at earlier gestational 
ages. Figure 5.5 supports this concept, indicating a significant trend (p = 0.004) towards 
progressively greater reductions in proteinuric preeclampsia with aspirin use the earlier 
the time of delivery. There were similar significant trends to less use of antihypertensive 
and anticonvulsant therapy among women who delivered early (figure 5.5). 
Olher outcomes*' 
Women allocated aspirin were slightly, though not significantly, less likely than those 
allocated placebo to go into labor spontaneously, and had greater use of induction and 
caesarean section before labor. On the other hand, intra- partum caesarean section was 
less common in the aspirin group (2p = 0.08; Table 5.5). 
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Gestational age 
at delivery 
(no of women 
delivered) 
,,28 weeks 
(124.132) 
<!28,,32 
(179,197) 
,,32,,37 
(617,704) 
'" (3739,3617) 
PROTEINURIC PRE·ECLAMPSIA 
No of events Odds ratio & CI 
Asp Pia (Aspirin: Placebo) 
17----/-
33 47 
99 128 
174 160 
0.5 1.0 15 
Aspirin Aspirin 
better worse 
Chl--square test for trend p'" 0.004 (x', '" 8.14) 
ANTlHYPERTENS1VETHERAPY ANTICONVULSANT THERAPY 
No treated Odds ratio & CI No tJealed Odds raUo 2. CI 
Asp Pia (Aspirin: Placebo) Asp Pia (Aspirin: Placebo) 
, "'-----1 
87 109 24 39 
1&3 239 
" 47 
475 452 
" " 
I t I I 
0.5 1.0 15 o 0.5 1.0 15 
Aspirin Aspirin Aspirin Aspirin 
better worse beller worse 
p'" 0.007 <X','" 7.35) 
Figure 5,5. Developmellt of proteillllric preeclampsia alld the lISe of a1lfihypertellsi~'e or ailticollWll.5ive 
therapy accordillg to gestatioll duratioll at delh'el)', 
Symbols alld cOI/WlltiollS (/S ill figure 5.1, Ratio of odds of (//1 evelll ill apsirill group to that ill placebo 
group is plotted separately for womell delh'erillg at differelll duratiolls of gestatioll after randomizatioll. ChP 
test for trelld in odds ratios with increasillg geJlatiollal age at deliw!IY is given below each plot, 
Asp=aspirill, Pla=placebo group. 
Because of its size CLASP provides especially reliable information about 
complications of aspirin use in pregnancy. Aspirin-allocated women were reported to have 
had more placental abruptions and fewer other ante-partum hemorrhages, but these 
differences were small and not statistically significant (fable 5.5). Moreover, concern 
about the use of aspirin at the time of epidural anesthesia was not substantiated. Among 
2783 women who had epidural anesthesia (1422 aspirin-allocated vs 1361 
placebo-allocated), 79 adverse experiences were reported in relation to the epidural (46 
[3.2%] vs 33 [2.4%]; not significant). Hemorrhage occurred on only 3 occasions (I vs 2) 
and was limited to blood-stained fluid in the cannula. Significantly more women allocated 
aspirin received blood transfusions after delivery, but this difference was not associated 
, 
with differences in the occurrence or degree of post-partum hemorrhage. Only I maternal 
death was recorded on the post-delivery follow-up form; this woman, allocated aspirin 
during pregnancy, died 2 days after delivery from a pulmonary embolus. 
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Table 5.5. Effect of aspirin 011 other Olllcome measures after ralldomizatioll. 
No (%~) In allocated treatment group 
Aspirin Placebo 
Total no. 
Pregnancies with data 4659 4650 
Fetal outcomes 4810 4821 
Treatment after randomisation 
Antihypertensive 785 (16.8) 844 (18.2) 
Anticonvulsant 126 (2.7) 152 (3.3) 
Labour and delivery 
Spontaneous onset 2124 (45.6) 2190 (47.1) 
Induced 1460 (31.3) 1406 (30.2) 
Pre· labour caesarean 1007 (21.6) 987 (21.2) 
Intra partum caesarean 376 (8.1) 423 (9.1) 
Maternal bleeding 
Placental abruption 86 (1.8) 71 (1.5) 
Other ante partum bleed 48 (1.0) 54 (1.2) 
Post·partum bleed >500 ml 1200 (25.8) 1182 (25.4) 
Transfusion 188 (4.0) 147 (3.2) 
Felal/neonatal complications 
Special care admissIon 946 (19.7) 1016 (21.1) 
Intraventricular haemorrhage 33 (0.7) 45 (0.9) 
Other neonatal bleeds 47 (1.0) 45 (0.9) 
Subsequent maternal follow-up was I10t done systematically (although it was, in general, 
blind to treatment allocation); 2 maternal deaths (at IO and 19 months after delivery) were 
reported among women allocated aspirin and 1 (at 18 months) among those allocated 
placebo. 
Findings on safety in the babies were reassuring (Table 5.5). 78 intraventricular 
haemorrhages were reported, of which 88% were diagnosed either by ultrasound or after 
death. Fewer were reported among babies born to women allocated aspirin (0.7% 
aspirin-allocated vs 0.9% placebo-allocated), but this difference was not significant. Nor 
were there significant differences in fetal or neonatal deaths. attributed to hemorrhage (20 
[0.4%] vs 32 [0,7%]) or in other neonatal hemorrhages. Slightly fewer newborn infants in 
the aspirin group were admitted to the special care nursery (2p~0.09), but there were no 
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significant differences in the duration of stay. 
5.4 Discussion 
Trial desigll 
The CLASP trial is a typical example of a large and simple trial as advocated in 1984 
by Yusuf, Collins and Peto."9 These authors state that the criteria for a good trial should 
always be the same with regard to common and serious conditions: a. ask an important 
question and, b. answer it reliably. These criteria can be used to test the possibility and 
the desirability of large, simple randomized trials of various widely practicable treatments 
for common conditions. Yusuf et a1. 289 present six main reasons to support their argument 
for large and simple clinical trials: 
I. The identification of effective treatments is likely to be more important if the disease 
to be studied is common than if it is rare, and studies of common conditions can be 
large. 
2. The identification of effective treatments for common disease is likely to be more 
important if the treatment is widely practicable than if it is so complex that it can be 
performed only in specialist centers, and treatment protocols for widely practicable 
treatments can be simple. 
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3. Study of the effects of treatment on major endpoints is likely to be more important 
than study of the effects on minor endpoints; and follow-up protocols for the 
assessment only of major endpoints can often be simple. 
4. No matter what prognostic features are recorded at entry, the duration of survival, etc. 
among apparently similar patients is likely to be rather unpredictable, so no great 
increase in statistical sensitivity is likely to be conferred by stratification andlor 
adjustment for such features. In other words, the reliability of the main treatment 
comparison is improved little by adjustment for initial imbalances in prognostic 
features, which suggests that entry protocols too can be simple. 
5. The direction -though not necessarily the magnitude- of the net effects of treatment on 
particular modes of death is likely to be similar in many different subcategories of 
randomized patients. Therefore, if there is no need to subcategorize patients to decide 
who needs which treatment, the entry protocol can be simple. 
6. If a widely practicable treatment would have a large effect on an important endpoint 
(e.g., mortality) in a common disease, this would probably already be known, so the 
true effeet is likely to be null or moderate. 
These arguments in favor of large and simple trials are challenged by Lubsen and 
Tijssen. 140 In their view a common condition, a simple treatment, and a simple outcome 
measure are opportunities rather than design options. Their main criticism regards the 
fifth argument of Yusuf et aI., that the direction of the net treatment effect can be 
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expected to be similar across patient subgroups. They reject this particular argument 
because, although attractive from a statistical point of view, it has no a priori biological 
foundation. It is important in this context to make a distinction between 'quantitative' 
interactions and 'qualitative' interactions:87 A qualitative interaction is one whereby the 
true treatment effects in different subgroups do not even point in the same direction, 
whereas a quantitative interaction is one whereby the direction of the true effect of 
treatment is similar, and only the size of the benefit is different. Because their is no 
reason to suspect a qualitative interaction in the different subgroups involved in the 
CLASP trial, the objections of Lubsen et al. seem to be not applicable to this trial. 
The same authors further object that 'simple' in the context of entry protocols means 
that very few patient characteristics are recorded at entry, and that data that have not been 
recorded cannot be involved in the analysis or interpretation of results. Although this is 
certainly true, it is important to realize that there is a balance between simple entry 
protocols stimulating the randomization of large numbers and extensive protocols 
inhibiting the randomization of large numbers; minimal documentation at entry and during 
follow-up may be expected to increase the willingness of physicians to participate in a 
clinical trial."6 
It is the sixth point of Yusuf et aI., the moderateness of what can plausibly be hoped 
for, that has perhaps the most profound implications for trial design. It is chiefly because 
one should be able to distinguish reliably between moderate and null effects that trials 
need to be strictly randomized, analyzed, interpreted unbiasedly, and larger than is 
currently usual. Moderate biases, introduced by sloppy methodology (e.g. non-
randomized controls, failure to use an 'intention-ta-treat' analysis etc.) may not matter 
much in those rare instances when large treatment effects await discovery, they matter 
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enormously when only moderate effects are to be assessed. '89 
CLASP in the Netherlands 
Ile<oause the trial was well designed. and because it was executed with the help of 
professional collaborators in the Clinical Trial Service Unit, no major problems appeared 
during the trial. Telephone randomization never took more than a few minutes. There was 
never a problem with the stocking of collaborating centers with treatment packs. In the 
majority of cases the follow-up forms were returned, on time and completely filled out, to 
the national coordinating center within six weeks after delivery of a participating patient. 
A major problem that appeared during the trial was a steady decrease in recruitment 
numbers, from an average of 20-30 per month to less than 10 per month during the final 
stages of the trial, most likely due to the incorporation of low-dose aspirin prophylaxis in 
clinical obstetric practice in the Netherlands (chapter 4). Comparing Dutch pre-
randomization characteristics to overall preHrandomization characteristics, it appears that a 
markedly larger proportion of women were randomized in the Netherlands with the 
intention to prevent or treat fetal growth retardation. This trend is in accordance with the 
results of the inquiry presented in chapter 4. 
Trial results' 
The impact of aspirin on proteinuric preeclampsia and its fetal sequelae in CLASP 
was certainly smaller than in some previous reviews. Moreover, despite the randomisation 
of more than 9000 high-risk women, there was no statistically significant effect on 
stillbirths or neonatal deaths, even those specifically attributed to preeclampsia. However, 
a potentially important effect of aspirin could be discerned on prevention or delay of 
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delivery with early-onset preeclampsia. 
It is important to consider CLASP in the context of previous trials of antiplatelet 
treatment in pregnancy. Most were of aspirin, but a few were of aspirin with 
dipyridamole (which in pregnancy247 or in other clinical settings' does not seem to 
produce any greater clinical benefit than aspirin alone). When the available results from 
all trials (including CLASP) were taken together (figure 5.6),44 antiplatelet therapy was 
associated with a reduction of about a quarter in the incidence of preeclampsia. The 
results in the different trials are, however I not consistent with each other (test for 
heterogeneity p < 0.001). Review of the earlier small randomised trials (i.e., those with 
fewer than 200 women) suggested that antiplatelet therapy reduced the incidence of 
proteinuric preeclampsia by about three-quarters (figure 5.6: 2p < 0.00001).44 By 
contrast, the overall effect on preeclampsia in the larger triais91 ,]07,127.247.257 was 
significantly smaller, indicating reductions of only about a quarter before CLASP, or a 
sixth after the addition of CLASP. In absolute terms, these more modest proportional 
reductions imply that antiplatelet therapy would on average prevent proteinuric 
preeclampsia in about 1 woman per 100 treated. 
There are several possible explanations for these discrepancies, All the trials that 
reported large effects of anti platelet therapy on preeclampsia (and on IUGR) were very 
small. At least as many women are known to have been randomised in other small but 
unpublished trials (figure 5.6),44 and it may be that some small trials with unpromising 
results have not been published because they were less remarkable. If this were true, the 
available results from small trials would give a biased estimate of the positive effects of 
anti platelet therapy, but large trials would not. This possibility is consistent with the less 
extreme results observed in the larger trials. 
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Figure 5.6. Overview of effects of aspirin reported from all trials of anti platelet therapy in pregnancy. 
Symbols and conventions as in figure 5.1. Available results from smaller trials (i.e., those that included 
fewer than 200 women) were combined and straJijied ratio plotted for these trials. Details of the trials 
included are given in ref.44. 
It is unlikely that differences in the definitions of preeclampsia can explain why the 
promising resulls of the early small trials are not replicated in the larger trials. The blood 
pressure criteria used to define preeclampsia in CLASP were at least as stringent as those 
used in other trials and select a high proportion of primiparae (which is a characteristic of 
preeclampsia) independently of proteinuria. 1OO The definition of proteinuria used in 
CLASP of 1 + or more on stick-testing might be thought to be too sensitive in 
comparison with 24-hour urine protein estimates. But the control rates of proteinuric 
preeclampsia in CLASP were similar to those in all other trials (7.6% and 6.7%, 
respectively). 
One theoretical possibility is that the benefits of antiplatelet therapy are confined to 
particular categories of women that were selectively inCluded in the small but not the 
large trials. In CLASP, various characteristics were recorded at entry, and the protocol 
specified that the results would be analysed separately in several subgroups. Such analyses 
did not, however, identify any particular category of women in whom the reduction in 
proteinuric preeclampsia was as great as that reported in the previous small trials (figure 
5.6). Similarly, there were no subgroups in whom clear effects on IUGR, stillbirths, or 
neonatal deaths could be demonstrated. It is still possible that some special category of 
women, identified in a way not tested in CLASP, can benefit substantially. If so, such 
women must comprise a smaller and more selected group than previously thought. 
Perhaps, anti platelet therapy moderates not the disease process but some underlying 
susceptibility factor possessed by a minority of women. The aetiology of preeclampsia is 
unknown, and there is substantial variability in its presentation. Hence, it is plausible that 
preeclampsia might be the outcome of several different processes or susceptibilities, such 
that antiplatelet therapy benefits only a small proportion of women. 
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With respect to this last possibility, there was evidence that the impact of aspirin on 
the occurrence of preeclampsia was related to the duration of gestation at delivery, with 
little effect among women delivering at term but with a significant trend towards a 
substantially lower incidence among those delivering earlier (figure 5.5). Moreover, in a 
retrospective analysis of women entered for prophylaxis of preeclampsia, the rates of 
stillbirth or neonatal death attributed to preeclampsia, hypertension, or IUGR that 
occurred before 32 weeks of gestation (when the effect of preventing early-onset disease 
should be greatest) was 5.3% among women allocated aspirin compared with 10.6% 
among those allocated placebo. 
Early-onset preeclampsia differs from that developing at term, not only in the poorer 
perinatal outcome resulting from the complications of prematurity, but also in higher rates 
of IUGR,156 recurrence, maternal morbidity, and mortality, 228 and a marked assocation 
with underlying maternal disorders, especially chronic maternal hypertension2" or renal 
disease.102 Therefore, susceptibility to early preeclampsia may involve distinct factors 
amenable to preventive therapies, such as antiplatelet therapy, that have little effect in 
women who develop preeclampsia later. 
The restricted benefits of antiplatelet therapy are important in relation to the possible 
adverse effects, the most likely of which is bleeding affecting the mother, fetus, or 
newborn baby. The results of CLASP are reassuring as regards the baby, with no excess 
of intraventricular hemorrhage, other neonatal bleeds, or mortality ascribable to bleeding. 
(Further follow-up of the development of the babies is in progress, and will be reported 
elsewhere.) In the aspirin-allocated mothers there were slightly, but not significantly, 
more placental abruptions and slightly fewer other ante-partum hemorrhages. About 1 in 
lOO more women allocated aspirin received blood transfusions after delivery. Although 
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this difference was significant, its size was uncertain, being consistent with an excess of 
as little as 1 or 2 per 1000 or as much as about 2 per 100. There was no evidence of an 
excess of bleeding or other complications with epidural anesthesia. 
5.5 Conclusions 
The results of the trials thus far available do not support the widespread routine 
prophylactic or therapeutic use of anti platelet therapy in pregnancy among all women 
considered to be at increased risk of preeclampsia and/or fetal growth retardation. 
However, low~dose aspirin appears justified in pregnant women thought to be at high risk 
of early~onset preeclampsia, that is before 32 weeks of gestation. It is known from the 
literature that women with early preeclampsia or eclampsia constitute a group at high risk 
of recurrence of preeclampsia in a next pregnancy. In a study of 159 women with 
eclampsia in their previous pregnancy Sibai et a1. found a recurrence rate of 44 % in the 
next pregnancy if the eclampsia in the previous pregnancy had occurred at a gestational 
age of less than 30 weeks, and a recurrence rate of 20% when the previous eclampsia had 
occurred at a gestational age of more than 30 weeks.217 Therefore, it seems appropriate to 
start low~dose aspirin early in the second trimester in women with a history of early 
preeclampsia. Because there is a familial tendency to preeclampsia,34 and because some 
medical complications - including chronic hypertension, diabetes ,and renal disease 
predispose to preeclampsia, 193 low~dose aspirin also seems justified in these instances. 
Finally, in the CLASP study low~dose aspirin was not associated with a significant 
increase in placental hemorrhages or in bleeding during preparation for epidural 
anesthesia. Low~dose aspirin was also safe for the fetus and newborn infant, with no 
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evidence of an increased likelihood of bleeding. A long term follow-up study of children 
born to mothers in the CLASP study is currently underway in the United Kingdom, to 
aSsess longterm adverse effects due to fetal exposure to aspirin. 
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Chapter 6 
EFFECTS OF LABOR AND DELIVERY ON 
FIDRINOLYSIS* 
6.1 Introduction 
In pregnancy impressive changes occur in coagulation and fibrinolysis thought to 
serve to protect the mother from the increased risk of bleeding imposed by placentation 
and delivery. 262 Coagulation capacity appears to be increased throughout uncomplicated 
pregnancy due to elevated concentrations of most plasma procoagulants, except factors XI 
and XIII, with a further increase in plasma concentrations of factors V, VII, and X in the 
first days after delivery.262 The alterations in the fibrinolytic system are characterized by 
increases in tissue-type plasminogen-activator (t-PA) and in the plasminogen activator 
inhibitors type I (PAl-I) and type 2 (PAI-2) until the end of the 38th gestational week, 
after which they all decrease except t-PA antigen.'" According to some authors l " these 
changes result in reduction of fibrinolytic activity in pregnancy, but other investigators 
found no effect on overall fibrinolytic activity,I" or observed an increase123. Although 
fibrinolysis appears to be enhanced after placental separation,78,I4) information on the 
effect of labor on fibrinolytic activity is limited. Prostaglandins, involved in the initiation 
and maintenance of labor, 116 also have an effect on fibrinolytic variables. 16 
* Vie main substance oj this chapter was published ill: Bremer HA, Brommer EJP, Wallenburg HeS. 
Effects of labor alld delh'elY 011 fibrinolysis. Eur J Obstel Gyncco/ Reprod mol 1994; 55: 163·8. 
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One report describes a significant increase in t-PA antigen levels in maternal plasma 
during the course of the second stage of labor. 287 In another study a significant increase in 
t-PA antigen levels in maternal plasma was detected immediately following childbirth, 
before delivery of the placenta.211 Exact definition of the timing of sampling could be 
crucial in an investigation of the effects of labor and delivery on fibrinolytic variables. 
For that reason, we conducted a study of variables of fibrinolysis in plasma of women in 
whom labor was induced, which allowed standardization of sampling times in relation to 
the course of labor and delivery. 
6.2 Material and Methods 
Palielll popu/alion 
Ten healthy multiparous women who opted for elective induction of labor at term 
following an uncomplicated singleton gestation participated in the study.256 None of the 
women had a history of thrombo-embolic disease. Cervical ripeness was assessed with the 
Burnhill score. 28 When the cervix was considered favorable, -a score greater than four-
the membranes were artificially ruptured and a fluid-filled open-tip catheter was 
introduced transcervically into the amniotic cavity for the recording of uterine activity. 
An electrode was attached to the fetal scalp for fetal heart rate monitoring. Uterine 
contractions were induced with intravenous infusion of an incremental dose of oxytocine 
starting with 2mU/min, until a uterine activity of 150-200 Montevideo units was 
obtained.256 In all cases induction of labor started at 08.15. a.m. Three women with 
uncomplicated pregnancies with a median gestational age of 38 weeks who underwent 
repeat elective cesarean section were also included in the study in order to compare levels 
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of variables of fibrinolysis in peripheral and uterine venous blood. The study protocol as 
approved by the University and Hospital Ethics Committee was explained, and informed 
consent was obtained in all cases. 
Blood sampling 
Blood samples were taken 5 minutes before the start of oxytocin infusion, at full 
cervical dilatation, and within 5 minutes after delivery of the placenta. A sample of 4.5ml 
was collected without stasis from an antecubital vein through a 19 G needle in CTAD 
tubes (Becton Dickinson, France, containing 0.5 ml of a solution of 0.11 M Citrate, 15 
mMol Theophyllin, 3.7 mMol Adenosin, and 0.198 mMol Dipyridamole, pH 5.2) for 
determination of tissue-type plasminogen activator (t-PA) antigen, plasminogen activator 
inhibitor type-I (PAl-I) antigen and activity, and plasminogen activator inhibitor type-2 
(PAI-2) antigen. Another 4.5ml sample was collected in Stabilyte tubes (Biopool, Sweden, 
containing 0.5ml 0.45 M sodium citrate buffer, pH 4.3) for determination of t-PA activi-
ty. A sample of mixed free-flowing cord blood was obtained after delivery with the 
placenta in situ. In patients undergoing cesarean section, blood was collected 
simultaneously from an antecubital vein and from both uterine veins before incision of the 
lower uterine segment. The localization of the placenta was carefully determined and 
mixed cord blood was obtained immediately after delivery of the placenta. All samples 
were put on ice, centrifugated for 30 minutes at 2,000 g and 4'C, and plasmas were 
stored at -70'C until analysis. 
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Assay of t-PA al1ligell 
t-PA antigen was determined using a commercially available enzyme immunoassay 
(Imulyse', Biopool, Umea, Sweden) that measures both free and complexed t-PA in the 
range of 1.5 - 30 ng/ml. The maximal sensitivity of the test was 1.5 ng/ml ; intra-assay 
variation was 8%, inter-assay variation 10%. 
Assay of t-PA activity 
t-PA activity was determined by the conversion of plasminogen to plasmin in the 
presence of soluble fibrinogen fragments, using a chromogenic substrate according to 
Verheijen et a!. 254 The detection limit of this assay was 50 mID/ml; intra-assay variation 
was 5-13%, inter-assay variation 15-20%. 
Assay of PAI-l al1ligell 
PAI-I antigen was measured with a commercially available enzyme immunoassay, 
using anti-PAI-I antibodies (TintElize' PAl-I, Biopool, Umea, Sweden). The test 
measures both free PAI-I and PAI-I complexed to activators. The detection limit was 2 
ng/ml PAl-I; the intra-assay variation was 2% at 40 ng/ml and 7% at 15 ng/ml. 
Assay of PAl activity 
PAl activity was measured by titration of diluted samples with t-PA according to 
Verheijen et a1. 253 Results are expressed as a percentage of a standard normal plasma pool 
obtained from 40 healthy volunteers. Intra-assay variation was 2-10%, inter-assay 
variation 10-15%. 
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Assay of PAI-2 allligell 
Plasminogen activator inhibitor type 2 (PAI-2) antigen was determined with a 
commercially available enzyme immunoassay, using anti-PAI-2 antibodies (TintElize' 
PAI-2, Biopool, Umea, Sweden. The test detects both the low molecular weight (46.6 
kD) form found in placental tissue and the glycosylated high molecular weight (60 kD) 
form in maternal blood. The detection limit was 6 ng/ml. 
Statistical allalysis 
Differences between time-related continuous variables were assessed with the 
Wilcoxon signed rank test. Relationships between maternal and cord variables were 
analyzed by Spearman's rank correlation test. Comparisons between maternal and cord 
samples were made with the Wilcoxon signed rank test. All p-values are two-tailed, and a 
level of < 0.05 is considered to represent statistical significance. 
6.3 Results 
General characteristics of the women who participated in the study are summarized in 
table 6.1. 
Table 6.}. General characterisfics a/womell studied (11=10), 
showlI as media" (range). 
Age (yr) 
parity 
30 
Gestation (wk) 39 4/7 
Blrthweight (9) 3245 
(20-41) 
( 1-3 ) 
(38-41 ) 
(2855-4160) 
III 
All deliveries were uncomplicated and resulted in live, healthy infants. The individual 
changes in fibrinolytic variables during labor and delivery are presented in figures 6.1-
6.5. The only significant change between the beginning of the induction and the end of 
the first stage of labor was a rise in t-PA antigen (p= 0.01). No significant correlation 
could be demonstrated between the rise in t-PA antigen and the duration of the first stage 
of labor. All variables, except PAI-2 antigen, showed significant changes after delivery of 
the placenta compared with the end of the first stage of labor. After delivery of the 
placenta t-PA antigen and activity showed a significant rise (p< 0.05), accompanied by a 
fall in PAI-! antigen and PAl activity (p< 0.01). PAI-2 antigen concentrations showed 
no consistent changes throughout labor and delivery. In comparison with concentrations in 
maternal plasma at the end of the first stage of labor, t-PA activity in fetal plasma was 
significantly higher (p< 0.01), t-PA antigen levels were similar, and PAI-! antigen, PAl 
activity and PAI-2 antigen levels were lower in cord plasma (p< 0.001). No significant 
correlations were demonstrated between the levels of fibrinolytic variables in maternal 
and cord plasma. 
In all three women who underwent cesarean section the placenta was located centrally 
on the anterior or posterior uterine wall.No marked differences between left and right 
uterine vein values were observed. The uterine venous concentrations of the variables 
studied were not different from the peripheral venous levels, except for t-PA activity, 
which showed a median value of 0.79 IU/ml (range 0.63 - 1.89) in peripheral plasma 
compared with a markedly higher median value of 2.!9 IU/ml (range 1.37 - 3.59) in 
uterine venous plasma. 
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6.4 Discussion 
Previous studies of hemostasis in uncomplicated childbirth have revealed marked but 
variable changes in fibrinolysis and fibrinolytic markers.I43.211.287 In these studies samples 
were obtained from women in spontaneous labor without standardized timing of blood 
sampling, which may have contributed to the variability of Ihe resulls. II has been shown 
thai fibrinolytic aclivily increases after placenlal separalion. 78 •143 ,211,226,287 The resulls of 
our study show Ihal I-PA anligen, one of the fibrinolylic variables, increases already 
during labor, before placenlal separalion, This may be caused by Ihe level of physical 
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exercise which is known to increase the release of t-PA from vascular endotheiium,20J 
possibly under neurohumoral control. 41 A positive correlation has been shown to exist 
between the increase in t-PA and the workload and duration of exercise," but such a 
relationship could not be demonstrated in our study. The further rise of t-PA antigen and 
activity following placental separation may be explained by vascular damage in the uterine 
placental bed,"7 and by release by vessel walls induced by the stress of childbirthl24. 
Oxytocin at levels found during active labor fails to stimulate the in vitro activity of t-
PA,I51 which makes it unlikely that oxytocin administered for induction of labor is 
involved in t-PA release. 
Because of the standardization of our study, all samples were obtained at 
approximately the same time of the day, which makes a contribution of circadian 
variation to the results unlikely. In the non-pregnant state, diurnal variations in blood 
fibrinolytic activity are caused by changes in the plasma levels of PAl-I, which are 
highest in the early morning and lowest in late afternoon. 120 However, PAI-I production 
is not influenced by diurnal variations in populations with high PAI-I levels, as in preg-
nancy."' Also, t-PA antigen levels are known to be higher in the morning compared to 
levels in the evening in non-pregnant individuals. 4 
An explanation for the marked fall of P AI activity following placental separation 
observed in our study, may be the increase in t-PA, virtually all of which is bound to 
PAI_I.'34 It is also possible that the rapid decline in PAl-activity after delivery may be 
explained by the arrest of PAl release from the endothelium of the vascular tree of the 
placenta after separation of the placenta. I24 ,I" The absence of marked changes in PAI-2 
levels after delivery of the placenta may be explained by its long half-life which appears 
to be in the order of magnitude of several days.124 Nevertheless, the observed increase in 
116 
t-PA activity after placental separation indicates an excess release of t-PA over PAl and 
thus an increase in fibrinolytic potential. 
The higher levels of t-PA activity in plasma obtained from uterine veins compared 
to levels in peripheral veins suggest that the uterus and/or placenta are involved in the 
regulation of t-PA activity, as proposed earlier."!·226 The low maternal t-PA activity as 
compared to cord values may be caused by the five (PAl-I) to 20-fold (PAI-2) higher PAl 
concentrations in maternal plasma, which reduces the amount of free unbound functionally 
active t_PA. 143 
In conclusion, our study shows that an increase in t-PA antigen can already be 
detected during labor before placental separation, with a marked further increase in 
fibrinolytic potential after placental separation. 
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Chapter 7 
EFFECT OF LOW-DOSE ASPIRIN DURING 
PREGNANCY ON FmRINOLYTIC VARIABLES 
BEFORE AND AFTER P ARTURITION* 
7.1 Introduction 
In recent years an increasing number of pregnant women at risk of pregnancy-
induced hypertensive disorders and fetal growth retardation are being prescribed low-dose 
aspirin," although its prophylactic effect remains disputed. 24 .!07.227 Aspirin in analgetic 
doses may have an anti-fibrinolytic effect, since it inhibits the endothelial release of 
tissue-type plasminogen activator (t-PA) after venous occlusion. 13!,132 This effect could be 
mediated by inhibition of prostacyclin synthesis because it is reversed by a synthetic 
prostacyclin analogue.16 Low-dose aspirin, 20 mg for 7 days, did not affect fibrinolytic 
activity after venous occlusion in healthy males," Although low-dose aspirin mainly 
inhibits platelet thromboxane synthesis, it may also cause a small reduction in prostacyclin 
synthesis in nonpregnant individuals71 and in pregnant women.'" For that reason an effect 
of long term low-dose aspirin on the fibrinolytic system of the pregnant woman cannot be 
excluded, Modulation of the fibrinolytic system by low-dose aspirin could be of particular 
importance after normal placental separation, when coagulation in the placental bed is 
balanced by a marked increase in fibrinolytic capacity,21! 
* Accepted for publication. Bremer HA, Rotmalls p. Brommer ElP, Wallellburg Hes. Effect of low-dose 
aspirill durillg pregl/aney olljibrillolylic variables before alld after parturitloll. A1II J Obstet Gynecol. 
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In the present study we compared variables of fibrinolysis and thromboxane and 
prostacyclin synthesis at the end of pregnancy before and immediately after parturition, in 
women using low-dose aspirin for prevention of preeclampsia and/or fetal growth 
retardation, and in women who had not taken aspirin. Because exact definition of the 
timing of sampling could be important in an investigation on fibrinolytic variables, we 
conducted this study in plasma of women in whom labor was induced, which allowed 
standardization of sampling times. In addition, we investigated the effect of low-dose 
aspirin on fibrinolytic variables in cord blood. 
7.2 Materials and Methods 
PatielllS 
Twenty-four healthy pregnant women were enrolled in the study. Of these women 
eight took a daily dose of 60-80 mg of aspirin (Img/kg bodyweight) from 12 weeks 
gestation until delivery because of a history of preeclampsia or fetal growth retardation; 
16 women did not use aspirin during pregnancy and served as controls. All women opted 
for elective induction of labor, an accepted procedure in the Department. 256 Cervical 
ripeness was assessed with the Burnhill score.28 When the cervix was considered 
favorable the membranes were ruptured, and a fluid-filled open-tip catheter was 
introduced transcervically into the amniotic cavity for the recording of uterine activity. 
An electrode was attached to the fetal scalp for fetal heart rate monitoring. Uterine 
contractions were induced with intravenous infusion of an incremental dose of oxytocin 
starting with 2mU/min, until a uterine activity of 150-200 Montevideo units was obtai-
ned.'56 In all cases induction of labor started at 0815 am. Low-dose aspirin users took 
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their last tablet at 0700 am. The study protocol as approved by the University and 
Hospital Ethics Committee was explained, and informed consent was obtained in all 
cases. 
Blood sampling 
Maternal venous blood samples were taken S minutes before the start of the oxytocin 
infusion and within S minutes after delivery of the placenta. All samples were obtained 
from an antecubital vein without occlusion through a 19 G needle. 
A sample of 4.Sml was collected in CTAD tubes (Beckton Dickinson, France, 
containing O.Sml 0.11 M Citrate, IS mMol Theophyllin, 3.7 mMol Adenosin, and 0.198 
mMol Dipyridamole, pH S.S) for determination of tissue-type plasminogen activator (t-
PAl antigen, plasminogen activator inhibitor type· 1 (PAl-I) and type-2 (PAI-2) antigen 
and PAl-activity. Another 4.Sml sample was collected in Stabilyte tubes (Biopool, 
Sweden, containing O.Sml O.4S M sodium citrate buffer, pH 4.3) for determination of t-
PA activity. A 9ml sample was taken in a plastic tube in Iml disodium·ethylene-diamine-
tetra-acetate (EDT A) for determination of synthesis of malondialdehyde (MDA) by 
stimulated platelets. For determination of 6-keto·prostaglandin F,., (PGF"" a stable 
metabolite of prostacyclin, a Sml sample was collected in cooled plastic tubes containing 
101'1 heparin and 2SI'I indomethacin (0.1 % in phosphate buffer, pH 7.4). Finally, a Sml 
blood sample was collected in glass tubes and allowed to clot for determination of serum 
levels of thromboxane B, (TXB,). 
Samples of mixed free flowing cord blood were collected immediately after 
clamping of the cord with the placenta in situ for determination of the same set of 
variables. 
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Analytical procedures 
Samples for determination of variables of fibrinolysis were transported on melting 
ice, centrifuged for 30 minutes at 2,000 g at 4'C, and stored at -70'C until analysis. 
Samples for determination of plasma POP,. were centrifuged for 10 minutes at 1,500 g at 
O'C, and stored at -20'C until analysis. The clotted blood samples for determination of 
serum TXB, were incubated for 60 minutes at 37'C to stimulate maximum platelet TXB, 
release. After centrifugation for 10 minutes at 2,500 g at 20'C, serum samples were kept 
at -20'C until analysis. 
Tissue-type plasminogen activator (t-PA) antigen was determined using a 
commercially available enzyme immunoassay (Imulyse', Biopool, Umea, Sweden) that 
measures both free and complexed t-PA in the range of 1.5 - 30 nglml. The maximal 
sensitivity of the test was 1.5 ng/ml; intra-assay variation was 8%, inter-assay variation 
10%. 
t-PA activity was determined by the conversion of plasminogen to plasmin in the 
presence of soluble fibrinogen fragments, using a chromogenic substrate according to 
Verheijen et a1. 254 The detection-limit of this assay was 50 mlU/ml; intra-assay variation 
was 5-13%, inter-assay variation was 15-20%. 
Plasminogen activator inhibitor type-I (PAl-I) antigen was measured with a 
commercially available enzyme immunoassay, using anti-PAI-I antibodies (TintElize' 
PAl-I, Biopool, Umea, Sweden). The test measures both free PAI-I and PAI-I 
complexed to activators. The detection limit was 2 nglml PAl-I; the intra-assay variation 
was 2 % at 40 nglml and 7% at 15 nglml. 
PAl-activity was measured by titration of diluted samples with t-PA according to 
Verheijen et aI.253 Results are expressed as a percentage of a standard normal plasma pool 
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obtained from 40 healthy volunteers. Intra-assay variation was 2-10%, inter-assay 
variation was 10-15%. 
Plasminogen activator inhibitor type-2 (PAI-2) antigen was determined with a 
commercially available enzyme immunoassay, using anti-PAI-2 antibodies (TintElizeR 
PAI-2, Biopool, Umea, Sweden). The detection limit was 6 ng/ml. 
The capacity of platelets to synthesize TXA, was determined within 30 minutes after 
venipuncture by measuring the amount of its stable by-product MDA produced upon 
stirring platelet-rich plasma with thrombin (I IU per milliliter final concentration), as 
described previouslyY' The concentration of MDA was measured by means of the 
thiobarbituric acid reaction and expressed as nanomoles of MDA produced by 10' 
platelets. 
Plasma concentrations of POP" and serum TXB, levels were determined by 
radioimmunoassay (E.!. Du Pont de Nemours-NEN Research Products, Boston). A Sep-
Pak C" cartridge (Waters, Milford, Mass.) was prewashed with 10 ml of absolute 
ethanol, 10 ml of distilled water, and 2 ml of air. Two ml of the sample were applied to 
the column, followed by 2 ml of distilled water and 2 ml of air. The prostaglandin 
metabolites were eluated with 2 ml of absolute ethanol, followed by 2 ml of air, and the 
eluate was brought to dryness at 40'C under a gentle stream of nitrogen. The residue was 
dissolved in radioimmunoassay buffer, and the assay was performed according to the 
instruction manual using 11SI-labeled antigen. 105 
Statistical analysis 
Because the results could not be accepted to follow a normal distribution, data are 
expressed as medians with 25th and 75th centiles or range. Differences between time-
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related continuous variables were assessed with the Wilcoxon signed rank test. 
Comparisons between maternal and cord samples and between aspirin and control groups 
were made with the Wilcoxon signed rank test. Relationships between maternal and cord 
variables were analyzed with Spearman's rank correlation test. All p-values are two-
tailed, and a level of < 0.05 is considered to represent statistical significance. 
7.3 Results 
General characteristics of the women who participated in the study are summarized in 
Table 7.1. 
None of the aspirin treated women developed a pregnancy-induced hypertensive 
disorder or fetal growth retardation. All deliveries were uncomplicated and resulted in 
live, healthy infants. 
Effects of labor and delivery on fibrinolytic markers are presented in Table 7.2. 
Concentrations of t-PA antigen, t-PA activity, PAl-I antigen, and PAI-2 antigen before 
labor and after delivery of the placenta were not different between aspirin users and 
controls. PAl-activity was significantly reduced in the aspirin group as compared with 
controls, before as well as after parturition (p=0.02). 
Both t-PA antigen and activity rose whereas PAI-l antigen and PAl-activity 
decreased significantly during labor and delivery. These changes were not affected by 
low-dose aspirin and were not related to the duration of labor. PAI-2 antigen showed a 
small but significant (p=0.03) reduction during parturition in the control group that could 
not be demonstrated in low-dose aspirin users. No significant correlations were 
demonstrated between the levels of fibrinolytic variables in maternal and cord plasma. 
Comparison of fibrinolytic variables in cord blood in the aspirin and control group 
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Table 7.1. General c/tarac/eris/ics (median, range). 
Age (yr) 
Parity 
Duration of use 
Aspirin 
(n=8) 
32 (26-38) 
I (1-4) 
25.5 (22-28) 
of low-dose aspirin(wk) 
Gestation(wk) 
Birthweight (g) 
Estimated 
bloodloss at 
delivery (ml) 
38.5 
(37.4 - 40.2) 
3305 
(2780 - 3715) 
200 (100-600) 
Control 
(n = 16) 
30 (20-41) 
I (1-7) 
39.4 
(36.5 - 42) 
3235 
(2670 - 4160) 
200 (100-1100) 
Table 7.2. Medial/ (illlerquartile I'tIl/ge) COllcellfrafiol/s of variables of fibril/olysis iI/ 
maternal venous plasma. 
Plasma Aspirin Control p(*) 
(n=8) (n= 16) 
t-PA antigen' 10.8 6.5 n.s 
(ng/ml) (6.2-12.6) (4.2-16.4) 
t-PA antigen2 17.6 13.9 n.s 
(ng/ml) (14.9-27.2) (10.5-29.3) 
p'" 0.01 <0.001 
t-PA activity' 0.8 1.0 n.s 
(lV/ml) (0.6-1.1) (0.4-1.6) 
t-PA activity' 2.8 1.7 n.s 
(IU1m!) (1.6-3.8) (1.0-2.7) 
p'" 0.01 0.003 
PAI-I antigen' 101.9 101.5 n.S 
(ng/ml) (52.6-127.5) (66.9-134) 
PAI-I antigen' 44.9 66.2 n.S 
(ng/ml) (42.9-62.7) (38.2-80.2) 
p'" 0.01 <0.001 
PAI-2 antigen' 168 189 n.s 
(ng/ml) (146.5-209.8) (134.4-225.8) 
PAI-2 antigen' 160.5 165.5 n.S 
(ng/ml (128.8-193.8) (130.8-192.8) 
p'" n.S. 0.03 
PAl activity' 326 556 0.02 
(%) (86-428) (431-829) 
PAl activity' 108 339 0,02 
(%) (70-167) (100-528) 
p'" 0.01 <0.001 
p('): Aspirin versus control; p(t): Values obtained 5 min before oxytocin infusion1 versus 
values 5 min after delivery of the placenta'; n.s= non significant. 
Table 7.3. Mediall (illlerqllartile rallge) COllcelllraliollS oj variables oj fibrillolysis alld 
proslalloid melaboliles ill cord blood. 
Aspirin Control p* 
(n=8) (n= 16) 
t-PA antigen 4.5 4.5 n.S 
(ng/mI) (2.3-26) (3.2-7.5) 
t-PA activity 7.5 3.0 n.s 
(IU/mI) (2.9-8.9) (1.5-11) 
PAI-l antigen 14.9 21.2 n.s 
(ng/mI) (10.6-77) (17.8-50) 
PAl activity 43 49 n.s 
(%) (25-100) (23-78) 
PAI-2 antigen 3.7 6.6 n.s 
(ng/ml) (0.5-68.2) (3.2-27) 
6-keto-PGF" 626 862 n.S 
(ng/l) (326-1164) (471-1182) 
TXB, 37.8 217 0.0002 
(I'g/I) (27.7-80) (123-326) 
MDA 2.2 5.2 0.0001 
(nmoIII O'platelets) (1.9-2.7) (4.7-5.8) 
n.s= non significant; * :=: aspirin versus control 
showed no significant differences (table 7.3). 
Levels of POF" before labor in the aspirin group (median 54.7, range 52-82.8 ng/l) 
were about 14% lower than in controls (median 63.3, range 50.6-73 ng/l) but the 
difference was not significant. Fig 7.1 shows the significant increase in POF" in maternal 
plasma during parturition; no significant differences could be demonstrated between the 
aspirin and control group. 
Cord plasma levels of PGF" were not different between groups and were about 14 times 
higher than maternal plasma concentrations (p<O.ool). 
Before labor maternal MDA formation in the aspirin group (median 0.52, range 0.48 -
1.00 nmol/lO' platelets) and serum TXB, concentrations (median 20,8 range 12,0 - 40,2 
I'gll) were significantly lower than those in controls ( MDA median 5.4, range 4.7 - 6.4 
nmol/lO' platelets; TXB, median 281 range 205 - 411 I'g/l; p< 0.0001). No significant 
changes were observed in platelet MDA formation and in serum TXB, concentrations 
during parturition in aspirin users and in controls. 
In the control group no differences could be demonstrated between platelet MDA 
synthesis and serum TXB, concentrations in maternal and cord samples, but in low-dose 
aspirin users MDA synthesis and serum TXB, concentrations were significantly reduced in 
maternal compared with cord samples (p<O.ool). 
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7.4 Discussion 
Results of previous studies suggest that a daily dose of 60-80 mg of aspirin has no 
demonstrable effect on hemostasis in pregnant women as indicated by the bleeding 
time,14,281 but no data could be found in the accessible literature on the effect on the 
fibrinolytic system. Throughout pregnancy marked alterations occur in the fibrinolytic 
system, characterized by increases in plasma concentrations of t-PA and its inhibitors 
PAl-I and PAI-2 until the end of the 38> week of pregnancy, 'Ifter which plasma 
concentrations of all these substances decrease, except those of t-PA antigenYs In a 
recent report on the effects of parturition on fibrinolysis, a significant increase in maternal 
plasma concentrations of t-PA antigen during labor was demonstrated, with a marked 
further increase in fibrinolytic potential after placental separation." In previous studies a 
high dose of aspirin (650 mg) ingested 18 and 2 hours before blood sampling was shown 
to inhibit the release of t-PA antigen by vascular endothelium induced by venous 
occlusion. 131 •132 A study of the effect of 20 mg aspirin taken for seven consecutive days 
showed no significant effect on fibrinolytic activity, measured by the euglobulin lysis area 
and the euglobulin lysis time. 57 In our study no effect of the long term use of low-dose 
aspirin on t-PA activity was observed. The only fibrinolytic variable affected by the use 
of low-dose aspirin during pregnancy was PAl-activity, which was significantly reduced 
in the aspirin group before as well as after labor. This could lead to a relative dominance 
of t-PA activity over PAl and hence to an increased fibrinolytic potential in low-dose 
aspirin users. The question whether or not this causes an increase in effective fibrinolysis 
in vivo remains to be answered. The observed significant changes in levels of all 
fibrinolytic markers during parturition, except PAI-2, may be caused by vascular damage 
in the uterine placental bed and appear to remain unaffected by low-dose aspirin.'87 In the 
130 
nonpregnant state, diurnal variations in blood fibrinolytic activity are caused by changes 
in the plasma levels of PAl-I, which are highest in the early morning and lowest in late 
afternoon. '20 However, PAl-production is not influenced by diurnal variations in 
populations with high PAl levels, as in pregnancy. "' Because of the standardization of 
our study all samples were obtained at approximately the same time of the day, which 
makes a contribution of circadian variation to the results unlikely. 
We could not demonstrate an inhibitory effect of the longtenn intake of 6O-80mg of 
aspirin on maternal prostacyclin synthesis, which confirms earlier observations by 
ourselves and by others. 14•267 The observed increased synthesis of prostacycJin during 
labor confirms earlier observations and appears also to be unaffected by low-dose 
aspirin.284 
It is known that in normal pregnancy platelet reactivity increases, not only associated 
with increasing activity of the cyclooxygenase pathway but also with an elevated 
sensitivity of the platelet membrane. 137 Previous studies have shown that approximately 
90-95 % inhibition of maternal platelet reactivity can be achieved with a daily dose of 60 
mg of aspirin,I37·264 as is confirmed in the present study. Negatively charged 
phospholipids are known to stimulate PAl activity'" and platelets, offering a net negative 
charge upon activation, may provide a site for activation of PAl.
'
" Therefore, the 
reduced platelet reactivity induced by low-dose aspirin could be responsible for the 
reduced PAl-activity in the aspirin group. 
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Chapter 8 
GENERAL CONCLUSIONS AND PRACTICAL 
IMPLICATIONS 
A synthesis will be presented of the results of the studies reported in this thesis in an 
attempt to formulate guidelines for the application of low-dose aspirin in obstetric 
practice. 
8.1 General conclusions. 
1. There appears to be a sound scientific rationale for attempts to prevent and treat 
maladaptation disorders in pregnancy through manipulation of the prostanoid cascade. 
In theory this can be achieved by selective dietary or pharmacologic inhibition or 
stimulation of the endogenous synthesis of prostanoids, and by modulation of the 
effects of prostanoids on end organ receptors. The effects of modulation of prostanoid 
synthesis in pregnancy by dietary supplementation with polyunsaturated fatty acids, in 
particular fish oil, on the prevention of hypertensive disorders are as yet completely 
speculative, but they deserve further investigation. It is concluded that selective 
pharmacologic inhibition of platelet thromboxane formation appears to yield the most 
promising clinical results. 
2. A large body of observational data has provided no scientific evidence that 
therapeutic doses of aspirin are associated with teratogenicity, increased maternal or 
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fetal bleeding tendency, premature closure of the ductus arterioslls, or any other 
complication of pregnancy. The results of ten controlled trials involving over 5400 
pregnant women with various risk factors indicate that selective inhibition of platelet 
thromboxane synthesis with a low daily dose of aspirin in the second and third 
trimester may significantly reduce the incidence of preeclampsia and fetal growth 
retardation. Such evidence is not available with regard to the prophylactic effects of 
low-dose aspirin in pregnant women with antiphospholipid antibodies. Also, the 
potential benefits of therapeutic low-dose aspirin in pregnant women with established 
pregnancy-induced hypertensive disease or fetal growth retardation remain to be 
established. It is concluded that, although low-dose aspirin appears to be safe in 
pregnancy, it should not be adopted into routine obstetric practice until reliable risk-
benefit ratios have been determined in large clinical trials. 
3. Between 1989 and 1991 a striking increase of about 25% appears to have occurred in 
the number of gynecologists in The Netherlands prepared to prescribe low-dose aspirin 
in pregnancy for prophylactic or therapeutic reasons. The increase in popularity of the 
use of low-dose aspirin in pregnancy may be explained by the publication of the 
promising results of three randomized controlled clinical trials published in the years 
1989-1991, and perhaps also by the recruitment for the CLASP trial. 
4. In CLASP, a randomized, placebo-controlled, double-blind, clinial trial on the effects 
of low-dose aspirin in pregnancy on preeclampsia and fetal growth retardation 
covering 9364 pregnancies, the impact of low-dose aspirin on the prevention of pree-
clampsia and its sequelae was smaller than in the earlier reports mentioned in chapter 
2. There was no evidence of a therapeutic effect of low-dose aspirin. The use of 
aspirin was associated with a non-significant reduction of 12% in the incidence of 
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preeclampsia, and no significant effect on birth weight was detected. However, a 
significant trend was found towards progressively greater reduction in the development 
of preeclampsia in aspirin-treated women in early as compared to later pregnancy, 
suggesting that the prophylactic use of low-dose aspirin moves the occurrence of 
preeclampsia forward to later stages of pregnancy, at wich time the risk for the fetus 
and neonate due to prematurity becomes smaller. 
A further important contribution of CLASP to our knowledge on the use of aspirin in 
pregnancy is the reassurence provided as to the safety of aspirin in pregnancy for both 
the pregnant woman and her baby. 
5. Tissue-type plasminogen activator (t-PA), one of the fibrinolytic variables, increases 
during labor, before placental separation, possibly due to physical exercise, known to 
increase the release of t-PA from vascular endothelium. After placental separation a 
marked fnrther increase in fibrinolytic potential can be detected, represented by a 
further increase in t-PA and a decrease of its inhibitor-type I (PAl-I). In conclusion, 
an increase in t-PA antigen can already be detected during labor before placental 
separation, with a marked further increase in fibrinolytic potential after placental 
separation. 
6. A study on the effect of a daily oral dose of 60-80 mg of aspirin from 12 weeks 
gestation until delivery on fibrinolytic variables before and after parturition, showed 
in the aspirin group a significant reduction of Plasminogen Activator Inhibitor (PAl)-
activity before and after parturition. It is concluded that low-dose aspirin reduces PAI-
activity and platelet reactivity before and after parturition, and that this reduction in 
PAl-activity may be caused by the inhibition of platelet reactivity. 
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8.2 Low-dose aspirin in obstetric practice, 
Acetylsalicylic acid, registered under the name 'aspirin' since 1899, is the most 
frequently consumed drug in pregnancy, taken mostly without prescription because of 
headache or a minor ailment. Until recently many gynecologists advised against the use of 
aspirin in pregnancy, as a result of a general tendency to discourage all drug-taking in 
pregnancy as well as due to fears of specific complications of aspirin, such as teratogenic 
effects, maternal and fetal hemorrhage, and preterm closure of the ductus arteriosus. The 
negative attitude towards the use of aspirin in pregnancy changed following the 
publication of reports that a daily low-dose aspirin may prevent the occurrence of 
preeclampsia and fetal growth retardation in women at risk, and could reduce the severity 
of these complications once they have developed; a review of small randomized trials 
suggested that antiplatelet therapy reduced the incidence of preeclampsia by about three-
quarters. An anonymous written inquiry held among gynecologists in The Netherlands in 
1989 and repeated in 1991 showed an increase from 53% to 79% in the preventive use, 
and from 25% to 48% with therapeutic intentions (Chapter 4). 
However, the results of the CLASP trial did not confirm the benefits of low-dose 
aspirin in pregnancy as promised earlier by smaller controlled studies. When the available 
results from all trials, including CLASP, are taken together, the use of antiplatelet 
therapy is associated with a reduction of about 25 % in the incidence of preeclampsia 
(Chapter 5). The results of available studies do not support the routine prophylactic or 
therapeutic use of low-dose aspirin in pregnant women considered to be at low or 
moderate risk of preeclampsia or fetal growth retardation. Women with early 
preeclampsia or eclampsia constitute a group at high risk of recurrence of preeclampsia in 
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a next pregnancy. In a study of 159 women with eclampsia in their previous pregnancy 
Sibai et al. found a recurrence rate of 44 % if the eclampsia had occurred at a gestational 
age of less than 30 weeks, and of 20% if it had occurred after 30 weeks.23o WaUenburg 
and Visser found a recurrence rate of 14% if preeclampsia had occurred before 30 weeks 
of gestation and 9% if it had occurred after 30 weeks (unpublished). Therefore, it seems 
appropriate to start low-dose aspirin early in the second trimester in women with a history 
of early preeclampsia. Because of the familial tendency to preeclampsia," and because 
some medical complications - including chronic hypertension, diabetes, and renal disease 
- predispose to preeclampsia,'o, the prophylactic use of low-dose aspirin also seems 
justified in these instances. Thus far, none of the studies reported justifies the therapeutic 
use of low~dose aspirin in pregnancy. 
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SUMMARY 
Chapter 1. 
In chapter I a general introduction is presented. After a summary of the epidemiology 
and pathophysiology of pregnancy-induced hypertensive disease, the prophylactic and 
therapeutic use of low-dose aspirin is introduced. The objectives of this thesis are 
summarized as follows: 
I. To review the literature on the general principles of manipulation of prostaglandin 
synthesis in pregnancy. 
2. To review the literature on the prophylactic and therapeutic use of - low-dose - aspirin 
in pregnancy. 
3. To describe changes in patterns of prescription by Dutch gynecologists of low-dose 
aspirin for prevention and treatment of pregnancy-induced hypertensive disorders and 
fetal growth retardation. 
4. To discuss the design, the execution, the results and the clinical consequences of the 
Collaborative Low-dose Aspirin Study in Pregnancy (CLASP). 
5. To investigate the effects of labor on variables of the fibrinolytic system. 
6. To investigate the effects of low-dose aspirin during pregnancy on fibrinolytic and 
eicosanoid variables before and after parturition. 
7. To formulate guidelines for the application of lOW-dose aspirin in obstetric practice. 
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Chapter 2. 
Based on theoretical considerations, prevention and early treatment of maladaptation 
disorders in pregnancy could be achieved by dietary or pharmacologic manipulation of 
prostanoid synthesis. The effects of dietary supplementation with polyunsaturated fatty 
acids on the prevention of hypertensive disorders and fetal growth retardation are 
specUlative. Pharmacologic inhibition of phospholipases, isomerases, and thromboxane 
receptors, or stimulation of prostacyclin synthesis, have undergone clinical testing with 
disappointing results. Selective inhibition of platelet thromboxane formation using low-
dose aspirin appears to yield promising clinical results. 
Chapter 3. 
The results of ten controlled trials involving over 5400 pregnant women with various 
risk factors indicate that selective inhibition of platelet thromboxane synthesis with daily 
low-dose aspirin in the second and third trimester of pregnancy may significantly reduce 
the incidence of preeclampsia and fetal growth retardation. Such evidence is not available 
with regard to the prophylactic effect of low-dose aspirin in pregnant women with 
antiphospholipid antibodies. There is no evidence that therapeutic doses of aspirin in 
pregnancy are associated with teratogenicity, increased maternal or fetal bleeding, 
premature closure of the ductus arteriosus, or any other complication of pregnancy. The 
potential benefits of therapeutic low-dose aspirin for pregnancy-induced hypertensive 
disease or fetal growth retardation remain to be established. 
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Chapter 4. 
With the objective to describe patterns of prescription of low-dose aspirin in pregnancy 
an anonymous written inquiry was held in 1989 and 1991 among gynecologists in the 
Netherlands (619 in 1989 and 618 in 1991) practicing in training and non-training 
hospitals. The response rates were 52% in 1989 and 58% in 1991, covering 
approximately 61 % and 62%, respectively, of the practicing gynecologists in the 
Netherlands. During the period of the study the use of low·dose aspirin for prevention 
increased from 53% to 79% and for treatment from 25% to 48%, without increasing 
evidence for its benefits from the literature published in the same time period. 
Chapter 5. 
The Collaborative Low·dose Aspirin Study in Pregnancy (CLASP) was performed 
from 1988-1993 as a randomized, double-blind, placebo-controlled trial of low-dose 
aspirin for the prevention or treatment of pre-eclampsia andlor fetal growth retardation. 
Women between 12 and 32 weeks of pregnancy received a daily dose of 60 mg of aspirin 
or matching placebo until delivery if they were thought to be at higher than average risk 
of developing severe preeclampsia andlor fetal growth retardation. A total of 9364 women 
from 213 centers in 16 countries were randomized; among them 486 from the 19 
participating Dutch centers. The impact of low-dose aspirin on the prevention of 
preeclampsia and its sequelae was smaller in CLASP than in the earlier reports discussed 
in Chapter 2, possibly due to the inclusion of relatively low-risk patients in the CLASP-
trial. The prophylactic use of aspirin was associated with a decrease of 13 % in the 
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incidence of preeclampsia, but the reduction was not statistically significant. No 
significant effect on birthweight was detected. A significant trend was found towards 
progressively greater reduction in the development of preeclampsia in aspirin treated 
women in early as compared to later pregnancy. There was no evidence of a therapeutic 
effect of low-dose aspirin. 
Finally, CLASP provided support with regard to the safety of aspirin for the pregnant 
woman and her baby. 
Chapter 6. 
A study was conducted on fibrinolytic variables in plasma of ten healthy multiparous 
women in whom labor was induced, which allowed standardization of sampling times in 
relation to the course of labor and delivery. Variables determined were tissue-type 
plasminogen activator (t-PA) and the plasminogen activator inhibitors type I (PAl-I) and 
type 2 (PAI-2). The only significant change between the beginning of the induction of 
labor and the end of the first stage of labor was a rise in t-PA antigen. All variables, 
except PAI-2 antigen, changed significantly after delivery of the placenta: t-PA antigen 
and activity showed an increase, accompanied by a fan in PAI-I antigen and activity. T-
PA activity in cord plasma was higher in comparison with maternal plasma concentrations 
at the end of the first stage of labor, t-PA antigen levels were similar, and PAI-I antigen 
and activity and PAI-2 antigen were lower in cord plasma. 
The study shows an activation of maternal fibrinolysis that can already be detected 
during labor, with a marked further increase after placental separation. 
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Chapter 7. 
The effects were assessed of a daily oral dose of low-dose aspirin from 12 weeks' 
gestation until delivery on fibrinolytic variables before and after parturition. Labor was 
electively induced in 24 patients, 8 on low-dose aspirin and 16 controls. Fibrinolytic 
variables determined in maternal and cord plasma were t-PA antigen and activity, PAI-l 
antigen, PAl-activity and PAI-2 antigen. Metabolites of endothelial prostacycIin and 
platelet thromboxane A, were also determined. The only maternal fibrinolytic variable 
affected by low-dose aspirin was PAl-activity, which showed a significant reduction 
before and after parturition of 40% and 70%, respectively, in low-dose aspirin users 
compared to controls. Concentrations of thromboxane B, in women using low-dose aspirin 
were 7% (maternal serum) and 17% (cord serum) of values in controls, but 
concentrations of 6-keto-prostaglandin F,. were not affected. 
It is concluded that low-dose aspirin reduces PAl activity and platelet reactivity, but 
not prostacyclin synthesis, before and after parturition. The reduction in PAl activity may 
be caused by inhibition of platelet reactivity. 
Chapter 8. 
The conclusions with regard to the objectives presented in Chapter 1 are as follows: 
1. Prevention of maladaptation in pregnancy through manipulation of prostanoid 
synthesis may be achieved by selective inhibition of platelet thromboxane 
formation. 
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2. Low-dose aspirin selectively inhibits platelet thromboxane synthesis. Aspirin 
appears to be safe in pregnancy, but its prophylactic use in obstetric practice should 
await the establishment of reliable risk - benefit ratios. 
3. Between 1989 and 1991 a striking increase occurred in the number of gynecologists 
in the Netherlands prepared to prescribe low-dose aspirin in pregnancy for 
prophylactic reasons. This increase was not based on an increase in reported 
scientific evidence. 
4. In CLASP the use of low-dose aspirin was associated with a reduction in the 
incidence of preeclampsia and its sequelae that did not reach statistical significance. 
A significant trend was found, however, towards a progressively greater reduction 
in the incidence of preeclampsia in aspirin treated women in early as compared to 
later pregnancy. Aspirin appeared to be safe for mother and baby. 
5. An increase in tissue-type plasminogen activator (t-PA) antigen was detected during 
labor before placental separation, with a marked further increase in fibrinolytic 
potential after placental separation. 
6. Low-dose aspirin reduces the activity of plasminogen activator inhibitor (PAl) and 
platelet reactivity before and after parturition. The reduction in PAl-activity may be 
caused by inhibition of platelet reactivity. 
7. It seems appropriate to start low-dose aspirin (60 mg/day) early in the second 
trimester in women with a history of early preeclampsia. Because of the familial 
tendency to preeclampsia, and because some medical complications - including 
chronic hypertension, diabetes, and renal disease - predispose to preeclampsia, the 
prophylactic use of low-dose aspirin also seems justified in these instances. There 
is no evidence to support the therapeutic use of low-dose aspirin in pregnancy. 
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SAMENV ATTING 
Hoofdstuk 1 
In hoofdstuk 1 wordt een algemene inleiding tot het proefschrift gegeven. Na een 
samenvatting van de epidemiologie en pathofysiologie van zwangerschapshypertensie en 
preec1ampsie, wordt het profylactische en therapeutische gebruik van aspirine in de 
zwangerschap besproken. 
De doelstellingen van het proefschrift worden als voigt samengevat: 
1. Een overzicht geven van de literatuur met betrekking tot de algemene principes van 
manipulatie van de prostaglandine synthese in de zwangerschap. 
2. Een overzicht geven van de literatuur over het profylactische en therapeutische gebruik 
van een lage dosis aspirine in de zwangerschap. 
3. Het beschrijven van veranderingen in het voorschrijf-gedrag van Nederlandse 
gynaecologen met betrekking tot aspirine in de zwangerschap ter preventie of 
behandeling van zwangerschapshypertensieve aandoeningen en foetale groeivertraging. 
4. Het bespreken van de opzet, de uitvoering, de resultaten en de klinische consequenties 
van het CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) onderzoek. 
5. Het onderzoeken van het effect van de baring op variabelen van het fibrinolytische 
systeem. 
6. Het onderzoeken van het effect van het dagelijkse gebruik van een lage dosis aspirine 
gedurende de zwangerschap op het fibrinolytische systeem voor en na de baring. 
7. Het formuleren van richtlijnen met betrekking tot het voorschrijven van een lage dosis 
aspirine in de verloskundige praktijk. 
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Hoofdstuk 2 
Op theoretische gronden kan preventie en/of vroege behandeling van aandoeningen die 
een gevolg zijn van maladaplalie in de zwangerschap worden uitgevoerd door manipulatie 
van hel prostaglandine systeem via het dieet of langs farmacologische weg. De resultaten 
van pagingen om met een dieet rijk aan meervoudig onverzadigde vetzuren 
zwangerschapshypertensieve aandoeningen en foelale groeivertraging te voorkomen zijn 
lot heden niet overluigend. De klinische resuItalen van farmacologische inlerventie door 
remming van phospholipasen of isomerasen, het gebruik van thromboxaan receptor 
antagonisten of slimulering van de proslacycline synthese zijn eveneens leleurstellend. 
Selectieve remming van de vorming van thromboxaan door thrombocyten door middel van 
een dagelijkse lage dosis aspirine biedt perspectief. 
Hoofdstuk 3 
Ben overzicht van 10 gecontroleerde onderzoeken met ruim 5400 zwangeren laat zien, 
dat selectieve remming van de thromboxaan produklie door thrombocylen door middel 
van een dagelijkse lage dosis aspirine gedurende hel tweede en derde trimester van de 
zwangerschap bij vrouwen met verschillende risicofactoren de kans op het onlstaan van 
preeclampsie en/of foetale groeiverlraging kan verkleinen. Ben dergelijk effect is niel 
aangeloond bij zwangeren met antilichamen tegen fosfolipiden. Er zijn geen aanwijzingen, 
dat het gebruik van aspirine in de zwangerschap in therapeutische doseringen samengaat 
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met een verhoogde kans op foetale afwijkingen, een verhoogde maternale en/of foetale 
bloedingsneiging, het prematuur sluiten van de ductus arteriosus, of enige andere 
complicatie. Het therapeutisch voorschrijven van een lage dosis aspirine bij reeds 
bestaande preeciampsie of foetale groeivertraging is niet bewezen effectief. 
Hoofdstuk 4 
In 1989 werd een enquNe gehouden onder de Nederlandse gynaecologen naar het 
voorschrijven van aspirine in de zwangerschap. Deze enquete werd herhaald in 1991. De 
respons was 52% in 1989 en 58% in 1991. In 1989 schreef 53% van de respondenten 
aspirine voor ter voorkoming van preeciampsie of foetale groeivertraging; in 1991 was 
dit gestegen tot 79%. De cijfers voor behandeling van reeds bestaande preeciampsie en 
groeivertraging waren respectievelijk 25 % en 48 %. De toeneming van de bereidheid van 
de gynaecologen om voor de genoemde indicaties een lage dosis aspirine voor te schrijven 
was niet gebaseerd op in de onderzochte periode verschenen literatuur. 
Hoofdstuk 5 
Het CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) onderzoek, een 
gerandomiseerd, dubbel-blind, placebo-gecontroleerd multicenter onderzoek naar het 
effect van een dagelijkse lage dosis aspirine in de zwangerschap ter voorkoming of 
behandeling van preeclampsie en/of foetale groeivertraging werd uitgevoerd van 1988 -
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1993. Vrouwen met een zwangerschapsduur van 12-32 weken gebruikten dageJijks 60 mg 
aspirine of placebo tot aan de bevalling, als zij naar de mening van hun gynaecoloog een 
verhoogd risico Jiepen op het ontwikkelen van preeciampsie of foetale groeivertraging. In 
het totaal werden 9364 zwangeren door 213 centra uit 16 landen aangemeld, waaronder 
486 uit 19 Nederlandse centra. 
Het resultaat van de CLASP met betrekking tot het voorkomen van preeclampsie was 
minder positief dan in voorgaande onderzoeken. Vergeleken met placebo ging het gebruik 
van een lage dosis aspirine gepaard met een vermindering van 13% in de incidentie van 
preeclampsie, cen verschil dat statistisch niet significant was. Een significant verschil in 
geboortegewicht kOIl evenmin worden aangetoond. Wei werd een significante trend 
gevonden tot het minder voorkomen van vroege preeciampsie bij aspirine gebruikende 
zwangeren. Het onderzoek gaf geen aanwijzingen voor cen therapeutisch effect van een 
lage dosis aspirine. Aspirine in de zwangerschap bleek veiJig voor moeder en kind. 
Hoofdstuk 6 
Bij 10 gezonde mu!tipare zwangeren werd het effect bestudeerd van de baring op 
variabelen van de fibrinolyse. Door de baring electief in Ie lei den werd het verzamelen 
van de bloedmonsters gestandaardiseerd. Bepaald werden tissue type plasminogen 
activator (I-PA) en de plasminogen activator inhibitor type I en 2. Tussen het begin van 
de inleiding en het eind van de ontsluitingsfase trad aileen een significante stijging op van 
het t-PA antigeen. Aile variabelen, met uitzondering van PAI-2 antigenen, veranderden 
statistisch significant na de geboorte van de placenta: t-PA antigeen en activiteit stegen, 
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terwijl PAI-I antigeen en activiteit significant daalden. De t-PA activiteit in 
navelstrengpiasma was hoger dan in het plasma van de moeder aan het eind van de 
ontsluitingsfase; de t-PA antigeen spiegels waren vergelijkbaar en PAI-I antigeen en 
activiteit en P AI-2 antigeen waren lager in navelstrengplasma. 
Dit onderzoek toont aan dat activatie van de fibrinolyse plaatsvindt gedurende de 
baring met een sterke toeneming na de geboorte van de placenta. 
Hoofdstuk 7 
Bij 24 zwangeren, 8 met aspirine en 16 con troles, werd het effect bestudeerd van een 
dagelijkse lage dosis aspirine gedurende de zwangerschap op fibrinolytische parameters 
gedurende de baring. Door de baring electief in te leiden werd het verzamelen van de 
bloedmonsters gestandaardiseerd. In moederlijk en navelstrengplasma werden t-PA 
antigeen en activiteit, PAI-I antigeen, PAI-activiteit en PAI-2 antigeen bepaald. Tevens 
werden metabolieten van thromboxaan A, en prostacycline gemeten. De enige maternale 
variabele van de fibrinolyse die werd beinvloed door het gebruik van aspirine was de 
PAI-activiteit, waarin reducties van 40% en 70%, respectievelijk v66r en na de bevalling, 
werden aangetoond bij aspirine gebruikende zwangeren vergeleken met controles. Bij 
aspirine gebruikende zwangeren waren de concentraties van thromboxaan B2 in maternaal 
en navelstrengplasma respectievelijk 7% en 17% van de waarden bij controles, maar de 
plasmaconcentraties van 6-keto-prostaglandine F,. waren niet verschillend. 
Geconcludeerd wordt dat een lage dosis aspirine de PAI-activiteit en thromboeyten 
reactiviteit onderdrukt, maar de prostacycline synthese intact laat. De vermindering van 
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de PAI-activiteit wordt mogelijk veroorzaakt door de onderdrukking van de reactiviteit 
van de thrombocyten. 
Hoofdstuk 8 
De conclusies betreffende de doelstellingen geformuleerd in hoofdstuk 1 zijn: 
1. Preventie van maladaptatie in de zwangerschap door manipulatie van het 
prostaglandine systeen kan worden verkregen door selectieve remming van de 
thromboxaan produktie door thrombocyten. 
2. Ben dagelijkse lage dosis aspirine in de zwangerschap remt de synthese van 
thromboxaan door thrombocyten. Aspirine lijkt veilig in de zwangerschap, maar het 
profylactische gebmik gebmik in de obstetrische praktijk dient nader te worden 
bestudeerd. 
3. Tussen 1989 en 1991 was er een opvallende toename van de bereidheid van 
Nederlandse gynaecologen om in de zwangerschap aspirine voor te schrijven. Deze 
toename was niet gebaseerd op in die tijd beschikbaar gekomen nieuwe gegevens. 
4. Uit het CLASP-onderzoek blijkt een verminderde incidentie van preeclampsie bij het 
gebruik van een lage dosis aspirine, maar het verschil met placebo is niet statistisch 
significant. Wei blijkt er bij zwangeren die een lage dosis aspirine gebruiken een 
significante trend te bestaan tot verminderd optreden van vroege preeclampsie. 
Aspirine is veilig voor moeder en kind. 
5. Tijdens de baring werd een toename van tissue-type plasminogeen activator (t-PA) 
antigeen gevonden; een duidelijke toename van de fibrinolytische potentie werd gezien 
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na de geboorte van de placenta. 
6. Een dageJijkse Iage dosis aspirine verminderde de activiteit van pIasminogcen activator 
inhibitor (PAl) en de thrombocyten reactiviteit voor en na de bevaIIing. De 
vermindering van de PAI-activiteit wordt mogeIijk verkIaard door de verminderde 
reactiviteit van de thrombocyten. 
7. Het voorschrijven van cen dageIijkse Iage dosis aspirine (60 mg) vanaf het tweede 
trimester tot aan de baring Iijkt geYndiccerd bij zwangeren met cen anamnese van 
vroege preecIampsie. Gezien de familiaire tendens tot het ontwikkeIen van 
preeclampsie en omdat preeclampsie vaker wordt gezien bij chronische hypertensie, 
diabetes, en nierziekten valt het te overwegen ook in deze gevallen ter profylaxe in de 
zwangerschap een lage dosis aspirine voor te schrijven. Er is zijn geen aanwijzingen 
die het therapeutische gebruik van een lage dosis aspirine in de zwangerschap 
rechtvaardigen. 
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